<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
<th>Location</th>
</tr>
</thead>
</table>
| 09:45 - 11:25 | **Type:** Opening session  
**Title:** Opening Ceremony  
Chair: Josep Tabernero, ES; Ravindran Kanesvaran, SG |                                                                     | Hall 406   |
| 09:45 - 09:50 | **Singapore Cultural Dance performance**                           |                                                                     |            |
| 09:50 - 10:00 | **Welcome address by the ESMO President**                             | J. Tabernero, Vall d’Hebron University Hospital, Barcelona, ES      |            |
| 10:00 - 10:10 | **Welcome address by the Senior Minister of State, Ministry of Transport & Ministry of Health** |                                                                      |            |
| 10:10 - 10:15 | **Welcome address by the President of the Singapore Society of Oncology** | S.P. Choo, NCCS - National Cancer Centre Singapore, Singapore, SG       |            |
| 10:15 - 10:35 | **Presentation of Token of Appreciation to the endorsing National Oncology Societies** |                                                                      |            |
| 10:35 - 10:45 | **Scientific address**                                               | R. Dent\(^1\), I. Chau\(^2\), NCCS - National Cancer Centre Singapore, Singapore, SG,  
\(^2\)The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB |            |
| 10:45 - 11:05 | **Keynote 1 - Cancer burden in the Asia-Pacific region**              | E. Weiderpass Vainio, Sodersjukhuset - Karolinska Institutet (KI SOS), Stockholm, SE |            |
| 11:05 - 11:25 | **Keynote 2 - Innate immunity, inflammation and cancer: The long journey to bedside** | A. Mantovani, Humanitas University, Milan, IT                         |            |
| 11:40 - 12:20 | **Type:** Mini Oral session  
**Title:** Mini Oral session - Sarcoma  
Chair: Tom Wei-Wu Chen, TW; Robin Jones, GB; Silvia Stacchiotti, IT |                                                                     | Room 311   |
| 11:40 - 11:40 | **Session DOI**                                                        |                                                                     |            |
| 11:40 - 11:45 | **403O - The efficacy of eribulin methylate for patients with taxane-resistant cutaneous angiosarcoma: Final results from a multi-center, prospective, observational study** | Y. Fujisawa\(^1\), K. Yoshino\(^2\), T. Fujimura\(^3\), Y. Yamamoto\(^4\), H. Uchi\(^5\), H. Hata\(^6\), A. Otsuka\(^7\), T. |            |
11:45 - 11:50 404O - A phase II single arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated Classical Kaposi Sarcoma (CKS)

A. Zer1, O. Icht1, O. Jacobi1, E. Fenig1, S. Shamai2, O. Merimsky2, R. Shapira3, H. Bernstine4, R. Weitzen5, O. Vornikova6, E. Ben-Ami5, G. Bar-Sela6, S. Stemmer1, M. Lotem7, 1Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL, 2Tel Aviv Sourasky Medical Center, Tel Aviv, IL, 3Ella Institute for Immuno-Oncology and melanoma, Sheba medical center, Tel Aviv, IL, 4Rabin Medical Center, Beilinson Campus, Petah Tikva, IL, 5Chaim Sheba Medical Center, Ramat Gan, IL, 6HaEmek Medical Center, Afula, IL, 7Hadassah Ein Kerem, Jerusalem, IL

11:50 - 12:00 Discussion led by moderators

T.W.-W. Chen1, R. Jones2, S. Stacchiotti3, 1NTU - National Taiwan University - College of Medicine, Taipei City, TW, 2The Royal Marsden Hospital - NHS Foundation Trust, London, GB, 3Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

12:00 - 12:05 405O - Neutrophil-lymphocyte and platelet-lymphocyte ratios as robust prognostic markers in sarcomas: A population-based analysis of 3746 sarcoma patients from Hong Kong

S.C.S. Kwan1, C. Wong2, C. Ho2, Y.Z. Zhang3, T. Tse4, Y.-M. Lau5, L. Leung5, T. Tan4, H. Loong6, 1Chinese CHUK - University of Hong Kong, Shatin, HK, 2The University of Hong Kong, Hong Kong, HK, 3Chinese University of Hong Kong, Sha Tin, HK, 4The Chinese University of Hong Kong, Sha Tin, HK, 5The Chinese University of Hong Kong, Hong Kong, HK, 6The Chinese University of Hong Kong, Shatin, HK

12:05 - 12:10 406O - VEGFR2 and ITGA polymorphisms as novel predictors of therapeutic response and toxicities for pediatric and young adult sarcoma undergoing anti-angiogenic therapy

Q. Bao1, Y. Hu2, J. Wen2, Y. Shen2, W. Zhang2, 1Jiangshan City People's Hospital, Jiangshan City, CN, 2ruijin hospital, shanghai, CN

12:10 - 12:20 Discussion led by moderators

T.W.-W. Chen1, R. Jones2, S. Stacchiotti3, 1NTU - National Taiwan University - College of Medicine, Taipei City, TW, 2The Royal Marsden Hospital - NHS Foundation Trust, London, GB, 3Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT
11:45 - 12:30  **Type: Challenge Your Expert session**
**Title: Optimal sequence and treatment choice in osimertinib failure**
Chair: Myung-Ju Ahn, KR

11:45 - 11:45  **Session DOI**

11:45 - 12:00  **Optimal sequence and treatment choice in osimertinib failure**
*T.S.K. Mok*, Prince of Wales Hospital, Shatin, HK

12:00 - 12:30  **Discussion**

11:45 - 12:30  **Type: Challenge Your Expert session**
**Title: Surgical management of ovarian cancer**
Chair: Amita Maheshwari, IN

11:45 - 11:45  **Session DOI**

11:45 - 12:00  **Surgical Management of Ovarian Cancer**
*C. Marth*, Innsbruck Medical University, Innsbruck, AT

12:00 - 12:30  **Discussion**

11:45 - 12:30  **Type: Challenge Your Expert session**
**Title: Locally advanced nasopharyngeal carcinoma (LA NPC): Asian and European perspectives**
Chair: Pierre Blanchard, FR; Anthony Chan, HK

11:45 - 11:45  **Session DOI**

11:45 - 12:15  **Locally advanced nasopharyngeal carcinoma (LA NPC): Asian and European perspectives**
*1A. Chan*, *2P. Blanchard*, 1Prince of Wales Hospital, Shatin, HK, 2Institut Gustave Roussy, Villejuif, FR

12:15 - 12:30  **Discussion**
<table>
<thead>
<tr>
<th>Time</th>
<th>Type</th>
<th>Title</th>
<th>Summit 2</th>
<th>Room 405</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45</td>
<td>Challenge Your Expert session</td>
<td>Immunotherapy in GU cancers: Focus on kidney and bladder</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>cancers</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair: Cora Sternberg, US</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td>Session DOI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td>Kidney</td>
<td>Y.L. Su, Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung, TW</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:55</td>
<td>Bladder</td>
<td>R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:05</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair: Mei-Kim Ang, SG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45</td>
<td>Introduction</td>
<td>M.-K. Ang, NCCS - National Cancer Centre Singapore, Singapore, SG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:50</td>
<td>Charting the course for the stage III NSCLC patient</td>
<td>N. Reinmuth, Asklepios-Fachklinikum, Gauting, DE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:35</td>
<td>Navigating the waters of ES-SCLC</td>
<td>M.-J. Ahn, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:10</td>
<td>Conclusions</td>
<td>M.-K. Ang, NCCS - National Cancer Centre Singapore, Singapore, SG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker Details</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45</td>
<td><strong>Type:</strong> Industry Satellite Symposium</td>
<td><strong>Hall:</strong> 404</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45 - 14:15</td>
<td><strong>Title:</strong> AstraZeneca - PARP inhibitors as targeted therapy for personalised medicine</td>
<td><strong>Chair:</strong> John Chia, SG; Byoung-Gie Kim, KR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45 - 12:50</td>
<td><strong>Introduction</strong></td>
<td>B.-G. Kim, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:15 - 13:30</td>
<td><strong>What’s new in metastatic pancreatic cancer management?</strong></td>
<td>T. Golan, Chaim Sheba Medical Center, Ramat Gan, IL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 13:45</td>
<td><strong>Recent advances in metastatic prostate cancer management</strong></td>
<td>S. Sandhu, Peter MacCallum Cancer Centre, Melbourne, AU</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td><strong>Expert Opinion on ‘PARP inhibitors as targeted therapy for personalized medicine’ - Panel Discussion</strong></td>
<td>J. Chia, NCCS - National Cancer Centre Singapore, Singapore, SG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 - 14:10</td>
<td><strong>Q&amp;A</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:10 - 14:15</td>
<td><strong>Closing</strong></td>
<td>B.-G. Kim, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
12:45 - 12:45  **Session DOI**

12:45 - 12:50  **Introduction**
R. Soo, National University Hospital, Singapore, SG

12:50 - 13:15  **Immune-Check Points Inhibitors (ICI) in non-oncogenic addicted mNSCLC**
M. Garassino, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

13:15 - 13:40  **EGFR mutant mNSCLC: Single agent or in combination?**
F. Barlesi, Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR

13:40 - 14:05  **Future development for the use of biomarkers**
R. Soo, National University Hospital, Singapore, SG

14:05 - 14:10  **Conclusion**
12:45 - 14:15  Type: Industry Satellite Symposium  
Room 324  
Title: Pfizer - From clinical trials to practice: Changing the trajectory for metastatic breast cancer patients  
Chair: Yen Shen Lu, TW; Yoon Sim Yap, SG

12:45 - 12:48  Introduction of Speaker  
Y.S. Lu, National Taiwan University Hospital, Taipei, TW

12:48 - 13:28  From clinical trials to practice: Changing the trajectory for metastatic breast cancer patients  
R. Finn, Geffen School of Medicine at UCLA, Los Angeles, US

13:28 - 13:30  Introduction of Speaker  
Y.S. Yap, NCCS - National Cancer Centre Singapore, Singapore, SG

13:30 - 13:45  Presentation of real world outcomes in ER+ HER2- mBC  
S. Rajappa, 2. Basavatkaram Indo American Cancer Hospital, Hyderabad, IN

13:45 - 14:05  Panel discussion on management of mBC in Asian patients  
S. Rajappa, 2. Basavatkaram Indo American Cancer Hospital, Hyderabad, IN

14:05 - 14:15  Q&A
12:45 - 14:15  **Type: Industry Satellite Symposium**

**Title: Roche - Precision oncology in Asia: A new dawn or a false hope?**

Chair: David SP Tan, SG

---

12:45 - 12:50 **Introduction**

_D.S. Tan_, NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG

12:50 - 13:10 **The clinical significance of comprehensive genomic profiling**

_S. Ikeda_, Tokyo Medical and Dental University, Tokyo, JP

13:10 - 13:30 **Generating meaningful evidence with novel trial designs and real-world data**

_R. Dienstmann_, Vall d'Hebron University Hospital, Barcelona, ES

13:30 - 13:45 **South Korea's journey with precision oncology**

_T.-Y. Kim_, SNUH-Seoul National University Hospital, Seoul, KR

13:45 - 14:00 **Singapore's journey with precision oncology**

_D.S. Tan_, NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG

14:00 - 14:15 **Q&A and closing remarks**

_D.S. Tan_, NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG

---

12:45 - 14:15  **Type: Industry Satellite Symposium**

**Title: MSD - A quantum leap in treatment of NSCLC and HNSCC with IO**

Chair: Daniel Shao Weng Tan, SG

---

12:45 - 12:50 **Welcome, introductions and objectives of the session**

_D.S.W. Tan_, National Cancer Center Singapore, Singapore, SG

12:50 - 13:25 **The landscape and role of IO-Chemo combination in NSCLC treatment**

_T. Mitsudomi_, Kindai University - Faculty of Medicine, Osaka, JP

13:25 - 14:00 **Is immuno-oncology going to replace chemotherapy in advanced HNSCC?**

_E. Cohen¹, D. Rischin², ¹Moores Cancer Center at UC San Diego Health, La Jolla, US, ²Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, AU

14:00 - 14:15 **Q&A**

_D.S.W. Tan_, National Cancer Center Singapore, Singapore, SG
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:30</td>
<td><strong>Session DOI</strong></td>
</tr>
</tbody>
</table>
| 14:30 - 14:55 | **HER2-positive breast cancer: Escalation and de-escalation strategies in the neo/adjuvant setting, who and when**  
|             | **D. Miles**, Mount Vernon Cancer Centre, Northwood, GB |
| 14:55 - 15:20 | **Triple negative advanced breast cancer: Immunotherapy incorporation, who and when**  
|             | **G. Curigliano**, Istituto Europeo di Oncologia, Milan, IT |
| 15:20 - 15:45 | **HR-positive advanced breast cancer: CDK4 inhibitors, who and when**  
|             | **S. Goel**, Peter MacCallum Cancer Centre, Melbourne, AU |
| 15:45 - 16:00 | **Discussion** |
14:30 - 16:00  |  Type: Multidisciplinary tumour board  
| Hall 404  
Title: Contemporary issues in cervical cancer management  
Chair: Mansoor Raza Mirza, DK

14:30 - 14:30  |  Session DOI

14:30 - 14:45  |  Primary and secondary prevention  
S. Ahsan, OMI Hospital, Karachi, PK

14:45 - 14:55  |  Presentation of case/condition  
T. Sadaf, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKM), Lahore, PK

14:55 - 15:10  |  Surgical management: When and how?  
K. Fujiwara, Saitama Medical University Internat Medical Centre, Saitama, JP

15:10 - 15:30  |  Is there a role of neoadjuvant chemotherapy? EORTC and Indian trial presentations  
S. Gupta1, G. Kenter2, 1Tata Memorial Hospital Centre, Mumbai, IN, 2Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL

15:30 - 16:00  |  Discussion  
K. Fujiwara1, S. Pignata2, M.R. Mirza3, 1Saitama Medical University Internat Medical Centre, Saitama, JP, 2Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, 3Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK

14:30 - 16:00  |  Type: Proffered Paper session  
| Hall 406  
Title: Proffered paper session - Thoracic cancers  
Chair: Myung-Ju Ahn, KR; Sanjay Popat, GB; Pilar Garrido Lopez, ES

14:30 - 14:30  |  Session DOI

14:30 - 14:42  |  LBA15 - Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia  
M. Nishio1, J.H. Ji2, K. Hotta3, C.-H. Chiu4, J.-S. Lee5, K. Azuma6, S.-W. Kim7, S.Y. Wu8, M. Dvorkin9, D. Trukhin10, L. Havel11, M.J. Hochmair12, M. Özgüroğlu13, J. Bar14, Y. Chen15, J.W. Goldman16, N. Byrne17, P.J. Lau18, N. Shire19, L. Paz-Ares20, 1The Cancer Institute Hospital of JFCR, Tokyo, JP, 2Samsung Changwon Hospital, Changwon, KR, 3Okayama, okayama, JP, 4Taipei Veterans General Hospital, Taipei City, TW, 5Seoul National University Bundang Hospital, Gyeonggi-do, KR, 6Kurume University Hospital, Fukuoka, JP, 7Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, 8National Cheng Kung University Hospital, Tainan City, TW, 9BHI of Omsk Region Clinical Oncology Dispensary, Omsk, RU, 10Odessa National Medical University, Odessa, UA,
14:42 - 14:54 474O - Efficacy and safety of first-line durvalumab (D) & tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC

B.-C. Cho1, K.H. Lee2, M.-J. Ahn3, S. Lucien Geater4, T.V. Ngoc5, C.-C. Wang6, E.K. Cho7, J.S. Lee8, V. Sriuranpong9, Q. Bui10, S. Clarke11, S. Kuyama12, K. Nakagawa13, F. Liu14, D. Clemett15, U. Scheuring16, S. Peters17, N. Rizvi18, Yonsei University, Seoul, KR, 2Chungbuk National University Hospital, Cheongju, KR, 3Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, 4Hat yai Hospital - Prince of Songkla University, Songkla, TH, 5Cho Ray Hospital, Ho Chi Minh, VN, 6Chang Gung Memorial Hospital, Taoyuan, TW, 7Gachon University, Incheon, KR, 8Seoul National University Bundang Hospital, Seoul, KR, 9King Chulalongkorn Memorial Hospital, Bangkok, TH, 10Hanoi Oncology Hospital, Hanoi, VN, 11Royal North Shore Hospital, St Leonards, AU, 12Chugoku Chuo Hospital, Fukuuyama, JP, 13Kindai University Hospital, Osaka, JP, 14AstraZeneca, Gaithersburg, US, 15AstraZeneca, Macclesfield, GB, 16AstraZeneca UK, Melbourn, GB, 17Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, 18Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US

14:54 - 15:09 Invited Discussant LBA15 and 474O

S. Popat.Royal Marsden Hospital NHS Foundation Trust, London, GB

15:09 - 15:21 475O - Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

Y.-L. Wu1, T.S.K. Mok2, J.-Y. Han3, M.-J. Ahn4, A. Delmonte5, S. Ramalingam6, S.-W. Kim7, F. Shepherd8, J. Laskin9, Y. He10, H. Akamatsu11, W. Theelen12, W.-C. Su13, T. John14, M. Sebastian15, H. Mann16, M. Miranda16, G. Laus17, Y. Rukazenkov18, V. Papadimitrakopoulou19, 1Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, 2Princess of Wales Hospital, Shatin, HK, 3National Cancer Center, Goyang, KR, 4Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, 5Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, 6Emory University Winship Cancer Institute, Atlanta, US, 7Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, 8Princess Margaret Cancer Center, Toronto, CA, 9BC Cancer Agency - Vancouver, Vancouver, CA, 10Daping Hospital, Chongqing, CN, 11Wakayama Medical University, Wakayama, JP, 12Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, 13National Cheng Kung University Hospital, Tainan, TW, 14Austin Health, Melbourne, AU, 15Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, 16AstraZeneca, Cambridge, GB,
15:21 - 15:33 **LBA16 - Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis**

B.C. Cho¹, Y. Ohe², C. Zhou³, T. Reungwetwattana⁴, Y. Cheng⁵, B. Chewaskulyong⁶, K.H. Lee⁷, D. Planchard⁸, J. Vansteenkiste⁹, J. Gray¹⁰, R. Shah¹¹, P.K. Cheema¹², M. Tiseo¹³, T. John¹⁴, R. Hodge¹⁵, Y. Rukazenkov¹⁶, J.-C. Soria¹⁷, M.-C. Lin¹⁸, F. Imamura¹⁹, S. Ramalingam²⁰, Yonsei University, Seoul, KR, ²National Cancer Center Hospital, Tokyo, JP, ³Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN, ⁴Ramathibodi Hospital, Bangkok, TH, ⁵Jilin Province Cancer Hospital, Changchun, CN, ⁶Maharaj Nakorn Chiang Mai Hospital Faculty of Medicine, Chiang Mai, TH, ⁷Chungbuk National University Hospital, Cheongju, KR, ⁸Institut Gustave Roussy, Villejuif, FR, ⁹University Hospitals Leuven, Leuven, BE, ¹⁰H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ¹¹Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Maidstone, GB, ¹²William Osler Health System, University of Toronto, Toronto, CA, ¹³University Hospital of Parma, Parma, IT, ¹⁴Austin Health, Melbourne, AU, ¹⁵AstraZeneca, Cambridge, GB, ¹⁶Astrazeneca, Macclesfield, GB, ¹⁷Early Oncology, Research & Development, AstraZeneca, Gaithersburg, Maryland / Université Paris-Sud, Villejuif / Orsay, FR, ¹⁸Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung, TW, ¹⁹Osaka International Cancer Institute, Osaka, JP, ²⁰Emory University Winship Cancer Institute, Atlanta, US

15:33 - 15:45 **LBA17 - Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA**

T. Reungwetwattana¹, J. Gray², A. Markovets³, N. Nogami⁴, J.S. Lee⁵, B.C. Cho⁶, B. Chewaskulyong⁷, M. Majem⁸, N. Peled⁹, K. Vishwanathan³, A. Todd¹⁰, Y. Rukazenkov¹¹, M. Johnson¹⁰, C. Barrett³, J. Chmielecki³, R. Hartmaier³, S. Ramalingam¹², Ramathibodi Hospital, Bangkok, TH, ²H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ³AstraZeneca, Boston, US, ⁴Shikoku Cancer Center, Matsuyama, JP, ⁵Seoul National University Bundang Hospital, Seoul, KR, ⁶Yonsei University, Seoul, KR, ⁷Maharaj Nakorn Chiang Mai Hospital Faculty of Medicine, Chiang Mai, TH, ⁸Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁹Ben-Gurion University, Beer Sheva, IL, ¹⁰AstraZeneca, Cambridge, GB, ¹¹Astrazeneca, Macclesfield, GB, ¹²Emory University Winship Cancer Institute, Atlanta, US

15:45 - 16:00 **Invited Discussant 475O, LBA16 and LBA17**

P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES
14:30 - 16:00  Type: Educational session  Title: Precision medicine in advanced gastrointestinal cancer  Chair: Tae Won Kim, KR; Chiara Cremolini, IT

14:30 - 14:30  Session DOI

14:30 - 14:50  Clinical applications of circulating tumour DNA in advanced setting  C. Cremolini, Azienda Ospedaliera Universitaria S.Chiara, Pisa, IT

14:50 - 15:10  Targeted treatment in gastroesophageal cancer: The present and the future  S. Lorenzen, Rechts der Isar Hospital, TUM, Munich, DE

15:10 - 15:30  Precision medicine in metastatic colorectal cancer  T.W. Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR

15:30 - 16:00  Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session DOI</th>
<th>Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:30</td>
<td></td>
<td><strong>Session DOI</strong></td>
<td></td>
</tr>
<tr>
<td>14:30 - 14:35</td>
<td><strong>Introduction</strong></td>
<td><strong>Overview of the (ESMO Clinical Practice) Guidelines adaptation initiative</strong></td>
<td>G. Pentheroudakis, University Hospital of Ioannina, Ioannina, GR</td>
</tr>
<tr>
<td>14:35 - 15:15</td>
<td><strong>Outcome of the Consensus Conference on agnostic treatments</strong></td>
<td><strong>Harmonisation and international consensus? Differences in evaluation of an agnostic approach between agencies (EMA, FDA, PMDA)</strong></td>
<td>T. Yoshino, National Cancer Center Hospital East, Kashiwa, JP</td>
</tr>
<tr>
<td>15:15 - 16:00</td>
<td><strong>Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer</strong></td>
<td><strong>Conclusions</strong></td>
<td>T. Yoshino, National Cancer Center Hospital East, Kashiwa, JP</td>
</tr>
</tbody>
</table>

**Type:** Collaborative session

**Title:** ESMO - JSMO Collaborative Session: Guideline harmonisations and international consensus

Chair: George Pentheroudakis, GR; Takayuki Yoshino, JP

<table>
<thead>
<tr>
<th>Time</th>
<th>Session DOI</th>
<th>Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:30</td>
<td></td>
<td><strong>Session DOI</strong></td>
<td></td>
</tr>
<tr>
<td>14:30 - 14:35</td>
<td><strong>LBA8 - PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations</strong></td>
<td><strong>LBA8 - PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations</strong></td>
<td>S. Sandhu1, M. Hussain2, J. Mateo3, K. Fizazi4, F. Saad5, N. Shore6, K. Chi7, O. Sarto8, N. Agarwal9, D. Olmos10, A. Thiery-Vuillemin11, P. Twardowski12, N. Mehra13, C. Goessl14, J. Kang15, J. Burgents16, W. Wu17, A. Kohlmann18, C. Adelman19, J. De Bono19, 1Peter MacCallum Cancer Centre, Melbourne, AU, 2Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, US, 3Vall d'Hebron University Hospital, Barcelona, ES, 4Institut Gustave Roussy, Villejuif, FR, 5Centre Hospitalier de l’Université de Montréal/CRCCHUM, Montreal, CA, 6Carolina</td>
</tr>
</tbody>
</table>

---

**Type:** Mini Oral session

**Title:** Mini Oral session - Genitourinary tumours

Chair: Arun Azad, AU; Manuela Schmidinger, AT; Ben Tran, AU
14:35 - 14:40  Discussion led by moderator
A. Azad, Monash Medical Centre, Clayton, AU

14:40 - 14:45  LBA9 - Real-world assessment of clinical effectiveness and safety of pazopanib in patients with advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: A prospective, observational study (PARACHUTE)

R. Kanesvaran1, B. Biswas2, P. Danchaivijitr3, C.S. Lim4, B. Karabulut5, Y.F. Wong6, H. Coskun7, C.-H. Chang8, I. Cicin9, S. Ingles10, K. Slimane11, M. Erman12, 1NCCS - National Cancer Centre Singapore, Singapore, SG, 2Tata Medical Center; Kolkata, IN, 3Siriraj Hospital, Mahidol University, Bangkok, TH, 4Hospital Sultan Ismail, Johor, MY, 5Ege University Medical Faculty, Izmir, TR, 6National Cancer Institute, Putrajaya, MY, 7Akdeniz University Medical Oncology, Antalya, TR, 8China Medical university Hospital, Taichung, TW, 9Trakya University, Edirne, TR, 10Novartis Pharma AG, Basel, CH, 11Novantis, Magny Le Hongre, FR, 12Hacettepe University, Ankara, TR

14:45 - 14:50  208O - Association between kidney function, proteinuria and the risk of kidney cancer: A nationwide cohort study involving 10 million participants

J. Park1, D.W. Shin2, K. Han3, S. Chun2, 1Eulji University Hospital, Daejeon, KR, 2Samsung Medical Center, Seoul, KR, 3The Catholic University of Korea, Seoul, KR

14:50 - 15:00  Discussion led by moderator
M. Schmidinger, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

15:00 - 15:05  209O - A novel risk-based approach simulating oncologic surveillance according to smoking status after radical nephroureterectomy with upper tract urothelial carcinoma

K. Shigeta, E. Kikuchi, T. Abe, M. Hagiwara, K. Ogiwara, N. Tanaka, T. Takeda, K. Matsumoto, R. Mizuno, M. Oya, Keio University School of Medicine, Tokyo, JP

15:05 - 15:10  210O - High incidence and mortality of transitional cell carcinoma in Thai kidney transplant patients

S. Laowalalert1, N. Prasongsook2, T. Ativitasvas2, W. Liwlompaisan1, P. Thanak1, N. Techawathanawanna1, R. Kunprakant1, V. Mavichak1, 1Kidney Transplantation Institute, Praram 9 hospital, Bangkok, TH, 2Cancer center, Praram 9 hospital, Bangkok, TH
15:10 - 15:20  
**Discussion led by moderator**

B. Tran, Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, AU

| 14:30 - 16:00 | **Type:** Educational session 
**Title:** Improving cancer care in Asia  
Room 326

Chair: Gouri Shankar Bhattacharyya, IN; Soe Aung, MM |
| 14:30 - 14:30 | **Session DOI** |
| 14:30 - 14:50 | **Challenges in implementing National Cancer Control Plans in LMCs**
A. Ilbawi, WHO - World Health Organization, Geneva, CH |
| 14:50 - 15:10 | **Population-based cancer registries in Asia**
G.S. Bhattacharyya, G M Cancer Research Trust Palliative Care Unit, Salt Lake City Medical Center, Kolkata, IN |
| 15:10 - 15:30 | **Using cancer registries for drug development**
G.B. Kanakasetty, Curie Centre Of Oncology-Hcg Hospital Koramangala, Bangalore, IN |
| 15:30 - 15:50 | **How to measure and improve quality of cancer care in Asia**
S. Aung, Myanmar Center of Chemotherapy, Yangon, MM |
| 15:50 - 16:00 | **Discussion** |

| 15:00 - 16:00 | **Type:** Mini Oral session 
**Title:** Mini Oral session - Developmental and precision medicine  
Room 311

Chair: Noboru Yamamoto, JP; Fabrice André, FR |
| 15:00 - 15:00 | **Session DOI** |
| 15:00 - 15:05 | **363O - Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)**

D.H. Lee¹, V. Subbiah², J. Gainor³, M. Taylor⁴, V. Zhu⁵, R. Doebeler⁶, G. Lopes⁷, C. Baik⁸, E. Garralda⁹, S. Gadgeel¹⁰, D.-W. Kim¹¹, C. Turner¹², M. Palmer¹², S. Miller¹³, G. Curigliano¹⁴, ¹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³Massachusetts General Hospital, Boston, US, ⁴OHsu Knight Cancer Institute - Northwest Portland, Portland, US, ⁵UC Irvine, Orange, US, ⁶University of Colorado, Aurora, US, ⁷University of Miami Sylvester Comprehensive Cancer Center, Miami, US, ⁸University of Washington/Seattle Cancer Care Alliance, Seattle, US, ⁹Vall d’Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ¹⁰University of Michigan, Ann Arbor, US,
364O - Clinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC

L. Mezquita1, D. Planchard1, M. Doria Suarez1, M. Aldea1, C. Naltet1, V. Lamberts1, M. Grecea1, P. Martin-Romano1, F. De Kievit2, C. Jovelet1, L. Lacroix1, J. Remon Masip3, P. Lavaud1, A. Gazzah1, C. Morris2, K. Howarth2, E. Green2, G. Vassal1, C. Massard4, B. Besse1, 1Institut Gustave Roussy, Villejuif, FR, 2Inviva Ltd, Cambridge, GB, 3Vall d’Hebron University Hospital, Barcelona, ES, 4Centre Oscar Lambret, Lille, FR, 5Hospital Clinic, Barcelona, ES, 6Istituto Europeo di Oncologia, Milan, IT

365O - Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

D. Hyman1, D.S.W. Tan2, C. Van Tilburg3, C. Albert4, B. Geoerger5, A. Farago6, T. Laetsch7, S. Kummar8, F. Doz9, U. Lassen10, S. Dubois11, R. Mcdermott12, L. Mascarenhas13, J. Berlin14, E. Rudzinski15, S. Nanda16, B. Childs16, A. Drilon17, D. Hong18, 1Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US, 2National Cancer Center Singapore, Singapore, SG, 3Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, DE, 4University of Washington, Fred Hutchinson Cancer Research Center, Seattle, US, 5Université Paris-Sud, Université Paris-Saclay, Villejuif, FR, 6Massachusetts General Hospital Cancer Center, Boston, US, 7Southwestern Medical Center/Children’s Health, Dallas, US, 8Stanford University, Palo Alto, US, 9Paris Descartes University, Paris, FR, 10Rigshospitalet, Copenhagen, DK, 11Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, US, 12St. Vincent's University Hospital and Cancer Trials Ireland, Dublin, IE, 13University of Southern California, Keck School of Medicine, Los Angeles, US, 14Vanderbilt University, Nashville, US, 15Seattle Children’s Hospital and University of Washington Medical Center, Seattle, US, 16Bayer HealthCare Pharmaceuticals, Inc., Whippany, US, 17Memorial Sloan Kettering Cancer Center, New York, US, 18MD Anderson Cancer Center, Houston, US

Discussion led by moderators

N. Yamamoto1, F. Andra2, 1National Cancer Center Hospital, Tokyo, JP, 2Gustave Roussy - Cancer Campus, Villejuif, FR

61O - Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours

15:35 - 15:40

620 - Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study

K. Park1, E. Felip2, R. Veillon3, A. Cortot4, J. Mazieres5, H. Sakai6, N. Reinmuth7, S. Viter8, Y.-M. Chen9, J.-Y. Han10, T.-W. Jang11, M. Morise12, T. Sakamoto13, T. Tokito14, B.C. Cho15, R. Bruns16, J. Scheele16, J. Straub16, X. Le17, P. Paik18, 1Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, 2Vall d’Hebron University Hospital, Barcelona, ES, 3Hospital Universitaire de Bordeaux, Pessac, FR, 4Lille University Hospital, Univ. Lille, Lille, FR, 5CHU de Toulouse-Hopital Larrey, Toulouse, FR, 6Saitama Cancer Center, Saitama, JP, 7Asklepios Lung Clinic, Munich-Gauting, DE, 8Dr Rosell Oncology Institute, Dexeus University Hospital, QuironSalud Group, Barcelona, ES, 9Taipei Veterans General Hospital, Taipei, TW, 10Research Institute, National Cancer Center, Gyeonggi-do, KR, 11Kosin University Gospel Hospital, Busan, KR, 12Nagoya University, Graduate School of Medicine, Nagoya, JP, 13Tottori University Hospital, Tottori, JP, 14Kurume University Hospital, Fukuoka-Ken, JP, 15Yonsei University, Seoul, KR, 16Merck KGaA, Darmstadt, DE, 17MD Anderson Cancer Center, The University of Texas, Houston, US, 18Memorial Sloan Kettering Cancer Center, New York, US

15:40 - 15:45

630 - NRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib


15:45 - 16:00

Discussion led by moderators

N. Yamamoto1, F. André2, 1National Cancer Center Hospital, Tokyo, JP, 2Gustave Roussy - Cancer Campus, Villejuif, FR
<table>
<thead>
<tr>
<th>Time</th>
<th>Type</th>
<th>Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:30</td>
<td>Young Oncologist session</td>
<td>Meet your mentor</td>
<td>Fatima Cardoso, PT; Florian Lordick, DE; Jyoti Bajpai, IN; John Haanen, NL; Marina Garassino, IT</td>
</tr>
<tr>
<td>16:30 - 18:00</td>
<td>Educational session</td>
<td>Precision immunotherapy</td>
<td>Han Chong Toh, SG; Emanuela Romano, FR</td>
</tr>
<tr>
<td>16:30 - 16:30</td>
<td>Session DOI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td>Basic concepts</td>
<td>arguing for the use of neoadjuvant immunotherapy</td>
<td>M. Teng, QIMR Berghofer Medical Research Institute, Brisbane, AU</td>
</tr>
<tr>
<td>16:45 - 17:00</td>
<td>Precision medicine in</td>
<td>cellular therapies: How can we identify patients who would benefit most</td>
<td>A. Gros, Vall d’Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES</td>
</tr>
<tr>
<td>17:00 - 17:15</td>
<td>New biomarkers for</td>
<td>checkpoint inhibitor therapy</td>
<td>J. Desai, Peter MacCallum Cancer Centre, Melbourne, AU</td>
</tr>
<tr>
<td>17:15 - 17:30</td>
<td>Basic concepts in</td>
<td>overcoming adaptive immune resistance</td>
<td>J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL</td>
</tr>
<tr>
<td>17:30 - 18:00</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 - 18:00</td>
<td>Proffered Paper session</td>
<td>Mixed Proffered paper session - Gastrointestinal tumours &amp; Head and neck cancers</td>
<td>Sjoukje Oosting, NL; Anthony T C Chan, HK; Takayuki Yoshino, JP; Sylvie Lorenzen, DE</td>
</tr>
<tr>
<td>16:30 - 16:30</td>
<td>Session DOI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td>LBA7</td>
<td>Randomised efficacy and safety results for atezolizumab (Atezo) &amp; bevacizumab (Bev) in patients (pts) with previously untreated, unreseetable hepatocellular carcinoma (HCC)</td>
<td>C.-H. Hsu, M. Lee, K.-H. Lee, K. Numata, S. Stein, W. Verret, S. Hack, J. Spahn, B. Liu, C. Huang, R. He, B.-Y. Ryoo, 1National Taiwan University Hospital, Taipei City, TW; 2University of North Carolina at Chapel Hill, Chapel Hill, US; 3Seoul National University Hospital, Seoul, KR; 4Yokohama City University Medical Center, Yokohama, JP; 5Yale School of Medicine, New Haven, US; 6Genentech, Inc., South San Francisco, US; 7Roche Product Development, Shanghai, CN; 8Georgetown University Medical Center;</td>
</tr>
</tbody>
</table>
Invited Discussant LBA7
S.P. Choo, NCCS - National Cancer Centre Singapore, Singapore, SG

16:55 - 17:10
2860 - Phase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis
N. Ngamphaiboon1, K. Tanaka2, R.-L. Hong3, W.Z. Wan Ishak4, C.-J. Yen5, V. Sriuranpong6, S. Takahashi7, V. Srimuninnimit8, S.-P. Yeh9, N. Oridate10, M.-H. Yang11, N. Nohata12, Y. Koh13, A. Roy14, B. Gumuscu15, R. Swaby16, M. Tahara17, 1Ramathibodi Hospital, Bangkok, TH, 2Kinki University School of Medicine, Osaka, JP, 3National Taiwan University Hospital, Taipei City, TW, 4University Malaya, Kuala Lumpur, MY, 5National Cheng Kung University, Tainan, TW, 6Chulalongkorn University Faculty of Medicine, Pathumwan, TH, 7Cancer Institute Hospital of JFCR, Tokyo, JP, 8Siriraj Piyamaharajkarun Hospital, TH, 9China Medical University Hospital, Taichung, TW, 10Yokohama City University Graduate School of Medicine, Yokohama, JP, 11Taipei Veterans General Hospital, Taipei, TW, 12MSD k.k., Tokyo, JP, 13Shizuoka Cancer Center, Shizuoka, JP, 14Merck & Co., Inc., Kenilworth, US, 15Merck, North Wales, US, 16Merck & Co Inc, North Wales, US, 17National Cancer Center Hospital East, Kashiwa, JP

Invited Discussant 2860
B. Ma, The Chinese University of Hong Kong, Shatin, HK

17:10 - 17:20
2870 - Development and validation of a risk model integrating plasma Epstein-Barr virus DNA (EBV DNA) level and TNM stage for stratification of nasopharyngeal cancer (NPC) to adjuvant therapy
E. Hui1, W.F. Li2, B.B.Y. Ma3, F. Mo3, W.K.J. Lam3, K.C.A. Chan3, Q.H. Ai3, A.D. King3, C.H. Wong3, R. Guo2, D.M.C. Poon3, M. Tong3, L. Li3, T.K.H. Lau3, K.C.W. Wong3, D.C.M. Lam3, Y.M.D. Lo3, J. Ma2, A.T.C. Chan3, 1The Chinese University of Hong Kong, Shatin, HK, 2Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, CN, 3State Key Laboratory of Translational Oncology, Sir YK Pao Cancer Center, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, HK

Invited Discussant 2870
M.L.K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td><strong>Session DOI</strong></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td><strong>Challenges of different genomic platforms used to select patients</strong></td>
<td>R. Bernards, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL</td>
</tr>
<tr>
<td>16:50</td>
<td><strong>Basket trial design in tumour agnostic drug development</strong></td>
<td>C. Dittrich, Angewandte Krebsforschung – Institution für Translationale Forschung Wien (ACR-ITR VIEnna), Vienna, AT</td>
</tr>
<tr>
<td>17:10</td>
<td><strong>Targeted therapy with TRK inhibitors in tumours with NTRK fusion</strong></td>
<td>D.S.W Tan, National Cancer Center Singapore, Singapore, SG</td>
</tr>
<tr>
<td>17:50</td>
<td><strong>Basket trials in rare cancer in Japan (and an overview of Asia)</strong></td>
<td>K. Yonemori, National Cancer Center Hospital, Tokyo, JP</td>
</tr>
<tr>
<td>18:00</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
</tbody>
</table>
16:30 - 16:30  **Session DOI**

16:30 - 16:35  **Introduction**
E.G.E. De Vries, University Hospital Groningen (UMCG), Groningen, NL

16:35 - 16:55  **ESMO Magnitude of Clinical Benefit Scale (MCBS): Present status and online tools**
E.G.E. De Vries, University Hospital Groningen (UMCG), Groningen, NL

16:55 - 17:15  **Precision medicine and ESMO Scale for Clinical Actionability of molecular Target (ESCAT) biomarkers**
F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

17:15 - 17:35  **Landscape of phase I oncology studies in China**
Z. Li, Sun Yat-sen University Cancer Center, Guangzhou, CN

17:35 - 17:55  **Development of biomarker driven clinical studies in China**
X. Zhang, Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN

17:55 - 18:00  **Conclusions**
J. Li, Merck Serono Pharmaceutical R&D Co, Beijing, CN
16:30 - 18:00  Type: Multidisciplinary tumour board  Summit 2
Title: The multi-modality approach to sarcomas: Balancing cure and quality of life
Chair: Anastasia Constantinidou, CY

16:30 - 16:30  Session DOI

16:30 - 16:32  Introduction
A. Constantinidou, Bank of Cyprus Oncology Centre, Nicosia, CY

16:32 - 16:47  Localized disease: Retroperitoneal
A. Miah, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

16:47 - 17:02  Locally advanced disease
M. Endo, Kyushu University - Graduate School of Medical Sciences - Faculty of medical Sciences, Fukuoka, JP

17:02 - 17:17  Oligo metastatic (focusing on lung metastases)
A. Constantinidou, Bank of Cyprus Oncology Centre, Nicosia, CY

17:17 - 17:32  Multi-focal metastatic
F. Gracieux Jr., Philippine General Hospital, Manila, PH

17:32 - 17:57  Panel discussion

17:57 - 18:00  Conclusions
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 16:30 - 18:00 | **Type:** Special Session  
**Title:** Biosimilars use in oncology: Clarifying concepts  
Chair: Josep Tabernero, ES |
| 16:30 - 16:30 | **Session DOI** |
| 16:30 - 16:35 | **Welcoming remarks**  
J. Tabernero, Vall d’Hebron University Hospital, Barcelona, ES |
| 16:35 - 16:55 | **Biosimilars use in clinical practice (Example of the EU)**  
R. Giuliani, The Christie NHS Foundation Trust, Manchester, GB |
| 16:55 - 17:15 | **Clarifying immunogenicity, switching & extrapolation in oncology biosimilars**  
G.S. Bhattacharyya, G M Cancer Research Trust Palliative Care Unit, Salt Lake City Medical Center, Kolkata, IN |
| 17:15 - 17:35 | **Do biosimilars really save cost in practice?**  
P. Basumatary, Singapore, SG |
| 17:35 - 17:55 | **Panel discussion** |
| 17:55 - 18:00 | **Concluding remarks**  
J. Tabernero, Vall d’Hebron University Hospital, Barcelona, ES |
| 16:30 - 17:30 | **Type:** Mini Oral session  
**Title:** Mini Oral session - Supportive and palliative care  
Chair: Matti Aapro, CH; Masanori Mori, JP; Kiley Loh, SG |
| 16:30 - 16:30 | **Session DOI** |
| 16:30 - 16:35 | **419O - Olanzapine combined with 5-HT3 RA plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in cancer patients: A systematic review and meta-analysis of randomized controlled trials**  
J.-G. Zhou¹, S.-H. Jin², H. Ma³, ¹Zunyi Medical College Affiliated Hospital, Zunyi, CN, ²Zunyi Medical College Affiliated Stemmatological Hospital, Zunyi City, CN, ³Zunyi Medical College Affiliated Hospital, Zunyi City, CN |
| 16:35 - 16:40 | **420O - Role of cardioprotective therapies for prevention of cardiotoxicity in breast cancer: A systematic review and meta-analysis**  
Y.C. Kong¹, M. Sener², S. Subramaniam³, N. Bhoo-Pathy⁴, ¹National Clinical Research Centre, Kuala Lumpur, MY, ²Erasmus University Medical Centre, Rotterdam, NL, ³Ministry of Health, Setia Alam, MY, ⁴University Malaya Medical Center, Kuala Lumpur,
16:40 - 16:50 **Discussion led by moderator**
M. Aapro, Clinique de Genolier, Genolier, CH

16:50 - 16:55 **421O - Effects of an educational program on knowledge and quality of life for Korean breast cancer survivors: A prospective cohort study**
J. Cheon, J. Bae, Y. Choi, B.K. Ko, J.S. Kim, C.R. Kim, J.H. Kim, S.-J. Koh, Ulsan University Hospital, Ulsan, KR

16:55 - 17:00 **422O - Needs of cancer patients in an Asian setting**
N. Bhoo-Pathy¹, Y.C. Kong², R.S. Bustamam³, A. Matin Mellor Bin⁴, H. Zaharah⁵, N.A. Taib¹, G.F. Ho¹, C.H. Yip⁴, ¹University Malaya Medical Center, Kuala Lumpur, MY, ²University of Malaya, Kuala Lumpur, MY, ³Kuala Lumpur Hospital, Kuala Lumpur, MY, ⁴Sime Darby Medical Centre Subang Jaya, Subang Jaya, MY, ⁵National Cancer Institute, Putrajaya, MY

17:00 - 17:10 **Discussion led by moderator**
K. Loh, Singapore Society of Oncology, Singapore, SG

17:10 - 17:15 **351O - The FAFA (FAn on FAce) trial: A randomized clinical trial on the effect of a fan blowing air on the face to relieve dyspnea in Filipino patients with terminal cancer**
F.I. Ting, C.E. Barbon, S. Estreller, H.M.J. Strebel, University of the Philippines - Philippine General Hospital, Manila, PH

17:15 - 17:20 **352O - Parenting experiences of cancer patients with minor children and their conversations about the possibility of death: A cross-sectional web-based survey for the online cancer community**
Y. Usui¹, K. Kosugi¹, Y. Nishiguchi², T. Miura¹, D. Fujisawa³, Y. Uehara¹, T. Kawaguchi⁴, K. Izumi⁵, J. Takehana⁵, Y. Matsumoto¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²General Incorporated Association Cancer Parents, Tokyo, JP, ³Keio University School of Medicine, Tokyo, JP, ⁴Tokyo University of Pharmacy and Life Sciences, Hachioji, JP, ⁵Medilead Inc, Tokyo, JP

17:20 - 17:30 **Discussion led by moderator**
M. Mori, Seirei Christopher University, Hamamatsu, JP
### 23-11-2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Type</th>
<th>Title</th>
<th>Location</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>08:00 - 08:45</strong></td>
<td><strong>Challenge Your Expert session</strong></td>
<td><strong>Immunotherapy in gastroesophageal cancers: Present and future</strong></td>
<td>Hall 404</td>
<td>Kei Muro, JP</td>
</tr>
<tr>
<td>08:00 - 08:00</td>
<td>Session DOI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00 - 08:15</td>
<td><strong>Immunotherapy in gastroesophageal cancers: Present and future</strong></td>
<td>F. Lordick, Universitätsklinikum Leipzig - Gefäßmedizinisches Zentrum, Leipzig, DE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:15 - 08:45</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>08:00 - 08:45</strong></td>
<td><strong>Challenge Your Expert session</strong></td>
<td><strong>To use or not to use: Genomics assays in guiding adjuvant treatment of HR positive breast cancer</strong></td>
<td>Hall 407</td>
<td>Soo Chin Lee, SG; Giuseppe Curigliano, IT</td>
</tr>
<tr>
<td>08:00 - 08:00</td>
<td>Session DOI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00 - 08:15</td>
<td><strong>To use or not to use: Genomics assays in guiding adjuvant treatment of HR positive breast cancer</strong></td>
<td>F. Cardoso, Champalimaud Foundation Cancer Center, Lisbon, PT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:15 - 08:45</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>08:00 - 08:45</strong></td>
<td><strong>Challenge Your Expert session</strong></td>
<td><strong>How to manage toxicity of immunotherapy</strong></td>
<td>Room 324</td>
<td>Mohamad Farid Harun Rashid, SG</td>
</tr>
<tr>
<td>08:00 - 08:00</td>
<td>Session DOI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00 - 08:15</td>
<td><strong>How to manage toxicity of immunotherapy</strong></td>
<td>J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:15 - 08:45</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Type: Challenge Your Expert session**
**Title: Management of irAEs in patients from Asia**

Chair: Emanuela Romano, FR

08:00 - 08:00  
Session DOI

08:00 - 08:25  
**Management of irAEs in patients from Asia**

H.-F. Kao, National Taiwan University Hospital, New Taipei city, TW

08:25 - 08:45  
Discussion

09:00 - 10:30  
**Type: Proffered Paper session**
**Title: Proffered paper session - Breast cancer**

Chair: Rebecca Dent, SG

09:00 - 09:00  
Session DOI

09:00 - 09:12  
**25O - Effects of immune architecture on response to adjuvant capecitabine in triple negative breast cancer (FinXX trial)**

D. Hinerfeld¹, S. Chumsri², K. Asleh³, H.A. Brauer⁴, J. Kacherqus², S. Lauttia⁵, H. Lindman⁶, T. Nielsen³, H. Joensuu⁷, A. Thompson², ¹NanoString Technologies, Seattle, US, ²Mayo Clinic, Jacksonville, US, ³The University of British Columbia, Vancouver, CA, ⁴Nanostring Technologies, Seattle, CA, ⁵University of Helsinki, Helsinki, FI, ⁶Uppsala University, Uppsala, SE, ⁷Helsinki University Central Hospital (HUCH), Helsinki, FI

09:12 - 09:24  
**LBA6 - First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer**

B. Xu¹, Q. Zhang², T. Sun³, W. Li⁴, Y. Teng⁵, X. Hu⁶, I. Bondarenko⁷, H. Adamchuk⁸, Y. Li⁹, B. Shan⁹, J. Cheng⁹, T. Peng⁹, X. Wang⁹, Y. Chen⁹, W. Jiang⁹, S. Liu⁹, X. Zhang⁹, E. Liu⁹, A. Luk¹⁰, Q. Wang⁹, ¹Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, ²Harbin Medical University Cancer Hospital, Harbin, CN, ³Liaoning Cancer Hospital and Institution., Shenyang, CN, ⁴The first Bethune Hospital of Jilin University, Shenyang, CN, ⁵The first hospital of China Medical University, Shenyang, Shenyang, CN, ⁶Fudan University Shanghai Cancer Center, Shanghai, CN, ⁷CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipo, UA, ⁸CI Kryvyi Rih Oncological Dispensary of DRC, Dnipropetrovsk, UA, ⁹Shanghai Henlius Biotech, Inc., Shanghai, CN, ¹⁰Shanghai Henlius Biopharm, Shanghai, CN

09:24 - 09:34  
**Invited Discussant 25O and LBA6**

S.-B. Kim, Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR
10:08 - 10:20 380 - Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): Data from phase III EMBRACA

K.-H. Lee¹, S.-B. Kim², J. Sohn³, A. Goodwin⁴, T. Usari⁵, S. Lanzalone⁵, Y.-H. Im⁶, ¹Seoul National University Hospital, Seoul, KR, ²Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ³Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, ⁴Concord Clinical School, University of Sydney, Sydney, AU, ⁵Pfizer, Milan, IT, ⁶Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR

10:20 - 10:30 Invited Discussant 370 and 380

Y.S. Yap, NCCS - National Cancer Centre Singapore, Singapore, SG
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 09:00 - 10:30| **Type:** Educational session  
 **Title:** Precision medicine for GU cancer  
 **Chair:** Arun Azad, AU; Cora Sternberg, US |
| 09:00 - 09:00| Session DOI                                                            |
| 09:00 - 09:25| **Precision Medicine in prostate cancer**  
 **C. Sternberg**, Weill Cornell Medicine, New York, US |
| 09:25 - 09:50| **Molecular dissection on bladder cancer**  
 **B. Tran**, Peter MacCallum Cancer Centre, Melbourne, AU |
| 09:50 - 10:15| **mRCC treatment in 2019: current paradigms and future directions**  
 **M. Schmidinger**, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT |
<p>| 10:15 - 10:30| Discussion                                                            |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/DOI</th>
<th>Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 10:30</td>
<td><strong>Type: ESMO Clinical Practice Guidelines session</strong></td>
<td><strong>Title: ESMO Clinical Practice Guidelines session</strong></td>
<td>Chair: Andres Cervantes, ES; George Pentheroudakis, GR</td>
</tr>
<tr>
<td>09:00 - 09:00</td>
<td>Session DOI</td>
<td><strong>Introduction</strong></td>
<td>G. Pentheroudakis, University Hospital of Ioannina, Ioannina, GR</td>
</tr>
<tr>
<td>09:05 - 09:35</td>
<td>Cervical cancer</td>
<td><strong>Cervical cancer</strong></td>
<td>G. Kenter¹, S. Gupta², ¹Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ²Tata Memorial Hospital Centre, Mumbai, IN</td>
</tr>
<tr>
<td>09:35 - 09:45</td>
<td>Questions and answers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:45 - 10:15</td>
<td>Immunotherapy in advanced NSCLC</td>
<td><strong>Immunotherapy in advanced NSCLC</strong></td>
<td>C. Baldini¹, M.-J. Ahn², ¹Gustave Roussy, Villejuif, FR, ²Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR</td>
</tr>
<tr>
<td>10:15 - 10:25</td>
<td>Questions and answers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:25 - 10:30</td>
<td>Conclusion</td>
<td><strong>Conclusion</strong></td>
<td>A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/DOI</th>
<th>Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 10:00</td>
<td><strong>Type: Mini Oral session</strong></td>
<td><strong>Title: Mini Oral session - Head and neck cancer</strong></td>
<td>Chair: Bhumsuk Keam, KR; Lisa Licitra, IT; Joseph Wee, SG</td>
</tr>
<tr>
<td>09:00 - 09:00</td>
<td>Session DOI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00 - 09:05</td>
<td>2880 - Molecular profiling and treatment patterns of advanced salivary gland cancers in head and neck region</td>
<td>2880 - Molecular profiling and treatment patterns of advanced salivary gland cancers in head and neck region</td>
<td>V. Talreja¹, V. Patil², V. Noronha¹, A. Joshi¹, N. Menon³, A. Chougule¹, M. Menon¹, N. Mittal¹, K. Prabhsh¹, ¹Tata Memorial Hospital, Mumbai, IN, ²Tata Memorial Hospital Centre, Mumbai, IN, ³Prince Aly Khan Hospital, Mumbai, IN</td>
</tr>
<tr>
<td>09:05 - 09:10</td>
<td>2890 - Spectrum of mitochondrial genomic variation in parathyroid neoplasms by ultra-deep targeted DNA sequencing</td>
<td>2890 - Spectrum of mitochondrial genomic variation in parathyroid neoplasms by ultra-deep targeted DNA sequencing</td>
<td>Y. Hu¹, X. Zhang¹, O. Wang¹, X. Xing¹, M. Cui¹, M. Wang¹, C. Song², Q. Liao¹, Y. Zhao¹, ¹PUMCH-Peking Union Medical College Hospital (East), Beijing, CN, ²Novogene Bioinformatics Institute, Beijing, CN</td>
</tr>
</tbody>
</table>
**09:10 - 09:20**  
**Discussion led by moderator**  
B. Keam, Seoul National University Hospital, Seoul, KR

**09:20 - 09:25**  
**2900 - Long-term results of phase II trial of reduced modified clinical target volume in low-risk nasopharyngeal carcinoma treated with intensity modulated radiotherapy**  
J. Miao¹, M. Di¹, Y. Cao², L. Wang¹, W. Xiao¹, M. Zhu¹, B. Chen¹, S. Huang¹, F. Han¹, X. Deng¹, Y. Xiang¹, M. L. K. Chua³, X. Guo¹, C. Zhao¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, CN, ³NCCS - National Cancer Centre Singapore, Singapore, SG

**09:25 - 09:30**  
**2910 - Survival outcome and prognostic factors of patients with nasopharyngeal cancer in Yogyakarta Indonesia**  
S. Hutajulu¹, D. Howdon², K. Taroeno Hariadi¹, M. Hardianti¹, I. Purwanto¹, S. Indrasari¹, C. Herdini¹, B. Hariwiyanto¹, A. Ghozali¹, H. Kusumo¹, W. Dhamiyati¹, S. Danarti¹, I. Tan³, J. Kurnianda¹, M. Allsop², ¹Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, ID, ²University of Leeds, Leeds, GB, ³Maastricht University Medical Center, Maastricht, Maastricht, NL

**09:30 - 09:40**  
**Discussion led by moderator**  
J. Wee, NCCS - National Cancer Centre Singapore, Singapore, SG

**09:40 - 09:45**  
**2920 - 90-day mortality in head and neck cancer after concurrent chemoradiotherapy**  
S.-Y. Wu, Taipei Medical University - Municipal Wan Fang Hospital, Taipei, TW

**09:45 - 09:50**  
**2930 - Survival outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting**  
F. Pontes¹, I. Rego¹, I. Domingues², L. Pinto³, R. Garcia¹, M. Teixeira², L. Khoury¹, T. Serra¹, M. Mariano⁴, G. Sousa², ¹Portuguese Oncology Institute of Coimbra, Coimbra, PT, ²Instituto Português Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT, ³Centro Hospitalar e Universitário de Coimbra, Coimbra, PT, ⁴Instituto Portugueses Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT

**09:50 - 10:00**  
**Discussion led by moderator**  
L. Licitra, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT
09:00 - 10:30  Type: Collaborative session
Title: ESMO – KSMO Collaborative Session: Going towards an agnostic treatment / approach
Chair: Kyong Hwa Park, KR; Josep Tabernero, ES

09:00 - 09:00  Session DOI

09:00 - 09:05  Introduction
K.H. Park, Korea University Anam Hospital, Seoul, KR

09:05 - 09:25  The concept of agnostic treatment and its impact in clinical trial design
A. Hollebecque, Institut Gustave Roussy, Villejuif, FR

09:25 - 09:45  ESMO recommendations for detecting MSI and TRK fusion (using NGS?)
C. Marchiò, IRCCS - Istituto di Candiolo - FPO, Candiolo, IT

09:45 - 10:05  Innovation of NGS driven basket trial (K-MASTER)
K.H. Park, Korea University Anam Hospital, Seoul, KR

10:05 - 10:25  DDR pathway with gBRCA mutation in Korean cancer patients
S.-A. Im, Seoul National University Hospital, Seoul, KR

10:25 - 10:30  Conclusions
J. Tabernero, Vall d’Hebron University Hospital, Barcelona, ES
09:00 - 10:30  Type: Educational session  
Title: The interface between histopathology, genomics and therapy  
Chair: Tom Wei-Wu Chen, TW; Silvia Stacchiotti, IT

09:00 - 09:00  Session DOI

09:00 - 09:15  New Insights in pathology: The WHO classification  
A. Yoshida, National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP

09:15 - 09:30  Genomic-guided precision therapy for soft tissue sarcoma  
TW-W. Chen, NTU - National Taiwan University - College of Medicine, Taipei City, TW

09:30 - 09:45  Surgical perspective on improved pathological classification of tumours  
M. Teo, SGH-Singapore General Hospital/Singhealth-Academia, Singapore, SG

09:45 - 10:00  Medical oncology on improved pathological classification of tumours  
S. Stacchiotti, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

10:00 - 10:30  Discussion
09:00 - 09:50  
**Type:** Mini Oral session  
**Title:** Mini Oral session - Public policy  
Chair: Fatima Cardoso, PT; Gouri Shankar Bhattacharyya, IN; Alexandru Eniu, RO

09:00 - 09:00  
**Session DOI**

09:00 - 09:05  
**391O** - Setting up breast services improvements and learning bridges in Kyrgyzstan: The SILK project  
O. Pagani¹, M. Del Grande¹, F. Peccatori², C. De Wolf³, G. Pruneri⁴, L. Mattei⁵, A. Richetti¹, S. Presilla¹, T. Sabyrbekova⁶, N. Bakirova⁶, T. Soldak⁷, D. Abdyladieva⁸, T. Abdyladieva⁸, I. Aliev⁸, R. Aralbaev⁸, S. Naizabekova⁸, B. Shaimurzaeva⁸, O. Shimkina⁸, R. Marti⁹, F. Cavalli¹⁰, ¹OSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH, ²European School of Oncology, Milan, IT, ³Development et évaluation des politiques de santé (ADSAN), Onex, CH, ⁴National Cancer Institute, Milan, IT, ⁵Istituto Cantonale Patologia, Locarno, CH, ⁶Public Foundation “Ergene”, Bishkek, KG, ⁷Resource & Policy Exchange, Inc, Delhi, NY, US, ⁸National Center of Oncology and Haematology, Bishkek, KG, ⁹Cancer League, Bern, CH, ¹⁰European School of Oncology, Bellinzona, CH

09:05 - 09:10  
**392O** - Treatment outcomes of colorectal cancer patients enrolled in a comprehensive benefits program of the National Health Insurance System in the Philippines: Data from the program pilot site  
D.B. Sacdalan¹, F.I. Ting², M.M. Tampo², H.I. Monroy², D. Sacdalan¹, ¹Philippine General Hospital, Manila, PH, ²University of the Philippines - Philippine General Hospital, Manila, PH

09:10 - 09:15  
**393O** - Timeliness of lung cancer treatment utilizing the rapid access lung cancer clinic in a regional Australian Hospital  
N. Chau, Epworth Healthcare, Melbourne, AU

09:15 - 09:20  
**537O** - Evaluating medical oncology outcomes: An Asian lung cancer study  
L. Mery¹, F. Bray¹, P. Sripan², R.A. Soo³, H. Storm⁴, R.A. Stahe³⁵, ¹International Agency for Research on Cancer, Lyon, FR, ²Chang Mai University - Faculty of Medicine - Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, TH, ³National University Hospital, ¹¹OSI, Singapore, SG, ⁴The Danish Cancer Society, Copenhagen, DK, ⁵University Hospital Zürich, Zurich, CH

09:20 - 09:45  
**Discussion led by moderators**  
F. Cardoso¹, G.S. Bhattacharyya², ¹Champalimaud Foundation Cancer Center, Lisbon, PT, ²G M Cancer Research Trust Palliative Care Unit, Salt Lake City Medical Center, Kolkata, IN

10:00 - 10:45  
**Type:** Young Oncologist session  
**Title:** Vesalius talk: How to prevent and deal with burn out in oncology  
Chair: Guillem Argiles Martinez, ES; Alena Gros, ES; Ravindran Kanesvaran, SG
11:00 - 11:00  
**Session DOI**

11:00 - 11:15  
**LBA1 - Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial**

R. Camidge\(^1\), H. R. Kim\(^2\), M.-J. Ahn\(^3\), J.C.-H. Yang\(^4\), J.-Y. Han\(^5\), M.J. Hochmair\(^6\), K.H. Lee\(^7\), A. Delmonte\(^8\), M.R. Garcia Campelo\(^9\), D.-W. Kim\(^10\), F. Griesinger\(^11\), E. Felip\(^12\), R. Califano\(^13\), A. Spira\(^14\), S. Gettinger\(^15\), M.-J. Ahn\(^3\), J.-Y. Han\(^5\), S. Popat\(^18\),

\(^1\)University Of Colorado Hospital, Aurora, US, \(^2\)Yonsei University Severance Hospital, Seoul, KR, \(^3\)Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, \(^4\)National Taiwan University Hospital and National Taiwan University Cancer Center, 100, Taipei, TW, \(^5\)National Cancer Center, Goyang, KR, \(^6\)Otto Wagner Hospital, Sanatoriumstrasse 2, 1140, Vienna, AT, \(^7\)Chungbuk National University Hospital, Cheongju, KR, \(^8\)Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, \(^9\)Complejo Hospitalario Universitario A Coruna Hospital Teresa Herrera-Materno Infantil, Coruna, ES, \(^10\)Seoul National University Hospital, Seoul, KR, \(^11\)Pius-Hospital Oldenburg, University of Oldenburg, Oldenburg, DE, \(^12\)Vall d'Hebron University Hospital, Barcelona, ES, \(^13\)The Christie NHS Foundation Trust, Manchester, GB, \(^14\)Virginia Cancer Specialists and US Oncology Research, The Woodlands, US, \(^15\)Yale Cancer Center, New Haven, US, \(^16\)University Hospital of Parma, Parma, IT, \(^17\)Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, US, \(^18\)Royal Marsden Hospital NHS Foundation Trust, London, GB

11:15 - 11:25  
**Invited Discussant LBA1**

S.-H. Ou, UCI Health Chao Family Comprehensive Cancer Center, Orange, US

11:25 - 11:40  
**LBA2 - TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI**

J.-Y. Han\(^1\), L. Sequist\(^2\), M.-J. Ahn\(^3\), B.C. Cho\(^4\), H. Yu\(^5\), S.-W. Kim\(^6\), J.C.-H. Yang\(^7\), J.S. Lee\(^8\), W.-C. Su\(^9\), D. Kowalski\(^10\), S. Orlov\(^11\), M. Cantarini\(^12\), R. Verheijen\(^13\), A. Mellemgaard\(^13\), P. Frewer\(^13\), X. Ou\(^13\), G. Oxnard\(^14\), \(^1\)National Cancer Center, Goyang, KR, \(^2\)Memorial Sloan Kettering Cancer Center, New York, US, \(^3\)Massachusetts General Hospital, Boston, US, \(^4\)Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, \(^5\)Yonsei University, Seoul, KR, \(^6\)Memorial Sloan Kettering Cancer Center, New York, US, \(^7\)Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, \(^8\)National Taiwan University Hospital and National Taiwan University Cancer Center, 100, Taipei, TW, \(^9\)Seoul National University Bundang Hospital, Seoul, KR, \(^10\)National Cheng Kung University Hospital, Tainan, TW, \(^11\)Oncology Centre and Institute, Wasaw, PL, \(^12\)Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, RU, \(^13\)Sandigrey Clinical Limited, Sandiway, GB, \(^14\)AstraZeneca, Cambridge, GB

11:40 - 11:50  
**Invited Discussant LBA2**
D. Planchard, Institut Gustave Roussy, Villejuif, FR

11:50 - 12:05

**LBA3 - IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) & bevacicuzumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)**

A.-L. Cheng¹, S. Qin², M. Ikeda³, P. Galle⁴, M. Ducreux⁵, A. Zhu⁶, T.Y. Kim⁷, M. Kudo⁸, V. Breder⁹, P. Merle¹⁰, A. Kaseb¹¹, D. Li¹², W. Verret¹³, Z. Xu¹⁴, S. Hernandez¹⁵, J. Liu¹⁶, C. Huang¹⁷, S. Mulla¹⁸, H.Y. Lim¹⁹, R. Finn²⁰, ¹National Taiwan University Hospital, Taipei City, TW, ²Nanjing Bayi Hospital, Nanjing, CN, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴Universitätsmedizin Mainz, Mainz, DE, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR, ⁶Massachusetts General Hospital, Boston, US, ⁷SNUH-Seoul National University Hospital, Seoul, KR, ⁸Kindai University - Faculty of Medicine, Osaka, JP, ⁹FSBI-N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ¹⁰Hôpital de la Croix-Rousse, Lyon, FR, ¹¹The University of Texas MD Anderson Cancer Center, Houston, US, ¹²City of Hope, Duarte, US, ¹³Genentech, Inc., South San Francisco, US, ¹⁴Roche, Beijing, CN, ¹⁵Genentech, Inc. - Member of the Roche Group, South San Francisco, US, ¹⁶Shanghai Roche Pharmaceuticals Ltd., Shanghai, CN, ¹⁷Roche Product Development, Shanghai, CN, ¹⁸F. Hoffmann-La Roche, Ltd., Mississauga, CA, ¹⁹Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ²⁰Geffen School of Medicine at UCLA, Los Angeles, US

12:05 - 12:15

**Invited Discussant LBA3**

I. Chau, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB
12:45 - 12:50  **Opening by the Chairperson**
S.-W. Wong, The Cancer Centre, Singapore, SG

12:50 - 13:10  **Newly diagnosed advanced EGFRm NSCLC: What information will help improve our treatment decision?**

13:10 - 13:25  **Planning the patient journey: How can we maximise all of the treatment opportunities?**
R.A. Soo, National University Hospital, 119047, Singapore, SG

13:25 - 13:40  **Exploring treatment options beyond progression**
B.J. Solomon, Peter MacCallum Cancer Centre, Melbourne, AU

13:40 - 13:55  **Expert opinions on hot topics: A panel discussion**
S.-W. Wong, The Cancer Centre, Singapore, SG

13:55 - 14:10  **Your opportunity to question the panel further: Audience Q & A**
S.-W. Wong, The Cancer Centre, Singapore, SG

14:10 - 14:15  **Closing remarks**
S.-W. Wong, The Cancer Centre, Singapore, SG
12:45 - 14:15  **Type: Industry Satellite Symposium**  
**Title: Pfizer - Treating EGFR+ NSCLC in 2020: New approaches, optimal outcomes**  
Chair: Hwai Loong Kong, AU  

12:45 - 12:50  **Opening and welcome remarks**  
H.L. Kong, Icon Cancer Centre Midland, Midland, AU  

12:50 - 13:10  **Upfront strategy: Third-generation EGFR TKI as first-line therapy**  
T. Reungwetwattana, Ramathibodi Hospital, Bangkok, TH  

13:10 - 13:30  **Sequencing strategy: First- or second-generation TKI followed by third-generation EGFR TKI**  
T.S.K. Mok, Prince of Wales Hospital, Shatin, HK  

13:30 - 13:45  **Combination strategy: EGFR TKI and chemotherapy/anti-angiogenic combinations**  
D.S.W. Tan, National Cancer Center Singapore, Singapore, SG  

13:45 - 14:10  **Expert panel interactive forum**  
H.L. Kong, Icon Cancer Centre Midland, Midland, AU,  
T.S.K. Mok, Prince of Wales Hospital, Shatin, HK,  
T. Reungwetwattana, Ramathibodi Hospital, Bangkok, TH,  
D.S.W. Tan, National Cancer Center Singapore, Singapore, SG  

14:10 - 14:15  **Closing remarks**  
H.L. Kong, Icon Cancer Centre Midland, Midland, AU
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 - 14:15</td>
<td>Type: Industry Satellite Symposium Title: MSD - Advances in immune-oncology: A Pan tumour perspective</td>
<td>Chair: Ravindran Kanesvaran, SG</td>
<td>Hall 407</td>
</tr>
<tr>
<td>12:45 - 12:50</td>
<td>Welcome, introductions and objectives of the session</td>
<td>R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG</td>
<td></td>
</tr>
<tr>
<td>12:50 - 13:10</td>
<td>A deep dive in the treatment of mHCC with IO: An Asian perspective</td>
<td>L. Chan, The Chinese University of Hong Kong, Shatin, HK</td>
<td></td>
</tr>
<tr>
<td>13:10 - 13:30</td>
<td>Next generation approach in 1L RCC: IO-TKI combination</td>
<td>B. Rini, Cleveland Clinic, Cleveland, US</td>
<td></td>
</tr>
<tr>
<td>13:30 - 13:50</td>
<td>Conquering TNBC in Asia: An insider’s view</td>
<td>S.-C. Chen, Chang Gung Memorial Hospital-Taipei, New Taipei city, TW</td>
<td></td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td>Q&amp;A</td>
<td>R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG</td>
<td></td>
</tr>
<tr>
<td>12:45 - 14:15</td>
<td>Type: Industry Satellite Symposium Title: Novartis - Evolving treatment landscape in ER+ breast cancer: Clinical practice</td>
<td>Chair: Yen Shen Lu, TW</td>
<td>Room 324</td>
</tr>
<tr>
<td>12:45 - 12:50</td>
<td>Introduction</td>
<td>Y.S. Lu, National Taiwan University Hospital, Taipei, TW</td>
<td></td>
</tr>
<tr>
<td>12:50 - 13:10</td>
<td>Achieving success when treating young patients with breast cancer</td>
<td>Y.S. Lu, National Taiwan University Hospital, Taipei, TW</td>
<td></td>
</tr>
<tr>
<td>13:10 - 13:30</td>
<td>Treatment paradigm in the era of CDK 4/6 inhibitors: An Asian perspective</td>
<td>Y.S. Yap, NCCS - National Cancer Centre Singapore, Singapore, SG</td>
<td></td>
</tr>
<tr>
<td>13:50 - 14:10</td>
<td>Panel discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Type:** Industry Satellite Symposium  
**Title:** Merck Pfizer Alliance - Recent advances and future possibilities with immunotherapy in renal and urothelial cancers

Chair: Ian Davis, AU

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45</td>
<td><strong>Introduction</strong></td>
<td>I. Davis, Monash University Eastern Health Clinical School, Box Hill, AU</td>
</tr>
<tr>
<td>12:50</td>
<td><strong>Selection and sequencing of therapies for RCC</strong></td>
<td>I. Davis, Monash University Eastern Health Clinical School, Box Hill, AU</td>
</tr>
<tr>
<td>13:10</td>
<td><strong>What is next on the horizon for RCC?</strong></td>
<td>Y.-C. Tsai, National Taiwan University Hospital, New Taipei city, TW</td>
</tr>
<tr>
<td>13:30</td>
<td><strong>The evolving IO treatment landscape in UC</strong></td>
<td>C. Sternberg, Weill Cornell Medicine, New York, US</td>
</tr>
<tr>
<td>13:55</td>
<td><strong>Q&amp;A</strong></td>
<td></td>
</tr>
<tr>
<td>14:10</td>
<td><strong>Conclusions</strong></td>
<td>I. Davis, Monash University Eastern Health Clinical School, Box Hill, AU</td>
</tr>
</tbody>
</table>
12:45 - 14:15  Type: Industry Satellite Symposium  
Title: Ipsen - Managing HCC today: How can we give our patients the best chance?  
Room 311

12:45 - 12:50  Welcome and introductions  
A.-L. Cheng¹, B.-Y. Ryoo², ¹National Taiwan University, Taipei, TW, ²Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR

12:50 - 13:10  Filling in the gaps: What does the data mean for HCC management?  
A.-L. Cheng, National Taiwan University, Taipei, TW

13:10 - 13:30  Looking ahead: What does the future hold for the management of HCC?  
T. Yau, Queen Mary Hospital, Hong Kong, HK

13:30 - 13:50  Insights from real-life practice: Optimising the use of systemic treatments  
S. Chan, The Chinese University of Hong Kong, Hong Kong, HK

13:50 - 14:10  Panel discussion

14:10 - 14:15  Meeting close  
B.-Y. Ryoo, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR

12:45 - 13:15  Type: Young Oncologist session  
Title: Meet your mentor

Exhibition area  
Chair: Caroline Robert, FR; Bhumsuk Keam, KR; Olivia Pagani, CH; Pasi Jänne, US
14:30 - 16:00  |  Type: Educational session  
Title: Immuno-oncology in specific populations  
Chair: Fabrice Barlesi, FR; Caicun Zhou, CN

14:30 - 14:30  |  Session DOI

14:30 - 14:55  |  Clinical considerations (PS2, Elderly and Brain mets, autoimmuno diseases)  
C. Baldini, Gustave Roussy, Villejuif, FR

14:55 - 15:20  |  Biological considerations (Hepatitis, HIV, TB)  
C. Zhou, Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN

15:20 - 15:45  |  Patient populations receiving corticosteroids asking for vaccination: What are the recommendations?  
F. Barlesi, Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR

15:45 - 16:00  |  Discussion

14:30 - 16:00  |  Type: Educational session  
Title: Immuno-oncology  
Chair: Anthony Chan, HK; Lisa Licitra, IT

14:30 - 14:30  |  Session DOI

14:30 - 14:55  |  Immune checkpoint inhibition and biomarkers in HNSCC  
L. Licitra, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

14:55 - 15:20  |  Immune checkpoint inhibition and biomarkers in NPC  
B. Ma, The Chinese University of Hong Kong, Shatin, HK

15:20 - 15:45  |  Beyond immune checkpoint inhibition  
S. Oosting, University Hospital Groningen (UMCG), Groningen, NL

15:45 - 16:00  |  Discussion
14:30 - 16:00  **Type:** Multidisciplinary tumour board  
**Title:** Management of young patients with residual disease after preoperative chemotherapy  
Chair: Olivia Pagani, CH

14:30 - 14:30  **Session DOI**

14:30 - 14:35  **Presentation of case/condition**  
O. Pagani, IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH

14:35 - 14:50  **Surgical challenges**  
P. Dubsky, Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, CH

14:50 - 15:05  **Loco-regional radiotherapy: Shall we target the initial or residual disease burden?**  
B. Chua, Peter MacCallum Cancer Center, Melbourne, AU

15:05 - 15:20  **Treatment side effects; balancing effectiveness and long-term sequaele**  
A. Eniu, The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca, RO

15:20 - 15:35  **Addressing residual disease in 2019**  
S.-B. Kim, Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR

15:35 - 16:00  **Discussion**

**14:30 - 15:30**  **Type:** Mini Oral session  
**Title:** Mini Oral session - Gastrointestinal tumours  
Chair: Chiara Cremolini, IT; Takayuki Yoshino, JP; Eiji Oki, JP; Sylvie Lorenzen, DE

**14:30 - 14:30**  **Session DOI**

**14:30 - 14:35**  **1240 - KEYNOTE-181; Pembrolizumab vs chemotherapy in patients (pts) with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line (2L) therapy**  
S.-B. Kim¹, T. Doi², K. Kato³, J. Chen⁴, M. Shah⁵, A. Adenis⁶, S. Luo⁷, S. Qin⁸, T. Kojima⁹, J.-P. Metges¹⁰, E. Francois¹¹, K. Muro¹², Y. Cheng¹³, Z. Li¹⁴, X. Yuan¹⁵, R. Wang¹⁶, Y. Cui¹⁶, P. Bhagia¹⁷, L. Shen¹⁸, ¹Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ²National Cancer Center Hospital East, Chiba, JP, ³National Cancer Center Hospital, Tokyo, JP, ⁴Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, CN, ⁵Weill Cornell Medical College, New York Presbyterian Hospital, New York, US, ⁶Institut du Cancer de Montpellier, Montpellier, FR, ⁷Henan Cancer Hospital, Zhengzhou, CN, ⁸Jingling Hospital, Nanjing, CN, ⁹Asan Medical Center, University of
14:35 - 14:40  **1250 - Pembrolizumab & pembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study**

H.C. Chung¹, Y.-J. Bang², J. Tabernero³, E. Van Cutsem⁴, C. Fuchs⁵, L. Wyrwicz⁶, K.-W. Lee⁷, I. Kudaba⁸, M. Garrido⁹, H. Castro¹⁰, W. Mansoor¹¹, M. Braghiroli¹², E. Goekkurt¹³, J. Chao¹⁴, Z. Wainberg¹⁵, U. Kher¹⁶, S. Shah¹⁶, K. Shitara¹⁷, Yonsei University, Seoul, KR, ²Seoul National University Hospital, Seoul, KR, ³Vall d`Hebron University Hospital, Barcelona, ES, ⁴University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁵Yale Cancer Center, Smilow Cancer Hospital, New Haven, US, ⁶The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, ⁷Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seoul, KR, ⁸Latvian Oncology Center Rakus Gailezers, Riga, LV, ⁹Pontificia Universidad Católica de Chile, Santiago, CL, ¹⁰Grupo Medico Angeles, Guatemala City, GT, ¹¹The Christie Hospital NHS Trust, Manchester, GB, ¹²Institute of Cancer of São Paolo, University of São Paulo, São Paolo, BR, ¹³Hematology Oncology Practice Eppendorf, and University Cancer Center Hamburg, Hamburg, DE, ¹⁴City of Hope Comprehensive Cancer Center, Duarte, US, ¹⁵David Geffen School of Medicine at UCLA, Los Angeles, Los Angeles, US, ¹⁶Merck & Co., Inc., Kenilworth, US, ¹⁷National Cancer Center Hospital East, Kashiwa, JP

14:40 - 14:45  **1260 - Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial**


14:45 - 15:00  **Discussion led by moderator**
15:00 - 15:05

780 - Immunoscore predicts significant differences in time to recurrence in stage I colon cancer patients


15:05 - 15:10

Discussion led by moderators

C. Cremolini¹, T. Yoshino². ¹Azienda Ospedaliera Universitaria S.Chiara, Pisa, IT, ²National Cancer Center Hospital East, Kashiwa, JP

15:10 - 15:15

790 - A multicenter phase II study of neoadjuvant FOLFOXIRI followed by concurrent capecitabine and radiotherapy for high risk rectal cancer: A final report

G. Lam¹, M. Tong², J. Lee³, S. Chu³, D. Ng⁴, D.C.M. Lam², C. Cho³, E. Hung³, L. Li², W.M. Ho², E. Hui³, A. Chan³, S. Hon⁷, T. Mak³, S. Ng³, J. Suen³, F. Mo², B. Ma⁵. ¹Chinese University of Hong Kong, Hong Kong, HK, ²State Key Laboratory of Translational Oncology, Sir YK Pao Cancer Center, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, HK, ³Prince of Wales Hospital, Hong Kong, HK, ⁴North District Hospital, Hong Kong, HK, ⁵The Chinese University of Hong Kong, Shatin, HK, ⁶The Chinese University of Hong Kong, Hong Kong, HK, ⁷Alice Ho Miu Ling Nethersole Hospital, Hong Kong, HK

15:15 - 15:20

Discussion led by moderators

C. Cremolini¹, T. Yoshino². ¹Azienda Ospedaliera Universitaria S.Chiara, Pisa, IT, ²National Cancer Center Hospital East, Kashiwa, JP

15:20 - 15:25

1230 - Multiplatform analysis of HCC tumours

J.-S. Lee¹, S. Yim², S. Lee³. ¹The M. D. Anderson Cancer Center, Houston, US, ²Korea University, Seoul, KR, ³MD Anderson Cancer Center, Houston, US
15:25 - 15:30 Discussion led by moderator
E. Oki, National Kyushu Cancer Center, Fukuoka, JP

14:30 - 16:00 Type: Educational session
Title: Precision medicine in ovarian and endometrial cancer
Chair: Mansoor Raza Mirza, DK; Sandro Pignata, IT; David SP Tan, SG

14:30 - 14:30 Session DOI

14:30 - 14:55 Therapeutic genetic testing
D.S. Tan, NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG

14:55 - 15:20 Integrating PARP inhibition
M.R. Mirza, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK

15:20 - 15:45 Novel treatments - immunotherapy and beyond
S. Pignata, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

15:45 - 16:00 Discussion

14:30 - 16:00 Type: Educational session
Title: New advances in frequent lymphomas
Chair: Martin Dreyling, DE; Soon Thye Lim, SG

14:30 - 14:30 Session DOI

14:30 - 14:55 Advances in the management of the NK-T cell lymphomas
W.S. Kim, Samsung Medical Center (SMC), Seoul, KR

14:55 - 15:20 What is new in the classification and management of DLBCL in 2019
K. Izutsu, National Cancer Center Hospital, Tokyo, JP

15:20 - 15:45 Novel management of follicular lymphoma based on biological insights and novel concepts
M. Ladetto, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT

15:45 - 16:00 Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Type</th>
<th>Title</th>
<th>Room 326</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 16:00</td>
<td>Educational session</td>
<td>Overcoming challenges in cancer research in Asia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair: Fatima Cardoso, PT; Pierce Chow, SG</td>
<td></td>
</tr>
<tr>
<td>14:30 - 14:30</td>
<td>Session DOI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30 - 14:50</td>
<td>Harmonization of regulatory requirements for clinical and translational research and treatment approvals</td>
<td>C.J. Cairo, Disease Prevention and Control Bureau, Metro Manila, PH</td>
<td></td>
</tr>
<tr>
<td>14:50 - 15:10</td>
<td>Hurdles imposed by regulatory agencies: are they all needed?</td>
<td>B. Gyawali, Brigham and Women's Hospital, Boston, US</td>
<td></td>
</tr>
<tr>
<td>15:10 - 15:30</td>
<td>Defining adequate endpoints and meaningful clinical benefit</td>
<td>F. Cardoso, Champalimaud Foundation Cancer Center, Lisbon, PT</td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:50</td>
<td>How to conduct multinational academic trials in Asia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:50 - 16:00</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td>Young Oncologist session</td>
<td>Meet your mentor</td>
<td>Exhibition area</td>
</tr>
<tr>
<td>Time</td>
<td>Session/Case</td>
<td>Speaker/Institution</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------</td>
<td>---------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>Session DOI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>Breast cancer early stage: What is the place of radiation in case of breast conservative surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>Clinical case</td>
<td>G. Kusumawidjaja, NCCS - National Cancer Centre Singapore, Singapore, SG</td>
<td></td>
</tr>
<tr>
<td>16:25</td>
<td>Discussion and update of the topic</td>
<td>Y.-J. Kim, National Cancer Center - Korea, Goyang, KR</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>IO (RT-OI combination for stage III NSCLC)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>Clinical case</td>
<td>K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG</td>
<td></td>
</tr>
<tr>
<td>17:10</td>
<td>Discussion and update</td>
<td>J. Belderbos, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL</td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Infectious disease and cancer therapy: Tips for daily practice of oncology

**Chair:** Matti Aapro, CH

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 - 16:30</td>
<td><strong>Session DOI</strong></td>
<td></td>
</tr>
</tbody>
</table>
| 16:30 - 16:55 | **Vaccinating your cancer patients - When to vaccinate your solid tumour patient**  
**and health care professionals** |            |
|            | **S. Cinieri**, Ospedale A. Perrino, Brindisi, IT |            |
| 16:55 - 17:20 | **Why to screen for hepatitis if immuno/chemotherapy is contemplated** |            |
|            | **W. Yeo**, The Chinese University of Hong Kong, Shatin, HK |            |
| 17:20 - 17:45 | **How to prevent reactivation of tuberculosis** |            |
|            | **T. Reungwetwattana**, Ramathibodi Hospital, Bangkok, TH |            |
| 17:45 - 18:00 | **Discussion**                         |            |
16:30 - 18:00  Type: ESMO Clinical Practice Guidelines session  Hall 404
Title: Pan Asia Adapted ESMO Guidelines: Adaptation of ESMO guidelines in Asia
Chair: George Pentheroudakis, GR; Takayuki Yoshino, JP

16:30 - 16:30  Session DOI

16:30 - 16:35  Welcome and introduction
T. Yoshino, National Cancer Center Hospital East, Kashiwa, JP

16:35 - 16:45  PAGA for hepatocellular carcinoma: Case presentation

16:45 - 17:00  PAGA for hepatocellular carcinoma: Review of adapted recommendations for HCC
L.T. Chen, National Health Research Institutes - National Institute of Cancer Research, Tainan City, TW

17:00 - 17:10  PAGA for early breast cancer: Case presentation

17:10 - 17:25  PAGA for early breast cancer: Review of adapted recommendations for early breast
Y.H. Park, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR

17:25 - 17:35  PAGA for locally advanced lung cancer: Case presentation

17:35 - 17:50  PAGA for locally advanced lung cancer: Review of adapted recommendations for locally advanced lung cancer
K. Park, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

17:50 - 18:00  The way forward: Other ESMO guidelines to adapt in 2020 - Perspective and challenges
G. Pentheroudakis, University Hospital of Ioannina, Ioannina, GR

16:30 - 17:50  Type: Mini Oral session  Hall 407
Title: Mini Oral session - Thoracic cancers
Chair: Mei-Kim Ang, SG; Byoung Chul Cho, KR

16:30 - 16:30  Session DOI
LBA18 - Survival and treatment patterns in patients (pts) with locally advanced or metastatic NSCLC treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs): Analysis of US insurance claims databases


LBA19 - Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations

T.S.K. Mo1, Y. Cheng2, X. Zhou3, K.H. Lee4, K. Nakagawa5, S. Niho6, R. Linke7, R. Rosell8, J. Corral9, M.R. Migliorino10, A. Pluzanski11, K. Noonan12, Y. Tang13, K. Wilner13, Y.-L. Wu14, 1Prince of Wales Hospital, Shatin, HK, 2Jilin Provincial Cancer Hospital, Changchun, CN, 3First Affiliated Hospital of Third Military Medical University, Chongqing, CN, 4Chungbuk National University Hospital, Cheongju, KR, 5Kindai University Hospital, Osaka, JP, 6National Cancer Center Hospital East, Kashiwa, JP, 7SFJ Pharmaceuticals®, Pleasanton, US, 8Catalan Institute of Oncology, Barcelona, ES, 9Hospital Universitario Virgen del Rocio, Seville, ES, 10San Camillo-Forlanini Hospital, Rome, IT, 11The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, PL, 12Pfizer Inc., Groton, US, 13Pfizer Oncology, La Jolla, US, 14Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN

LBA20 - Keynote-407 China Extension study: Pembrolizumab (pembro) plus chemotherapy in Chinese patients with metastatic squamous NSCLC

Y. Cheng1, L. Zhang2, J. Hu3, D. Wang4, C. Hu5, J. Zhou6, L. Wu7, L. Cao8, J. Liu9, H. Zhang10, H. Sun11, Z. Wang12, H. Gao13, J. Ge14, H. Wang15, Y. Tian16, B. Piperdi16, L. Paz-Ares17, 1Jilin Province Cancer Hospital, Changchun, CN, 2Peking Union Medical College Hospital, Beijing, CN, 3Zhongshan Hospital Fudan University, Shanghai, CN, 4Chongqing Cancer Hospital, Chongqing, CN, 5Xiangya Hospital Central South University, Changsha, CN, 6The First Affiliated Hospital of Zhejiang University, Hangzhou, CN, 7Hunan Cancer Hospital, Changsha, CN, 8Anhui Provincial Hospital, Hefei, CN, 9The First Affiliated Hospital of Dalian Medical University, Dalian, CN, 10Tang Du Hospital, Xi'an, CN, 11The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, 12Beijing Cancer Hospital, Beijing, CN, 13Affiliated Hospital of Academy of Military Medical Sciences, Beijing, CN, 14MSD China, Shanghai, CN, 15MSD China, Beijing, CN, 16Merck & Co., Inc., Kenilworth, US, 17Hospital Universitario 12 de Octubre, Madrid, ES

4760 - A phase I study to evaluate safety and efficacy of BPI-7711 in EGFRm&

Y. Shi1, J. Fang2, Y. Shen3, D. Wang4, H. Yu5, Y. Zhao5, L. Zhang6, B. Zhu7, X. Li8, G. Chen9, J. Shi10, R. Zheng11, J. Huang12, S. Yang1, J. Long2, W. Gao3, M. Greco13, G. Hu14, X. Li15, 1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, 2Beijing Cancer Hospital, Beijing, CN, 3Jiangsu Province Hospital, Nanjing, CN, 4Chongqing Cancer Hospital, Chongqing, CN, 5Henan Cancer Hospital, Zhengzhou, CN
16:50 - 16:55 4770 - Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study

K. Park¹, J. Zhou², D.-W. Kim³, A. Ahmad⁴, R.A. Soo⁵, R. Bruns⁶, A. Johne⁶, J. Scheele⁶, J.C.-H. Yang⁷, Y.-L. Wu⁸, ¹Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ²First Affiliated Hospital of Zhejiang University School of Medicine, hangzhou, CN, ³Seoul National University Hospital, Seoul, KR, ⁴Beacon International Specialist Centre Sdn Bhd, Selangor, MY, ⁵National University Hospital, 119047, Singapore, SG, ⁶Merck KGaA, Darmstadt, DE, ⁷National Taiwan University Hospital and National Taiwan University Cancer Center, 100, Taipei, TW, ⁸Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN

16:55 - 17:00 4640 - Induction gefitinib followed by standard chemoradiotherapy in locally advanced (LA) non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations: The LOGIK0902/OLCSG0905 intergroup phase II study

S. Saeki¹, K. Hotta², M. Yamaguchi³, D. Harada⁴, A. Bessho⁵, K. Tanaka⁶, K. Inoue⁷, K. Gemba⁸, K. Inoue⁹, E. Ichihara¹⁰, J. Kishimoto⁶, T. Sasaki¹¹, Y. Shioyama¹², K. Katsui¹³, J. Sasaki¹⁴, K. Kura¹⁰, K. Sugio¹⁵, ¹Kumamoto University, Kumamoto, JP, ²Okayama, JP, ³National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ⁴National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, ⁵Japanese Red Cross Okayama Hospital, Okayama, JP, ⁶Kyushu University Hospital, Fukuoka, JP, ⁷Kitakyushu Municipal Medical Center, Kitakyushu, JP, ⁸Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers, Fukuyama, JP, ⁹Ehime Prefectural Central Hospital, Matsuyama, JP, ¹⁰Okayama University Hospital, Okayama, JP, ¹¹Graduate School of Medical Sciences,Kyushu University, Fukuoka, JP, ¹²Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, ¹³Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, JP, ¹⁴Kitasato University School of Medicine, Sagamihara, JP, ¹⁵Oita University, Yufu, JP

17:00 - 17:05 4780 - Phase II study of fruquintinib plus gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations

S. Lu¹, J. Zhou², X. Niu³, Y. Chen⁴, W. Su⁵, ¹Shanghai Chest hospital, shanghai, CN, ²First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, ³Shanghai Chest Hospital, Shanghai Jiao Tong University,, Shanghai, CN, ⁴Hutchison MediPharma Limited - Development Center (C), Shanghai, CN, ⁵Hutchison MediPharma Limited, shanghai, CN

17:05 - 17:10 4790 - Patient-focused outcomes in RELAY, a phase III trial of ramucirumab plus erlotinib (RamErl) versus placebo plus ERL (PboErl) in untreated EGFR-mutated metastatic NSCLC (EGFR#x0002B; mNSCLC)
### Discussion led by moderators

M.-K. Ang¹, B.C. Cho²
¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²Yonsei University, Seoul, KR

### Type: Collaborative session

#### Title: ESMO - AACR Collaborative Session: Challenges in the use of genomics platforms

Room 324

Chair: Daniel Shao Weng Tan, SG; Kenna R. Mills Shaw, US

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>DOI</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 - 16:30</td>
<td>Session</td>
<td>DOI</td>
</tr>
<tr>
<td>16:30 - 16:50</td>
<td>Overview of the ESMO Precision Medicine Working Group accomplishments in 2018/19</td>
<td>F. André, Gustave Roussy - Cancer Campus, Villejuif, FR</td>
</tr>
<tr>
<td>16:50 - 17:10</td>
<td>Building a scalable genomic medicine programme: MSK IMPACT experience</td>
<td>M. Berger, Memorial Sloan Kettering Cancer Center, New York, US</td>
</tr>
<tr>
<td>17:10 - 17:30</td>
<td>Disparity and diversity in Asia: Obstacle or opportunity for precision oncology?</td>
<td>D.S.W. Tan, National Cancer Center Singapore, Singapore, SG</td>
</tr>
<tr>
<td>17:30 - 17:50</td>
<td>Pragmatic considerations for implementing molecular profiling</td>
<td>K.R. Mills Shaw, The University of Texas MD Anderson Cancer Center - Main Building, Houston, US</td>
</tr>
<tr>
<td>17:50 - 18:00</td>
<td>Panel discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Type: Young Oncologist session

#### Title: YO Case presentations

Summit 2

Chair: Guillem Argiles Martinez, ES; Chiara Cremolini, IT; Fortunato Ciardiello, IT

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>DOI</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 - 16:30</td>
<td>Session</td>
<td>DOI</td>
</tr>
<tr>
<td>16:30 - 16:30</td>
<td>Session</td>
<td>DOI</td>
</tr>
</tbody>
</table>
16:30 - 16:35  Introduction

16:35 - 16:40  YO1 - Is metastatic breast cancer curable?
S. Gandhi, S. Hingmire, D. Kelkar, S. Pingle, S. Joshi, Deenanath Mangeshkar Hospital & Research Centre, Pune, IN

16:40 - 16:45  Q&A and discussion led by the Chairs

16:45 - 16:50  YO2 - Paraneoplastic encephalitis in a gastrointestinal stromal tumor
L.I. Catedral¹, J.J. Torres², M. Ando¹, H.N. Tan¹, R. Velasco, Jr¹, J. Tan¹, ¹University of the Philippines - Philippine General Hospital, Manila, PH, ²Department of Medicine, Manila, PH

16:50 - 16:55  Q&A and discussion led by the Chairs

16:55 - 17:00  YO3 - Squamous cell carcinoma of renal parenchyma in a 30 year old female with renal calculi
N. Abu Bakar¹, S. Mokhtar², M. Nik Eezamuddeen³, A.B. Peter³, T. Charng Chee², R. Malek², ¹University of Malaya Faculty of Medicine, Kuala Lumpur, MY, ²Hospital Selayang, SELANGOR, MY, ³University technology Mara, Sungai buloh, Sungai Buloh, MY

17:00 - 17:05  Q&A and discussion led by the Chairs

17:05 - 17:10  YO4 - pelvic nut carcinoma
K. Bajaj, Tata Memorial Hospital, Mumbai, IN

17:10 - 17:15  Q&A and discussion led by the Chairs

17:15 - 17:20  YO5 - Molecular and clonal evolution in recurrent metastatic gliosarcoma
A. Tan¹, K. Anderson², J. Parkinson³, M. Back³, M. Kastelan³, A. Newey³, J. Brewer³, H. Wheeler³, R. Verhaak², M. Khasraw⁴, ¹RNSH - Royal North Shore Hospital, St Leonards, AU, ²Jackson Laboratory for Genomic Medicine, Farmington, US, ³Royal North Shore Hospital, St Leonards, AU, ⁴Duke University Medical Center, Durham, US

17:20 - 17:25  Q&A and discussion led by the Chairs

17:25 - 17:30  YO7 - Intracranial Extra-skeletal Myxoid Chondrosarcoma with EWSR1 gene fusion
V. Selvaraj, D.K. Gudipudi, Basavataraman Indo American Cancer Hospital & Research Institute, Hyderabad, IN

17:30 - 17:35  **Q&A and discussion led by the Chairs**

<table>
<thead>
<tr>
<th>16:30 - 18:00</th>
<th>Room 326</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type:</strong> Special Session</td>
<td><strong>Title:</strong> Rare cancers: What is different between Asia and Europe?</td>
</tr>
<tr>
<td><strong>Chair:</strong> Paolo G. Casali, IT</td>
<td></td>
</tr>
</tbody>
</table>

16:30 - 16:30  **Session DOI**

16:30 - 16:45  **Rare Cancers Europe**

P.G. Casali, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

16:45 - 17:05  **Epidemiological differences in survival across rare cancers**

A. Trama\(^1\), T. Matsuda\(^2\), \(^1\)Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, \(^2\)National Cancer Center Hospital, Tokyo, JP

17:05 - 17:25  **Biological/clinical differences in nasopharyngeal carcinoma**

A.T. Chan\(^1\), L. Licitra\(^2\), \(^1\)State Key Laboratory of Translational Oncology, Sir YK Pao Cancer Center, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, HK, \(^2\)Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

17:25 - 17:45  **Pathologic diagnosis: Improving accuracy in Asia and Europe**

B. Rekhi\(^1\), A.P. Dei Tos\(^2\), \(^1\)Tata Memorial Hospital, Mumbai, IN, \(^2\)Istituto Oncologico Veneto IRCCS, Padova, IT

17:45 - 18:00  **Rare Cancers Asia**

A. Kawai, National Cancer Center Hospital, Tokyo, Japan, Tokyo, JP
18:00 - 19:00  Type: Special Session
Title: Radiation oncology
Chair: Françoise Mornex, FR; Melvin Lee Kiang Chua, SG

18:00 - 18:00  Session DOI

18:00 - 18:00  Oligometastatic disease: How can RTX help improving disease control?

18:00 - 18:10  Clinical case
H. Sun, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, CN

18:10 - 18:40  Discussion of the topic
Y.C. Ahn, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

18:40 - 19:00  Should additional combination or RT-CT be used or is Radiation alone to be recommended? Issues with Concurrent TKIs? SBRT/IO? /Current trials?
J. Belderbos, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

18:00 - 19:00  Type: Poster Display
Title: Poster display session

18:00 - 18:00  Breast cancer, early stage

18:00 - 18:00  4P - Impact of chemotherapy and radiotherapy on tissue expander or implant removal in breast cancer patients
S. Jung, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

18:00 - 18:00  5P - Long-term prognostic effect of hormone receptor subtype on breast cancer
K.-T. Hwang, Boramae Medical Center, Seoul, KR

18:00 - 18:00  6P - Effect of apparent diffusion coefficient in predicting pathologic responses in patients with breast cancer treated with neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel
Y. Mizuno, Yokkaichi Municipal Hospital, Yokkaichi, JP

18:00 - 18:00  7P - Current diagnostic strategy for mammographic microcalcification without specific ultrasound abnormality
N. Sato, Okazaki City Hospital, Okazaki, JP
18:00 - 18:00  **8P - Comparison of standard uptake value of 18F-FDG-PET-CT with tumour-infiltrating lymphocytes in breast cancer with tumour infiltration lymphocytes in breast cancer**

S. Park, E.K. Min, S.J. Bae, C. Cha, D. Kim, J. Lee, Y.J. Cha, J. Jeong, S.G. Ahn, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR

18:00 - 18:00  **9P - (Withdrawn)**

18:00 - 18:00  **10P - Prognosis and effect of adjuvant treatment in small, node(-), HER2(+) breast cancer**

S. Lim1, J. Sohn2, G. Kim2, Y. Moon3, J.H. Kim4, 1Wonju Severance Christianity Hospital, Gangwon-do, KR, 2Yonsei Cancer Center, Seoul, KR, 3Bundang Cha Hospital, Bundang, KR, 4Gangnam Severance Hospital, Seoul, KR

18:00 - 18:00  **11P - The prognosis of rare histopathologic subtype of breast cancer**

S.Y. Bae1, J.Y. Kim2, 1Korea University Anam Hospital, Seoul, KR, 2Jeju National University Hospital, Jeju, KR

18:00 - 18:00  **12P - Daily collection of physical activity via smartphone application and smart band for development of distress screening tools in breast cancer survivors: A feasibility study**

Y. Shin1, I.Y. Chung2, 1Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, 2Asan Medical Center - Asan Institute for Life Science, Seoul, KR

18:00 - 18:00  **13P - Breast cancer distribution in East Azerbaijan, Iran: Results of population-based cancer registry**

S. Pashaei1, R. Dolatkhah2, M.H. Somi3, R. Asghari4, 1Ghazi Hospital-Tabriz University, Tabriz, IR, 2Epidemiologic Profile of Gastric Cancer in East Azerbaijan, Iran: 2 years Population Based Cancer Registry Results, Tabriz, IR, 3Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Tabriz, IR, 4Urmia university of medical sciences, Tabriz, IR

18:00 - 18:00  **14P - Validation of the optimum timing of assessment of tumour infiltrating lymphocytes during preoperative chemotherapy for breast cancer**

S. Kashiwagi1, Y. Asano1, R. Kouhashi2, S. Ishihara2, Y. Tauchi2, T. Morisaki2, S. Noda2, T. Takashima2, N. Onoda2, K. Hirakawa2, M. Ohira2, 1Osaka City University Medical School, Osaka, JP, 2Osaka City University Graduate School of Medicine, Osaka, JP

18:00 - 18:00  **15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons**

N. Takeda, Yokkaichi Municipal Hospital, Yokkaichi, JP

18:00 - 18:00  **16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy**

K. Taroeno Hariadi1, R. Pudyasari2, L. Choridah3, T. Aryandono1, 1Gadjah Mada
18:00 - 18:00  **17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia**  
A. Khan¹, H. Martin², L. Spalding³, A. Redfern³, ¹Sir Charles Gairdner Hospital, Nedlands, AU, ²Fiona Stanley Hospital, Perth, AU, ³University of Western Australia, Perth, AU

18:00 - 18:00  **18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center**  
Y. Raof Al-Bairmany, Baghdad Medical City (Teaching Hospital), Baghdad, IQ

18:00 - 18:00  **19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts**  
M. Paulpandi, K. Murugan, Bharathiar University, Coimbatore, IN

18:00 - 18:00  **20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis**  
A. Shamshirian¹, K. Heydari², A.R. Aref³, R. Alizadeh-Navaei⁴, D. Shamshirian⁵, Z. Hamzehgardeshi⁶, M. Moosazadeh⁶, ¹School of Allied Medical Science, Mazandaran University of Medical Sciences, Sari, IR, ²School of Medicine, Mazandaran University of Medical Sciences, Ramsar, IR, ³Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, ⁴Mazandaran University of Medical Sciences, Imam Khomeini Hospital, Sari, IR, ⁵Shahid Beheshti University of Medical Sciences, Tehran, IR, ⁶Mazandaran University of Medical Sciences, Sari, IR

18:00 - 18:00  **21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients**  
T.T. Aye¹, S. Mon¹, M. Khine², N. Sein², N. Than², A. Win², E. Aung², P. Hnin², ¹Bahosi Medical Centre Bahosi Housing Complex, Yangon, MM, ²Thurein Mon Clinic, Yangon, MM

18:00 - 18:00  **22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients**  
H.Y. Lee¹, D.Y. Yu², Y.W. Chang³, G.S. Son³, ¹Korea University College of Medicine, Seoul, KR, ²Korea University Ansan Hospital, Ansan-si, Gyeonggi-do, KR, ³Korea University Ansan Hospital, Ansan, KR

18:00 - 18:00  **23P - The correlations between knowledge and attitudes of productive age women toward &**  
Y. Brahmantya¹, A.B.S. Satyarsa¹, S.A. Arta Suryantari², K. Puspitasari³, A.T. Adiputra¹, ¹Medical Faculty Of Udayana University, Denpasar, ID, ²Medical Faculty of Udayana University, Denpasar, ID, ³Faculty of Medicine Udayana University, Denpasar, ID

18:00 - 18:00  **24TP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant**
endocrine therapy for high-risk, early-stage, ER&


18:00 - 18:00 Breast cancer, locally advanced

18:00 - 18:00 27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
S.J. Bae, S. Park, C. Cha, J. Lee, D. Kim, S.G. Ahn, J. Jeong, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR

18:00 - 18:00 28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast &#x0213; CRBr): A feasibility study
N. Hariharan¹, T.S. Rao¹, S. Rajappa², C.C.K. Naidu¹, K.V.V.N. Raju¹, V. Koppula¹, R. Sudhir¹, S. Murthy¹, S. Kodandapani¹, D. Fonseca¹, ¹Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, IN

18:00 - 18:00 29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
B. Tribukait, Karolinska Institutet, Stockholm, SE

18:00 - 18:00 30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
H.-H. Ryu¹, S.H. Ahn¹, B.H. Son¹, J.W. Lee¹, B.S. Ko¹, J. Kim¹, I.Y. Chung², H. Kim¹, ¹Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ²Asan Medical Center - Asan Institute for Life Science, Seoul, KR

18:00 - 18:00 31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
S.L. Anwar, T. Aryandono, S. Haryana, Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, ID

18:00 - 18:00

Last update: 18-11-2019 08:34:53am Final Programme
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
C. Aryanti, I.G.B. Setiawan, I.W. Sudarsa, Medical Faculty Of Udayana University, Denpasar, ID

18:00 - 18:00

33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
B.H. Choi, Gyeongsang National University Changwon Hospital, Changwon, KR

18:00 - 18:00

34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Y. Asano1, S. Kashiwagi1, R. Kouhashi2, S. Ishihara2, Y. Tauchi2, T. Morisaki2, S. Noda2, T. Takashima2, N. Onoda2, K. Hirakawa2, M. Ohira2. 1Osaka City University Medical School, Osaka, JP; 2Osaka City University Graduate School of Medicine, Osaka, JP

18:00 - 18:00

35TP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+
Y.-S. Lu1, S. Malwinder2, H. Azim3, Y. Erals4, S.-A. Im5, Y.S. Yap6, T. Delgar Alfar7, M. Gao7, N. El Saghi8. 1National Taiwan University Hospital, Taipei City, TW; 2University Malaya Medical Center, Kuala Lumpur, MY; 3Cairo University Hospital, Giza Governorate, EG; 4Istanbul Florence Hospital, Istanbul, TR; 5Seoul National University Hospital, Seoul, KR; 6NCCS - National Cancer Centre Singapore, Singapore, SG; 7Novartis, Basel, CH; 8American University of Beirut Medical Center, Beirut, LB

18:00 - 18:00

36TP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
S. Goyal1, A. Rudresha1, D. Lokanatha1, L. Jacob1, S. Babu Mc1, K. Lokesh1, L. Rajeev1, S. Smitha1, A. Thottian2. 1Kidwai Cancer Institute, Bangalore, IN; 2AIIMS - All India Institute of Medical Sciences, New Delhi, IN

18:00 - 18:00

Breast cancer, metastatic

18:00 - 18:00

41P - Clinical verification on the relationship between serum lipid metabolism and the immune microenvironment in breast cancer patients
W. Goto1, Y. Kamei2, C. Watanabe2, S. Kashiwagi1, K. Ikeda2, Y. Ogawa2. 1Osaka City University Medical School, Osaka, JP; 2Osaka City General Hospital, Osaka, JP

18:00 - 18:00

42P - Genome wide copy number analysis of circulating tumour cells in breast cancer liver metastasis
S. Imani1, Z. Linglin2, M. Maghsoudloo3, Q. Wen2. 1Southwest Medical University, Luzhou, CN; 2The Affiliated Hospital of Southwest Medical University, Luzhou, CN; 3Kish International Campus, University of Tehran, kish, IR

18:00 - 18:00

Z. Linglin1, S. Imani2, M. Dehghan Shasaltaneh3, Q. Wen1. 1The Affiliated Hospital of
18:00 - 18:00  **44P - Correlation of circulating tumour cells with PET-CT in metastatic breast cancer**  
V.P.B. Koyyala¹, S. Saini², D.C. Doval¹, A. Mehta², M. Suryavanshi², P. Goyal¹, U. Maheshwari¹, A. Jajodia¹, M. Sharma¹, S. Goyal¹, ¹Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, ²Rajiv Gandhi Cancer Institute and Research Centre, Delhi, IN

18:00 - 18:00  **45P - The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumour location**  
H. Beaumont¹, N. Faye², A. Iannessi³, C. Klifa¹, C.-Y. Hsieh⁴, ¹MEDIAN Technologies, Valbonne, FR, ²MEDIAN Technologies, valbonne, FR, ³Centre Anticancer Antoine Lacassagne, Nice, FR, ⁴ASLAN Pharmaceuticals, Singapore, SG

18:00 - 18:00  **46P - Plasma soluble CD36 of breast cancer based on pathological and clinical characteristics**  
A. Romadhoni¹, A. Rachman², C. Irawan², S. Koesnoe², ¹RSUPN - Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo, Central Jakarta/Jakarta Pusat, ID, ²Cipto Mangunkusumo General Hospital (RSCM) University of Indonesia, Jakarta, ID

18:00 - 18:00  **47P - Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer**  
M. Miki¹, S. Takao², M. Konishi³, Y. Shigeoka⁴, M. Miyashita⁵, H. Suwa⁶, M. Imamura⁷, T. Okuno⁸, K. Hirokaga², Y. Miyoshi⁷, K. Murase⁷, A. Yanai⁷, K. Yamagami⁹, K. Akazawa¹⁰, ¹Kobe University Hospital, Kobe, JP, ²Hyogo Cancer Center; Akashi, JP, ³Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, JP, ⁴Yodogawa Christian Hospital, Osaka, JP, ⁵Konan Hospital, kobe, JP, ⁶Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, JP, ⁷Hyogo College of Medicine, Nishinomiya, JP, ⁸Nishikobe Medical Center, Kobe, JP, ⁹Shinko Hospital, Kobe, JP, ¹⁰Niigata University, Niigata, JP

18:00 - 18:00  **48P - Development of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis**  
A. Murtadha¹, N.F. Mokhtar², ¹INFORMM - Institute for Research in Molecular Medicine - Universiti Sains Malaysia, Kubang Kerian, MY, ²Universiti Sains Malaysia, Kubang Kerian, MY

18:00 - 18:00  **49P - Biochemical study on modifying role of variants of leptin gene and its receptor on serum leptin levels in breast cancer**  
A. Alhana³, S. Tayel², S. Ahmed³, A. Altorgoman³, I. Elsayed³, ¹Faculty of Medicine - Menoufia University, Shebin El Kom, EG, ²Faculty of Medicine - Menoufia University, sheben elkom, EG, ³Faculty of Science - Menoufia University, sheben elkom, EG

18:00 - 18:00  **50P - Prognostic factors of recurrence or distant metastasis in elderly breast cancer patients**  
S. Lee, Pusan National University Yangsan Hospital, Yangsan, KR
18:00 - 18:00  
**51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator**

H. Xiong, W. Zheng, X.-F. Yu, The Second Affiliated Hospital - Zhejiang University School of Medicine - East Gate 1, Hangzhou, CN

18:00 - 18:00  
**52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma**

B.W. Choi, Y.J. Jeong, S.H. Park, H.K. Oh, S. Kang, Daegu Catholic University Hospital, Daegu, KR

18:00 - 18:00  
**CNS tumours**

18:00 - 18:00  
**53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report**

A. Altwairgi1, F. Alnajjar2, H. Alhussain2, E. Alsaeed2, A. Balbaid2, S. Aldandan2, Y. Orz2, A. Lary2, W. Alghareeb2, A. Alsharn2, 1King Fahad Medical City-(KFMC), Riyadh, SA, 2King Fahad Medical City, riyadh, SA

18:00 - 18:00  
**54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study**

J.-H. Park, Korea University Medical Center, Seoul, KR

18:00 - 18:00  
**55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma**

K.S.-P. Yuan, C.-L. Chang, S.-Y. Wu, Taipei Medical University - Municipal Wan Fang Hospital, Taipei, TW

18:00 - 18:00  
**56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment**

V. Pareek1, R. Bhalavat2, M. Chandra2, 1Jupiter Hospital, Mumbai, IN, 2Jupiter Hospital, Thane, IN

18:00 - 18:00  
**57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?**

A. Rajpurohit1, V. Patil2, V. Noronha3, A. Joshi3, N. Menon4, A. Puranik3, N. Purandare3, A. Mahajan3, N. Mummudi3, R. Krishnatry3, R. Kumar3, S. Yadav3, K. Prabhah3, 1Tata Memorial Hospital - Parel, Mumbai, IN, 2Tata Memorial Hospital Centre, Mumbai, IN, 3Tata Memorial Hospital, Mumbai, IN, 4Prince Aly Khan Hospital, Mumbai, IN

18:00 - 18:00  
**58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy**

J. Ayala Alvarez1, R. Trejo Rosales2, R. Riera Salas1, M. Chilaca Rosas1, S. Rivera Rivera1, J. Silva Godinez1, B. Salvador Bonilla1, 1Instituto Mexicano del Seguro Social,
18:00 - 18:00  **59P - Pattern of care in high-grade gliomas after recurrence**  
N. Menon, V. Simha, A. Abhyankar, D. Kalra, R. Krishnathry, T. Gupta, R. Jalali, V. Patil, Prince Aly Khan Hospital, Mumbai, IN, 2Tata Memorial Hospital, Mumbai, IN, 3JJ Hospital, Mumbai, IN, 4Tata Memorial Hospital Centre, Mumbai, IN

18:00 - 18:00  **60P - Five fractions plus**  
A. Rashid, M.A. Memon, A.S. Hashim, Neurospinal & Cancer Care Institute (NCCI), Karachi, PK

18:00 - 18:00  **Developmental therapeutics**

18:00 - 18:00  **64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001**  
F. De Braud, S. Siena, A. Drilon, B. Simmons, X. Huang, S. Osborne, R. Doebele, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, IT, 2Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, IT, 3Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, 4Memorial Sloan Kettering Cancer Center, New York, US, 5Genentech, South San Francisco, US, 6University of Colorado, Aurora, US

18:00 - 18:00  **65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001**  
C. Rolfo, R. Dziadziuszko, R. Doebele, G. Demetri, B. Simmons, A. Aziez, X. Huang, S. Osborne, L. Paz-Ares, 1Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, IT, 2Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, IT, 3Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, 4Memorial Sloan Kettering Cancer Center, New York, US, 5Genentech, South San Francisco, US, 6F. Hoffmann-La Roche, Basel, CH, 7F. Hoffmann-La Roche, Basel, US, 8University Hospital 12 De Octubre, Madrid, ES

18:00 - 18:00  **66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers**  

18:00 - 18:00  **67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours**
18:00 - 18:00  **68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck**

M.M. Hou¹, C.L. Ho², H.Y. Lin³, W. Jiang⁴, S. Liu⁴, Y. Hong⁴, A. Luk⁵, S.F. Lin⁶, T.C. Hsieh⁵, E. Liu⁴, Linkou Chang Gung Memorial Hospital, Taipei, TW, ²Tri-Service General Hospital, National Defense Medical Center, Taipei, TW, ³Changhua Christian Hospital, Changhua, TW, ⁴Shanghai Henlius Biotech, Inc., Shanghai, CN, ⁵Shanghai Henlius Biopharm, Shanghai, CN, ⁶Taiwan Henlix Biotech., Co., LTD., Taipei, TW

18:00 - 18:00  **69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer**

H. Ishikawa¹, D. Tsuji², T. Miyagi², Y. Kawasaki³, K. Yamamoto⁴, M. Nakao⁵, S. Nakagaki⁶, T. Hayashi⁷, H. Ayuhara⁸, T. Harada⁹, S. Tamaki¹⁰, A. Maeda¹¹, Y. Ohashi¹², Y. Arakawa¹³, Y. Fujita¹⁴, Y. Miyamoto¹⁵, T. Yano¹⁶, R. Tanaka¹⁷, K. Itou², Shizuoka Cancer Center, Shizuoka, JP, ²Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, JP, ³Clinical Research Center, Chiba University Hospital, Chiba, JP, ⁴Seirei Hamamatsu General Hospital, Hamamatsu, JP, ⁵Osaka City General Hospital Osaka, JP, ⁶Shizuoka General Hospital, Shizuoka, JP, ⁷Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, JP, ⁸Tokyo Medical University Hospital, Tokyo, JP, ⁹Kanagawa Cancer Center, Kanagawa, JP, ¹⁰National Hospital Organization Hokkaido Cancer Center, Hokkaido, JP, ¹¹Aichi Cancer Center Hospital, Aichi, JP, ¹²National hospital Organization Tokyo medical center, Tokyo, JP, ¹³Tochigi Cancer Center, Tochigi, JP, ¹⁴Gunma prefectural cancer center, Gunma, JP, ¹⁵Hamamatsu Medical Center, Hamamatsu, JP, ¹⁶Sumitomo Besshi Hospital, Ehime, JP, ¹⁷Tokyo university of Science, Chiba, JP

18:00 - 18:00  **70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis**

J. Cao¹, M. Chen², B. Zhang³, X. Cai², Sir Run Run Shaw Hospital - Zhejiang University School of Medicine - Xixia Campus, Hangzhou, CN, ²Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, CN, ³Sir Run Run Shaw Hospital Zhejiang University, School of Medicine, Hangzhou, CN

18:00 - 18:00  **71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis**

C. He, Sun Yat-sen University Cancer Center, Guangzhou, CN
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study

W. Peng¹, X. Fu², ¹Affiliated Hospital of North Sichuan Medical College, Nanchong, CN, ²Affiliated hospital of North Sichuan Medical College, Nanchong, CN

18:00 - 18:00

73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models


18:00 - 18:00

74TIP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours

K. Yamazaki¹, T. Koyama², T. Shimizu², T. Takahashi¹, J. Watanabe¹, Y. Tanaka³, H. Myobudani³, N. Yamamoto², ¹Shizuoka Cancer Center, Shizuoka, JP, ²National Cancer Center Hospital, Tokyo, JP, ³Nippon Boehringer Ingelheim Co., Ltd, Tokyo, JP

18:00 - 18:00

General interest

18:00 - 18:00

75P - A parallel deep learning network framework for whole-body bone scan image analysis

X. Pu¹, G. Tang², K. Cai³, Y. Huang², M. Ping³, Z. Peng³, H. Qiu¹, ¹University of Electronic Science and Technology of China, Chengdu, CN, ²Sichuan University, Chengdu, CN, ³Electronic Science and Technology of China, Chengdu, CN

18:00 - 18:00

76P - Perception and satisfaction of cancer patients in clinical trials

J. Jeon¹, J.H. Kim¹, K.P. Kim², ¹Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ²Asan Medical Center, Seoul, KR

18:00 - 18:00

77P - A prognostic nomogram for the prediction of neuroblastoma

J.-G. Zhou¹, H. Ma², ¹Zunyi Medical College Affiliated Hospital, Zunyi, CN, ²Zunyi Medical College Affiliated Hospital, Zunyi City, CN

18:00 - 18:00

GI, crc

18:00 - 18:00

80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study

S. Fujino¹, N. Miyoshi², M. Ohue³, M. Yasui³, M. Sakon³, N. Matsuura³, ¹Graduate School of Medicine / Faculty of Medicine, Osaka University, Osaka, JP, ²Osaka International Cancer Institution, Osaka, JP, ³Osaka International Cancer Institute, Osaka, JP
18:00 - 18:00  **81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study**

J. Zhang, Y. Deng, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN

18:00 - 18:00  **82P - Body mass index, tumour location, and colorectal cancer survival**

D. Chu, J. Zhang, X. Bu, C. Dang, W. Wang, Z. Zhang, First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, CN

18:00 - 18:00  **83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4**

X. Fu¹, W. Peng², ¹Affiliated hospital of North Sichuan Medical College, Nanchong, CN, ²Affiliated Hospital of North Sichuan Medical College, Nanchong, CN

18:00 - 18:00  **84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation**

J. Xu¹, Y. Chen¹, W. Chang², Y. Wei², ¹Zhongshan Hospital, Fudan University, Shanghai, CN, ²Zhongshan Hospital, Fudan University, shanghai, CN

18:00 - 18:00  **85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center**

J. Wang¹, J. Zhu², ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²fudan university shanghai cancer center, Shanghai, CN

18:00 - 18:00  **87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer**

P. Jonnada¹, R. C², R. C², A. Syed², S. C², ¹Kidwai Cancer Institute, Bangalore, IN, ²Kidwai Cancer Institute, bengaluru, IN

18:00 - 18:00  **88P - The Sidra LUMC advanced colon cancer NGS cohort**

W. Hendrickx¹, J. Roelands², P. Kuppen³, F. Marincola⁴, D. Bedognetti⁵, ¹Sidra Medical and Research Center, Al-Rayyan, QA, ²Sidra Medicine, Doha, QA, ³Leiden University Medical Center, Leiden, NL, ⁴Refuge Biotechnologies, Redwood City, US, ⁵Sidra Medicine, Doah, QA

18:00 - 18:00  **89P - A phase II trial of adjuvant chemotherapy for patients with high-risk rectal submucosal invasive cancer after local resection**

M. Noguchi¹, K. Shitara², A. Kawazoe³, D. Yamamoto⁴, Y. Takii⁵, Y. Saito⁶, T. Sato⁷, T. Horimatsu⁸, H. Ishikawa⁹, Y. Ito¹⁰, M. Ito¹¹, H. Ikematsu², ¹Jikei University School of Medicine, Tokyo, JP, ²National Cancer Center Hospital East, Kashiwa, JP, ³National Cancer Center Hospital, Tokyo, JP, ⁴Ishikawa Prefectural Central Hospital, Ishikawa, JP, ⁵Niigata Cancer Centre, Niigata-shi, JP, ⁶National Cancer Center Hospital East, Chuo-ku, JP, ⁷Yamagata Prefectural Central Hospital, Yamagata, JP, ⁸Kyoto University-Graduate school of medicine, Kyoto, JP, ⁹Kyoto Prefectural University of Medicine, Kyoto, JP, ¹⁰Showa University School of Medicine, Shinagawa-ku, JP, ¹¹National Cancer Center Hospital East, Chiba, JP
18:00 - 18:00  **90P - High MICB expression confers prognostic benefit in colorectal cancer**  
S. Yu, Zhongshan Hospital - Fudan University, Shanghai, CN

18:00 - 18:00  **91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study**  
C.-H. Chen, S.-Y. Wu, Taipei Medical University - Municipal Wan Fang Hospital, Taipei, TW

18:00 - 18:00  **92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma**  
V. Goel, Basavataram Ind American Cancer Hospital & Research Institute, Hyderabad, IN

18:00 - 18:00  **93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis**  
Y. Chen, W. Chang, Y. Wei, J. Xu, Zhongshan Hospital, Fudan University, Shanghai, CN

18:00 - 18:00  **94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis**  
M. Nakamura, S. Yuki, N. Takahashi, T. Shichinohe, H. Nakatsumi, Y. Kawamoto, T. Kusumi, A. Ishiguro, K. Harada, I. Iwanaga, K. Hatanaka, K. Oomori, N. Senmaru, K. Iwai, M. Koike, N. Sakamoto, A. Taketomi, Y. Komatsu, Sapporo City General Hospital, Sapporo, JP, Hokkaido University Hospital, Sapporo, JP, Keiyukai Sapporo Hospital, Sapporo, JP, Kitami Red Cross Hospital, Kitami, JP, Kokado Hospital, Hakodate, JP, Keiwakai Ebetsu Hospital, Ebetsu, JP, Steel Memorial Muroran Hospital, Muroran, JP, Oji General Hospital, Tomakomai, JP, KKR Sapporo Medical Center, Sapporo, JP

18:00 - 18:00  **95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases**  
Y. Wei, Y. Chen, W. Chang, J. Xu, Zhongshan Hospital, Fudan University, Shanghai, CN

18:00 - 18:00  **96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases**  

18:00 - 18:00  **97P - The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer**  
J.H. Lee, St Vincent Hospital The Catholic University of Korea, Suwon, KR
18:00 - 18:00  **98P - Influence of DPYD&&**  
A. Varma, JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IN

18:00 - 18:00  **99P - Patient-derived tumour model by new culture method leading to the precision medicine**  
N. Miyoshi¹, S. Fujino², K. Saso², M. Sasaki², T. Ogino², H. Takahashi³, M. Uemura², M. Chu¹, T. Mizushima³, M. Mori⁴, Y. Doki³, ¹Osaka International Cancer Institution, Osaka, JP, ²Osaka University, Suita, JP, ³Osaka University, ¼Kyusyu University, Fukuoka, JP

18:00 - 18:00  **100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer**  
K.-Y. Lin¹, C.-L. Fang², Y.-H. Uen³, D.-P. Sun⁴, ¹Chi-Mei Medical Center, Tainan City, TW, ²Taipei Medical University, Taipei, TW, ³Asia University Hospital, Taichung, TW, ⁴Chi Mei Medical Center, Tainan, TW

18:00 - 18:00  **101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer**  
C. Wang, L. Xie, Y. Wang, T. Liang, H. Wu, H. He, The First Hospital of Jilin University, Changchun, CN

18:00 - 18:00  **102P - Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study**  
K. Watanabe¹, A. Kohyama², H. Suzuki², T. Kajiwara², H. Karasawa³, S. Ohnuma³, H. Musha², T. Kamei⁴, T. Naitoh⁴, M. Unno⁴, ¹Graduate School of Dentistry, Tohoku University, Sendai, JP, ²Graduate School of Medicine, Tohoku University, Sendai, JP, ³Tohoku University Hospital, Sendai, JP, ⁴Tohoku University Graduate School of Medicine, Sendai, JP

18:00 - 18:00  **103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy**  
Y. Yang¹, J. Yang², ¹West China Medical Center of Sichuan University, Chengdu, CN, ²West China Hospital of Sichuan University, Chengdu, CN

18:00 - 18:00  **104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer**  
S. Hosseini, OMID Hospital Mashhad University of Medical Sciences, Mashhad, IR

18:00 - 18:00  **105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer**  
S. Dong, Qilu Hospital of Shandong University, Jinan, CN

18:00 - 18:00  **106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum**
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
M. Shibutani¹, H. Nagahara¹, T. Fukuoka¹, Y. Iseki¹, K. Hirakawa², M. Ohira², ¹A2 Healthcare Corporation, Osaka, JP, ²Osaka City University Graduate School of Medicine, Osaka, JP

108P - Influence of liver metastasis locations on overall survival in patients with colorectal cancer
T. Sone, T. Murai, K. Itaya, Y. Koike, Y. Ono, M. Nakamura, Sapporo City General Hospital, Sapporo, JP

109P - ¹⁸F-FDG PET/CT textural features as predictors of outcomes in patients with primary advanced colorectal cancer
J. Yang¹, Y. Cheng², X. Ma³, ¹West China Hospital of Sichuan University, Chengdu, CN, ²West China Hospital, Sichuan University, Chengdu, CN, ³State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China., Chengdu, CN

110P - D3 lymph node dissection may be necessary in clinical stage I right colon cancer
W.B. Ji, Y.W. Chang, Korea University Ansan Hospital, Ansan, KR

111P - Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective study
J. Madyarov, A. Rasulov, Z. Mamedli, D. Kuzmichev, N. N. Blokhin National Medical Research Center of Oncology, Moscow, RU

112P - A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer

113P - Dicer contributes to chemoresistance in colorectal cancer via regulating a set of miRNAs and their downstream mRNAs
L.-Y. Hung, National Cheng Kung University, Tainan, TW

114P - Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
J. Zhu¹, S. Li¹, C. Zhu², ¹Jiangsu Province Cancer Hospital, Nanjing, CN, ²The First Affiliated Hospital of Soochow University, Suzhou, CN
18:00 - 18:00  **115P - Expression of Ki-67 as a prognostic factor in patients with colorectal cancer**  
K. Zhabagin, Semey Nuclear medicine and oncology center, Semey, KZ

18:00 - 18:00  **116P - Clinical significance and conversion rate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study**  
M. Li, W. Tang, Zhongshan Hospital, Fudan University, Shanghai, CN

18:00 - 18:00  **117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study**  
W. Huang1, Y. Chen1, W. Chang2, Y. Wei2, J. Xu1, 1Zhongshan Hospital, Fudan University, Shanghai, CN, 2Zhongshan Hospital, Fudan University, Shanghai, CN

18:00 - 18:00  **119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)**  
F. Liu1, J. Zhou2, H. Luo3, S. Li3, X. Tan3, Y. Wu3, Y. Wang3, 1Chongqing Cancer Hospital, Chongqing, CN, 2Southwest University of Political Science and Law, Chongqing, CN, 3Chongqing University Cancer Hospital, Chongqing, CN

18:00 - 18:00  **120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer**  
A. Bilici1, B. Cakan1, T. Demir2, B.B. Oven3, O. Acikgoz4, J. Hamdar4, O.F. Olmez4, O. Olmuscelik4, M. Seker2, O. Yildiz4, 1Medipol Mega Hospitals Complex (University Hospital), Istanbul, TR, 2Bezmialem Vakif University, Istanbul, TR, 3Bahçeşehir University, Medical Faculty, Istanbul, TR, 4Medipol University, Medical Faculty, Istanbul, TR

18:00 - 18:00  **121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer**  
L. Li1, Y. Guo2, X. Yang3, W. Zhang3, F. Lili3, 1The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, 2Lanzhou university second hospital, Lanzhou, CN, 3Gansu Provincial Hospital, Lanzhou, CN

18:00 - 18:00  **GI, non-crc**

18:00 - 18:00  **127P - Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)**  
S. Chan1, R. Miksad2, I. Cicin3, Y. Chen4, H.J. Klumpen5, S. Kim6, Z.Z. Lin7, J. Youkstetter8, S. Sen8, A.-L. Cheng9, A. El-Khoueiry10, T. Meyer11, R.K. Kelley12, G. Abou-Alfa13, 1The Chinese University of Hong Kong, Department of Clinical Oncology, Hong Kong, HK, 2Flatiron Health, New York, US, 3Trakya University Rektörlü?ü, Edirne, TR, 4The Chinese University of Hong Kong, Hong Kong, HK, 5Academic Medical Center (AMC), Amsterdam, NL, 6CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, 7National
18:00 - 18:00  
**128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)**

Y. Bai¹, N. Xu², X. Yuan³, B. Wang⁴, E. Li⁵, X. Li⁶, Y. Li⁶, X. Wang⁶, S. Yang⁷, J. Xu⁸.
¹Harbin Medical University Cancer Hospital, Harbin, CN, ²The First Affiliated Hospital of Zhejiang University, Hangzhou, CN, ³Tongji Hospital, Wuhan, CN, ⁴Northern Jiangsu People’s Hospital, Yangzhou, CN, ⁵First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, CN, ⁶Beijing (Beijing) Co., Ltd., Beijing, China, ⁷Beijing Co., Ltd., Beijing, CN, ⁸307 Hospital of the Chinese People’s Liberation Army, Beijing, CN

18:00 - 18:00  
**129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)**

T. Fu, Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN

18:00 - 18:00  
**130P - Development of a liver cancer risk prediction model for the general population in China: A potential tool for screening**

X. Feng¹, N. Li¹, G. Wang², S. Chen³, Z. Lyu⁴, L. Wei¹, X. Li¹, Y. Wen⁵, E. Giovannucci⁶, S. Wu³, M. Dai¹, J. He⁷, ¹ICAMS and PUMC - National Cancer Center, Cancer Hospital, Beijing, CN, ²Kailuan General Hospital, Tangshan, CN, ³Kailuan Group, Tangshan, CN, ⁴Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ⁵Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing, CN, ⁶Harvard T. H. Chan School of Public Health, Boston, US, ⁷National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN

18:00 - 18:00  
**131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis**

C.-H. Hsu¹, L. Nguyen², A.-L. Cheng³, T.X.Q. Nguyen⁴, K. Brendel⁵, V. Aslanis⁶, F. Bengzaghou⁷, ¹National Taiwan University Hospital, Taipei City, TW, ²Exelixis Inc., Alameda, US, ³National Taiwan University, Taipei, TW, ⁴Ipsen Innovation, Les Ulis, FR

18:00 - 18:00  
**132P - Liposomal irinotecan (nal-IRI) plus 5-fluourouracil/levoleucovorin (5FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)**

T. Ioka¹, S. Nakamori², K. Sugimori³, M. Kanai⁴, M. Ikeda⁵, M. Ozaka⁶, M. Furukawa⁷, T. Okusaka⁸, K. Kawabe⁹, J. Furuse¹⁰, Y. Komatsu¹¹, A. Sato¹², S. Shimizu¹³, P. Chugh¹⁴, R. Tang¹⁵, M. Ueno¹⁶, ¹Osaka International Cancer Institute, Osaka, JP, ²NHO Osaka National Hospital, Osaka, JP, ³Gastroenterological Center, Yokohama, JP, ⁴Graduate School of Medicine, Kyoto University, Kyoto, JP, ⁵National Cancer Center Hospital East, Kashiwa, JP, ⁶Cancer Institute Hospital of JFCR, Tokyo, JP, ⁷NHO Kyushu Cancer Center, Fukuoka, JP, ⁸National Cancer Center Hospital, Tokyo, JP, ⁹Kyushu University, Fukuoka,
18:00 - 18:00 133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)

T. Yau1, T. Meyer2, R.K. Kelley3, M. Mangeshkar4, A.-L. Cheng5, A. El-Khoueiny6, G. Abou-Alfa7, 1Queen Mary Hospital, Hong Kong, HK, 2UCL Cancer Institute/Paul O’Gorman Building, London, GB, 3University of California San Francisco Parnassus Campus, San Francisco, US, 4Exelixis, Alameda, US, 5National Taiwan University, Taipei, TW, 6University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, 7Memorial Sloan-Kettering Cancer Center, New York, US

18:00 - 18:00 134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer

D. Izumi1, F. Gao2, Y. Chen3, T. Ishimoto4, K. Horino1, S. Shimada1, Y. Kodera5, H. Baba4, J. Chen3, X. Wang6, A. Goel7, 1CHO Kumamoto General Hospital, Yatsushiro, JP, 2City University of Hong Kong, Hong Kong, HK, 3Nanjing Medical University, Nanjin, CN, 4Kumamoto University, Kumamoto, JP, 5National Taiwan University, Taipei, TW, 6City University of Hong Kong, Hong Kong, CN, 7Baylor University Medical Center, Dallas, US

18:00 - 18:00 135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma

J. Fang, L. Pan, X. Cai, Y. Wang, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, CN

18:00 - 18:00 136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features

Y. Cheng, X. Ma, J. Yang, West China Hospital of Sichuan University, Chengdu, CN

18:00 - 18:00 137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer

Z. Chen, Y. Xu, J. Gong, M. Zhang, T. Tian, X. Zhang, C. Zhang, J. Gao, L. Shen, Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN

18:00 - 18:00 138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre

A. Palod1, A. Jain2, M. Sadhwani2, S. J Pandya3, 1Shreeji Hospital, Indore, IN, 2GUJARAT CANCER RESEARCH INSTITUTE, AHMEDABAD, IN, 3Gujarat Cancer Research Institute, Ahmedabad, IN

18:00 - 18:00 139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy

A. Besen1, E. Topkan2, 1Adana Numune Research and Training Hospital, Adana, TR,
18:00 - 18:00 140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
M. Abdelkader, Faculty of Medicine - Suez Canal University, Ismailia, EG

18:00 - 18:00 141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
J. Chang, M. Xu, W. Li, H. Sun, X. Zhu, Fudan University Shanghai Cancer Center, Shanghai, CN

18:00 - 18:00 142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
S. Gohar¹, B. Montaser², N. Elabd², M. Elhamoly², A. Saleh², E. Salem², G. Abo-Zeid², M. Rizk², ¹Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG, ²Faculty of Medicine - Menoufia University, Shebin El Kom, EG

18:00 - 18:00 143P - NOTCH3 expression predicts poor survival in advanced esophageal squamous cell cancers
R. Pramanik¹, P. Das², A. Sharma², S. Kumar², S. Bhorival², S. Pathy², A. Saraya², ¹Institute Rotary Cancer Hospital, New Delhi, IN, ²All India Institute of Medical Sciences, New Delhi, IN

18:00 - 18:00 144P - Severe hypovitaminosis D in metastatic gastric cancer patients from the Northern and Southern hemispheres: Data from the EXPAND phase III trial
R. Obermannova¹, D. Valik¹, D. Hasenclever², L. Zdrazilova-Dubska³, U. Hacker⁴, R. Demlova¹, I. Selingerova¹, F. Lordick⁵, ¹Masaryk Memorial Cancer Institute, Brno, CZ, ²Medical Faculty of University Leipzig, Germany, Leipzig, DE, ³Masaryk University Faculty of Medicine, Brno, CZ, ⁴University of Leipzig, Leipzig, DE, ⁵Uniklinikum Leipzig - Gefaessmedizinisches Zentrum, Leipzig, DE

18:00 - 18:00 145P - Role of Glasgow prognostic score in chemo-naïve patients with advanced biliary tract cancer and good performance status
T. Moriwaki¹, N. Hasegawa¹, Y. Yamamoto¹, T. Yamada¹, M. Kanai², S. Kobayashi³, H. Eguchi⁴, S. Seo⁵, A. Taketomi⁶, K. Yoshimura⁷, E. Hatano⁸, H. Nagano⁹, T. Ioka³, ¹University of Tsukuba, Tsukuba, JP, ²Graduate School of Medicine, Kyoto University, Kyoto, JP, ³Osaka International Cancer Institute, Osaka, JP, ⁴Osaka University, Suita, JP, ⁵Kyoto University, Kyoto, JP, ⁶Hokkaido University Hospital, Sapporo, JP, ⁷Kanazawa University, Kanazawa, JP, ⁸Hyogo College of Medicine, Nishinomiya, JP, ⁹Yamaguchi University Graduate School of Medicine, Ube, JP

18:00 - 18:00 146P - Anatomic versus non-anatomic resection for hepatocellular carcinoma: A meta-analysis of high-quality studies
B. Zhang¹, M. Chen², J. Cao¹, L. Pan², Y. Liang², X. Cai², ¹Sir Run Run Shaw Hospital Zhejiang University, School of Medicine, Hangzhou, CN, ²Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, CN
18:00 - 18:00  **147P - Clinical outcomes of proximal gastrectomy versus total gastrectomy for locally advanced proximal gastric cancer: a propensity score matching analysis**

Y. Chen, L. Zhao, S. Hu, D. Zhao, Cancer Hospital - Chinese Academy of Medical Sciences, Beijing, CN

18:00 - 18:00  **148P - Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage**

S. Lee, I.-H. Kim, K. Shin, 1Seoul St. Mary's Hospital, of the Catholic University, Seoul, KR, 2The Catholic University of Korea, College of Medicine, Seoul, KR

18:00 - 18:00  **150P - A Phase Ib Study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction**

Y. Chao, M. Maglakelidze, L. Bulat, T. Yau, S. Tatasanvimon, C. Charoentun, W. Arpornwirat, J. Maneechavakajorn, A. Dechapunthuk, T. Ungtrakul, C.-J. Yen, L.-Y. Bai, W.-C. Chou, U. Weidermann, E. Garner-Spitzer, N. Ede, L. Chong, A. Good, 1Taipei Veterans General Hospital, Taipei, TW, 2ARENSIA, Tbilisi, GE, 3Institute of Oncology-Chisinau, Chisinau, MD, 4Queen Mary Hospital, Hong Kong, HK, 5Chulalongkorn University Faculty of Medicine, Pathumwan, TH, 6Maharaj Nakorn Chiang Mai Hospital, TH, 7National Cancer Institute, Bangkok, TH, 8Rajavithi Hospital, Pathumwan, TH, 9Songkla University Hospital, Hat Yai, TH, 10Chulabhorn Hospital, Bangkok, TH, 11National Cheng Kung University Hospital, Tainan, TW, 12China Medical University Hospital, Taichung, TW, 13Linkou Chang Gung Memorial Hospital, Taoyuan, TW, 14Medical University Vienna, Vienna, AT, 15MedUni Wien - Institute of Specific Prophylaxis and Tropical Medicine, Wien, AT, 16Imugene, Sydney, AU

18:00 - 18:00  **151P - Gene expression profiling for a better understanding of gastric cancer: From the perspective of metabolic rearrangement**

M. Xu, J. Chang, X. Wang, M. Ye, W. Weng, C. Tan, S.-J. Ni, D. Huang, L. Wang, W. Sheng, Fudan University Shanghai Cancer Center, Shanghai, CN

18:00 - 18:00  **152P - Long-term outcomes of three-dimensional conformal radiotherapy-based and intensity-modulated radiotherapy-based concurrent chemoradiotherapy in patients with thoracic esophageal squamous cell carcinoma**

C.-L. Chang, S.-Y. Wu, Taipei Medical University - Municipal Wan Fang Hospital, Taipei, TW

18:00 - 18:00  **153P - Exosomal LINC00174 facilitates epithelial-mesenchymal transition in residual hepatocellular carcinoma after insufficient radiofrequency ablation by regulating c-JUN/MYCBP/c-Myc axis**

D. Ma, Zhejiang Cancer Hospital, Hangzhou, CN

18:00 - 18:00  **154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study**

K. Murali, A. Collins, L. Salmon, M. Nikfarjam, T. John, 1Austin Hospital, Heidelberg, AU, 2Austin Health, Heidelberg, AU, 3Austin Health, Melbourne, AU
18:00 - 18:00 155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?
G. M. S¹, R. Arjunan², C. Ramachandra², S. Alta², ¹Kidwai Memorial Institute of Oncology, Bangalore, IN, ²Kidwai Cancer Institute, Bangalore, IN

18:00 - 18:00 156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Z. Xiang, Shanghai Jiao Tong University School of Medicine, Shanghai, CN

18:00 - 18:00 157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy
J. Yadav¹, J. Purkayastha², A. Talukdar¹, ¹Dr B Borooah Cancer Institute, Guwahati, IN, ²Dr. B. Borooah Cancer Institute, Guwahati, IN

18:00 - 18:00 158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer
K. Jinkook, SNUBH - Seoul National University Bundang Hospital, Seongnam, KR

18:00 - 18:00 159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016
H.M. Kim¹, J.S. Choi², ¹Yonsei University Wonju College of Medicine, Wonju, KR, ²Catholic Kwandong University, Incheon, KR

18:00 - 18:00 160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
J. Ha¹, K. Bang², C. Yoo¹, J. Jeong¹, H.-M. Chang¹, D. Oh¹, T.J. Song¹, D.H. Park¹, S.S. Lee¹, S.K. Lee¹, M.-H. Kim¹, J.-H. Park¹, K.-P. Kim¹, B.Y. Ryoo¹, ¹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ²Asan Medical Center, Seoul, KR

18:00 - 18:00 161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma
A. Alhanafy¹, S. El-Hefnawy², A. Saleh³, O. Elbahr³, ¹Faculty of Medicine - Menoufia University, Shebin El Kom, EG, ²Faculty of Medicine - Menoufia University, sheben elkom, EG, ³National Liver Institute - Menoufia University, sheben elkom, EG

18:00 - 18:00 162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival
J.Y. Je¹, M.-S. Kim², J.S. Seong³, J.W. Kim³, H.C. Park⁴, T.H. Kim⁵, J.H. Lee⁶, W.S. Yoon⁷, Y.H. Lee⁸, C.-S. Kay², ¹Soon Chun Hyang University Hospital, Cheonan, Cheonan, KR, ²St.mary hospital, incheon, Incheon, KR, ³Yonsei University College of Medicine, Seoul, KR, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁵Research Institute and Hospital, National Cancer Center, Goyang, KR, ⁶St Vincent Hospital The Catholic University of Korea, Suwon, KR, ⁷Korea University College of Medicine, Ansan, KR, ⁸Gyeongsang National University Hospital, Jinju, KR
18:00 - 18:00  **163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma**  
T. Sanlung, Srinagarind Hospital, Khon Kaen, TH

18:00 - 18:00  **164P - Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCG51502)**  
Y. Sasaki¹, T. Muranaka², Y. Kawamoto³, K. Sawada⁴, H. Nakatsumi⁵, K. Harada⁵, T. Miyagishima⁵, K. Hatanaka⁶, M. Dazai⁷, A. Ueda⁸, T. Sasaki³, K. Shinada⁹, Y. Tsuij¹⁰, S. Yuki¹¹, N. Sakamoto¹², N. Nishimoto³, Y. Sakata¹¹, Y. Komatsu³, ¹Hakodate Central General Hospital, Hakodate, JP, ²Municipal Wakkani Hospital, Wakkani, JP, ³Hokkaido University Hospital, Sapporo, JP, ⁴National Cancer Center Hospital East Japan, Chiba, JP, ⁵Kushiro Rosai Hospital, Kushiro, JP, ⁶Hakodate Municipal Hospital, Hakodate, JP, ⁷Sapporo Medical Center NTT EC, Sapporo, JP, ⁸Toyama Red Cross Hospital, Toyama, JP, ⁹Keiwaike Ebetsu Hospital, Ebetsu, JP, ¹⁰KKR Tonan Hospital, Sapporo, JP, ¹¹Misawa City Hospital, Misawa, JP

18:00 - 18:00  **165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety**  
T. Oikawa, K. Yusa, T. Okamoto, M. Yonezawa, T. Satou, T. Abe, K. Endo, K. Sawara, H. Kuroda, Y. Takikawa, Iwate Medical University School of Medicine, Morioka, JP

18:00 - 18:00  **166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study**  
T. Sasaki¹, S. Nakano¹, S. Yuki¹, K. Sawada², T. Muranaka³, Y. Kawamoto¹, H. Nakatsumi¹, T. Ando¹, H. Yoshita¹, K. Harada⁵, Y. Kobayashi⁵, T. Miyagishima⁵, K. Hatanaka⁶, A. Tanimoto⁷, A. Ishiguro⁷, T. Honda⁸, M. Dazai⁹, Y. Komatsu¹, ¹Hokkaido University Hospital, Sapporo, JP, ²National Cancer Center Hospital East Japan, Chiba, JP, ³Municipal Wakkani Hospital, Wakkani, JP, ⁴Toyama University Hospital, Toyama, JP, ⁵Kushiro Rosai Hospital, Kushiro, JP, ⁶Hakodate Municipal Hospital, Hakodate, JP, ⁷Teine Keijinkai Hospital, Sapporo, JP, ⁸Nagasaki University Hospital, Nagasaki, JP, ⁹Sapporo Medical Center NTT EC, Sapporo, JP

18:00 - 18:00  **167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)**  
A. Makiyama¹, J. Nakazawa², T. Otsuka³, M. Shimokawa⁴, F. Koga³, Y. Ueda⁵, A. Komori⁶, S. Arima⁷, M. Fukahori⁸, T. Honda⁹, T. Shibuki¹⁰, T. Shirakawa¹¹, K. Nio¹², Y. Ide¹³, N. Ureshino⁵, K. Mitsugi¹⁴, ¹JCHO Kyusyu Hospital, Kitakyushu, JP, ²Kagoshima City Hospital, Kagoshima, JP, ³Saga-ken Medical Centre Koseikan, Saga, JP, ⁴National Hospital Organization Kyusyu Cancer Center, Hakata, JP, ⁵Japanese Red Cross Kumamoto Hospital, Kumamoto, JP, ⁶Oita University Faculty of Medicine, Oita, JP, ⁷Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, JP, ⁸Kurume University Hospital, Fukuoka, JP, ⁹Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JP, ¹⁰Imari Arita Kyoritsu Hospital, Saga, JP, ¹¹Fukuoka Wajiro Hospital, Fukuoka, JP, ¹²Sasebo Kyosai Hospital, Nagasaki, JP, ¹³Japanese Red Cross
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)

T. Honda¹, S. Nakano², S. Yuki³, K. Sawada³, T. Muranaka⁴, Y. Kawamoto², H. Nakatsumi², H. Yoshita⁵, T. Andō⁵, K. Harada⁶, Y. Kobayashi⁶, T. Miyagishima⁶, K. Hatanaka⁷, A. Tanimoto⁸, A. Ishiguro⁸, M. Dazai⁹, T. Sasaki², Y. Komatsu², ¹Nagasaki University Hospital, Nagasaki, JP, ²Hokkaido University Hospital, Sapporo, JP, ³National Cancer Center Hospital East Japan, Chiba, JP, ⁴Municipal Wakkanai Hospital, Wakkanai, JP, ⁵Toyama University Hospital, Toyama, JP, ⁶Kushiro Rosai Hospital, Kushiro, JP, ⁷Hakodate Municipal Hospital, Hakodate, JP, ⁸Teine Keijinkai Hospital, Sapporo, JP, ⁹Sapporo Medical Center NTT EC, Sapporo, JP

169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways

Y. Wang¹, C. Wang¹, H. Xiao², H. Wu¹, H. He¹, J. Cui¹, W. Li¹, ¹The First Hospital of Jilin University, Changchun, CN, ²ChinaJapan Union Hospital of Jilin University, Changchun, CN

170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma

Y. Ashraf¹, M. Mostafa², ¹Suez Canal University - Faculty of Medicine, Ismailia, EG, ²faculty of medicine sue canal university, Ismailia, EG

171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy

Y. Wang, 4th Hospital Hebei Medical University, Shijiazhuang, CN

172P - Preoperative neutrophil&

T. Miura¹, T. Aoki², H. Ohtsuka², S. Aoki², T. Hata², M. Iseki², T. Takadate², K. Ariake², K. Kawaguchi², K. Masuda², M. Ishida², M. Mizuma², H. Hayashi², K. Nakagawa², T. Morikawa², F. Motoi², H. Sasano², T. Naitoh², T. Kamei², M. Unno², ¹Tohoku University Hospital, Sendai, JP, ²Tohoku University Graduate School of Medicine, Sendai, JP

173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells

R. Tsunedomi¹, K. Yoshimura², Y. Kimura¹, M. Nishiyama¹, S. Matsukuma¹, Y. Tokumitsu¹, S. Tomochika¹, M. Iida¹, N. Suzuki¹, S. Takeda¹, S. Yoshino³, S. Hazama⁴, H. Nagano¹, Yamauchi University Graduate School of Medicine, Ube, JP, ²Showa University, Shinagawa, JP, ³Yamauchi University Hospital, Ube, JP, ⁴Yamauchi University, Ube, JP

174P - Progression of computer aided diagnosis on gastric cancer

Y. Yu, Shanghai Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CN
18:00 - 18:00  175P - Hypermethylation of the PCDHB15 promoter predicts the prognosis in gastric cancer
Y.-T. Lee1, P.-Y. Hsu2, Y.-M. Chuang2, H. Jin3, A.S.L. Cheng4, E.K.W. Ng4, C.-J. Liu5, Y.-C. Chen6, F. Cheng6, M.W.Y. Chan6, 1Chia Yi Christian Hospital, Chiayi City, TW, 2National Chung Cheng University, Min Hsiung, TW, 3Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, CN, 4Chinese University of Hong Kong, Hong Kong, HK, 5Taipei Veterans General Hospital, Taipei, TW, 6National Chung Cheng University, Min Hsiung, Chiayi, TW

18:00 - 18:00  176P - DCLK1 promotes tumour invasion and metastasis through epithelial-mesenchymal transition and the MEK/ERK pathway in esophageal squamous cell carcinoma
J. Yao1, X. Fan1, Y. Ge1, J. Liu1, N. Weygant2, G. An1, 1Beijing Chaoyang Hospital - Capital Medical University, Beijing, CN, 2The University of Oklahoma Health Sciences Center, Oklahoma City, US

18:00 - 18:00  177P - Comparison of nab-paclitaxel plus ramcipuram and paclitaxel plus ramcipuram in patients with pretreated metastatic gastric cancer
Y. Horita, Y. Mihara, T. Hamaguchi, Saitama Medical University International Medical Center, Hidaka, JP

18:00 - 18:00  178P - Chief cell in stomach have stem cell activity and potential to develop gastric cancer
A. Yamamura1, J. Matsuo2, M. Lim Yi Hui2, D. Liana Heng2, K. Kofu2, Z.H. Md2, D. Douchi2, K.G. Yeoh3, T. Kamei4, T. Naitoh4, M. Osato2, M. Unno4, Y. Ito2, 1Tohoku University, Sendai, JP, 2National University of Singapore, Singapore, SG, 3National University Health System, Singapore, SG, 4Tohoku University Graduate School of Medicine, Sendai, JP

18:00 - 18:00  179P - Postoperative Adjuvant transarterial chemoembolization versus surgery alone for resected hepatocellular carcinoma: A propensity-score matching study
M. Chen1, J. Cao1, L. Pan2, B. Zhang1, X. Cai2, 1Sir Run Run Shaw Hospital Zhejiang University,School of Medicine, Hangzhou, CN, 2Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, CN

18:00 - 18:00  180P - LHPP inhibit the cell proliferation and EMT via the TGFβ&#x003B2;/SMAD3 signaling pathway in iCCA
D. Wang, Fudan University Shanghai Cancer Center, Shanghai, CN

18:00 - 18:00  181P - The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
A. Dean1, A. Das2, M. McNulty3, N. Travers3, 1Saint John of God Hospital Subiaco, Subiaco, AU, 2St. John of God, SUBIACO, AU, 3St. John of God Subiaco, SUBIACO, AU

18:00 - 18:00  182P - Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less
A. Das1, A. Dean2, N. Travers3, M. Johansson3, I. Yusoff3, 1St. John of God, SUBIACO, AU,
183P - Epidemiologic profile of gastric cancer in East Azerbaijan, Iran: 2 years population-based cancer registry results
P. Jabbaripour1, Z. Sanaat2, R. Dolatkhah3, M.H. Somi4, 1Ghazi Hospital-Tabriz University, Tabriz, IR, 2Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Tabriz, IR, 3Epidemiologic Profile of Gastric Cancer in East Azerbaijan, Iran: 2 years Population Based Cancer Registry Results, Tabriz, IR, 4Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Tabriz, IR

184P - Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression
J. Ji, Shanghai Ruijin Hospital, Shanghai Jiao Tong University, College of Medicine, Shanghai, CN

185P - Evaluation of the effect of cholesorption on the concentration of TNF-α and CCL3B1; in the serum of the blood in tumours of the biliopancreatoduodenal zone
M. Salokhiddinov1, S. Matmuratov1, E. Stamou2, 1Tashkent Medical Academy, Tashkent, UZ, 2University of Aberdeen, QP, GB

186P - Efficacy and safety of sorafenib following hepatic resection in patients with hepatocellular carcinoma: A meta-analysis
Y. Yuan1, Y. Yun2, L. Lei3, N. Junsheng3, Z. Weiping4, 110th People's Hospital of Shanghai, Tongji University, Shanghai, CN, 2Ministry of Education, Shanghai, CN, 3Shanghai Key Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai, CN, 4Second Military Medical University, Shanghai, CN

187P - Correlation between splenic dose and grade of hematological toxicity in chemoradiation of stomach
U. Velu, A. Singh, D. Fernandes, Kasturba Medical College - Manipal, Manipal, IN

188P - Survival and prognostic factors in cholangiocarcinoma: A single-center experience
S. Payapwattanawong1, K. Maneenil2, S. Limtapatip2, S. Laohavinij2, 1Rajavithi Hospital, Pathumwan, TH, 2Rajavithi Hospital, Bangkok, TH

189P - Stereotactic body radiotherapy in primary hepatocellular carcinoma and oligometastasis to liver: A single Institution experience
S. Paul, V.A.R. Palkonda, L. Kashyap, K. Bhattacharya, P. Upadhyay, Apollo Cancer Institute, Hyderabad, IN

190P - Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
Y. Nagata1, C. Kinoshiba1, U. Ishimoto2, T. Kano3, M. Ishikawa4, H. Mikuni5, K. Nakatsuka6, K. Harada1, T. Nishimura1, M. Noguchi1, R. Sawada1, K. Amano1, M.
18:00 - 18:00  **191P - Assessment of efficacy and safety of sorafenib versus no treatment in Egyptian hepatocellular carcinoma patients**

N. El Baghdady¹, L. El Wakeel², M. Ellithy³, N. Eltohamy⁴, S. Shaheen⁵, A.E.R. El Naggar⁶, ¹Modern University for Technology and Information, Cairo, EG, ²Ain Shams University Faculty of medicine, Cairo, EG, ³Electricity Hospital, Cairo, EG, ⁴Ain Shams University - Faculty of Pharmacy, Cairo, EG, ⁵Cairo University- Faculty of Medicine, Giza, EG

18:00 - 18:00  **192P - Clinical importance of the determination of interleukin-6 in bile and blood in tumours of biliopancreatoduodenal zone**

M. Salokhiddinov¹, S. Matmuratov¹, E. Stamou², ¹Tashkent Medical Academy, Tashkent, UZ, ²University of Aberdeen, QP, GB

18:00 - 18:00  **193P - Metastatic carcinoma gall bladder: A clinicoepidemiological profile of Indian patients**

A. Rathore, Army Hospital Research & Referal, New Delhi, IN

18:00 - 18:00  **195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P&x002B;GEM) for unresectable locally advanced pancreatic cancer (LAPC)**

A. Tanimoto¹, M. Yagisawa², S. Nakano², Y. Kawamoto², S. Yuki², A. Ishiguro³, T. Takahata¹, A. Sato³, I. Iwanaga⁴, N. Ehira⁴, M. Ueyabashi⁴, O. Muto⁵, T. Sasaki⁶, K. Hatanaka⁶, M. Tateyama⁷, T. Wakabayashi⁸, M. Dazaï⁹, S. Minami¹⁰, Y. Sakata¹¹, Y. Komatsu¹², ¹Teine Keijinkai Hospital, Sapporo, JP, ²Hokkaido University Hospital, Sapporo, JP, ³Hirosaki University Graduate School of Medicine, Hirosaki, JP, ⁴Kitami Red Cross Hospital, Kitami, JP, ⁵Japanese Red Cross Akita Hospital, Akita, JP, ⁶Hakodate Municipal Hospital, Hakodate, JP, ⁷Tomakomai Nisshou Hospital, Tomakomai, JP, ⁸Akita City Hospital, Akita, JP, ⁹Sapporo Medical Center NTT EC, Sapporo, JP, ¹⁰Oji General Hospital, Tomakomai, JP, ¹¹Misawa City Hospital, Misawa, JP

18:00 - 18:00  **196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma**

N. Travers¹, A. Dean², K. Armstrong¹, L. Peeperkorn¹, M. Tan¹, A. Das³, ¹St. John of God Subiaco, SUBIACO, AU, ²Saint John of God Hospital Subiaco, Subiaco, AU, ³St. John of God, SUBIACO, AU

18:00 - 18:00  **197TP - GLOW: Zolbetuximab & &**

R.-H. Xu¹, Z. Dongsheng², J. Ajani³, S.-E. Al-Batran⁴, Y.-J. Bang⁵, D. Catenacci⁶, P. Enzinger⁷, D. Ilson⁸, S. Kim⁹, F. Lordick¹⁰, K. Shitara¹¹, E. Van Cutsem¹², A. Arozullah¹³, J. Wook Park¹³, M. Shah¹⁴, ¹SunYat-Sen University Cancer Center, Guangzhou, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN, ³The University of Texas, MD
18:00 - 18:00  **198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo & &**


18:00 - 18:00  **199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy**

T. Yau¹, L. Rimassa², A.-L. Cheng³, J.-W. Park⁴, F. Braiteh⁵, A. Chaudhry⁶, F. Benzaghou⁷, P. Thuluvath⁸, S. Hazra⁹, S. Milwee⁹, B. Tan¹⁰, R. Sinha¹¹, Z. Kayali¹², A. Zhu¹³, R.K. Kelley¹⁴, 1Queen Mary Hospital, Hong Kong, HK, 2Istituto Clinico Humanitas, Rozzano, IT, 3National Taiwan University, Taipei, TW, 4National Cancer Center, Goyang, KR, 5Comprehensive Cancer Centers of Nevada, Las Vegas, US, 6Summit Cancer Centers, Spokane, US, 7Ipsen Innovation, Les Ulis, FR, 8Mercy Medical Center, Baltimore, US, 9Exelixis, Alameda, US, 10Siteman Cancer Center, St. Louis, US, 11Piedmont Cancer Institute, Atlanta, US, 12Riverside Community Hospital, Rialto, US, 13Massachusetts General Hospital, Boston, US, 14University of California San Francisco Parnassus Campus, San Francisco, US

18:00 - 18:00  **GU, pca**

18:00 - 18:00  **200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study**

B.H. Chung¹, K. Mcquarrie², A. Bjartell³, S. Chowdhury⁴, A. Pereira De Santana Gomes⁵, M. Özgüroğlu⁶, Á. Júarez Soto⁷, A. Merseburger⁸, H. Uemura⁹, D. Ye¹⁰, R. Given¹¹, B. Miladinovic¹², N. Li¹³, S. Hudgens¹³, L. Floden¹³, A. Lopez-Giltilz¹⁴, K. Chi¹⁵, N. Agarwal¹⁶, 1Yonsei University College of Medicine and Gangnam Severance Hospital,
Seoul, KR, 2Janssen Research & Development, Spring House, US, 3Skåne University Hospital, Lund University, Malmö, SE, 4Guy’s, King’s, and St Thomas’ Hospitals, and Sarah Cannon Research Institute, London, GB, 5Liga Norte Riograndense Contra O Cancer, Natal, BR, 6Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Fatih/Istanbul, TR, 7Hospital Universitario de Jerez de la Frontera, Cadiz, ES, 8University Hospital Schleswig-Holstein, Lübeck, DE, 9Kindai University Faculty of Medicine, Osaka, JP, 10Fudan University Shanghai Cancer Center, Shanghai, CN, 11Urology of Virginia, Eastern Virginia Medical School, Norfolk, US, 12Janssen Research & Development, San Diego, US, 13Clinical Outcomes Solutions, Tucson, US, 14Janssen Research & Development, Los Angeles, US, 15BC Cancer, Vancouver, CA, 16Huntsman Cancer Institute, Salt Lake City, US

18:00 - 18:00 201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial

J.S.-T. Pang1, N. Shore2, M. Smith3, T. Tammela4, A. Ulys5, E. Vjaters6, S. Polyakov7, M. Jievaltas8, M. Luz9, B. Alekseev10, I. Kuss11, M.-A. Le Berre12, A. Snapir13, T. Sarapohja13, K. Fizazi14, Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, 2Atlantic Urology Clinics, Myrtle Beach, US, 3Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, US, 4Tampere University Hospital, Tampere, FI, 5Institute of Oncology, Vilnius, LT, 6Pauls Stradins Clinical University Hospital, Riga, LV, 7N.N. Alexandrov National Cancer Centre, Minsk, BY, 8Lithuanian University of Health Sciences, Medical Academy, Kaunas, LT, 9Hospital Erasto Gaertner, Curitiba, BR, 10Hertzen Moscow Oncology Research Institute, Moscow, RU, 11Bayer AG, Berlin, DE, 12Bayer Healthcare, Loos, FR, 13Orion Corporation Orion Pharma, Espoo, FI, 14Institut Gustave Roussy, Villejuif, FR

18:00 - 18:00 202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis

T.H. So1, C.L. Chiang2, T.C. Lam3, F.T. Chan3, H. Choi4, 1Queen Mary Hospital, Hong Kong, HK, 2Tuen Mun Hospital, Tuen Mun, HK, 3Private Oncologist, Hong Kong, HK, 4University of Hong Kong, Hong Kong, HK

18:00 - 18:00 203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer

S. Singla1, S. Maheboob Hussain1, G. Shrivastav2, N. Sonthwal3, H. Chaturvedi2, A. Gupta4, 1Max Institute of Cancer Care, New Delhi, IN, 2Max Super Specialty Hospital, Delhi, IN, 3All India Institute of Medical Sciences, Delhi, IN, 4Institute Rotary Cancer Hospital, New Delhi, IN

18:00 - 18:00 204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)


18:00 - 18:00 205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong

Last update: 18-11-2019 08:34:53am
18:00 - 18:00  **206P - Population-based validation of the risk stratification among prostate cancer patients**  
**M. Xie**, Peking University First Hospital, Beijing, CN

18:00 - 18:00  **GU, non pca**

18:00 - 18:00  **211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis**  
**C.F. Ng**, T.G. Kwon, M. Eto, H. Miyake, S.I. Seo, S.-S. Byun, J.L. Lee, B. Rosbrook, E. Grande, M. Gross-Goupil, D. Quinn, The Chinese University of Hong Kong, Hong Kong, HK, School of Medicine, Kyungpook National University, Daegu, KR, Kyushu University, Fukuoka, JP, Hamamatsu University School of Medicine, Hamamatsu, JP, Sungkyunkwan University, Seoul, KR, Seoul National University Bundang Hospital, Seongnam, KR, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, Pfizer Oncology, San Diego, US, MD Anderson Cancer Center Madrid, Madrid, ES, CHU Bordeaux Hopital St. André, Bordeaux, FR, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US

18:00 - 18:00  **212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice**  
**A. Rauthan**, P. Patil, S. Sampige Prasannakumar, S. Zaveri, Manipal Comprehensive Cancer Center Manipal Hospital, Bangalore, IN

18:00 - 18:00  **213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre**  
**R. Kanesvaran**, J. Chan, H.-S. Tan, J. Hong, C.K. Toh, Q.S. Ng, T. Rajasekaran, L. Sivabalan, C. Ng Yi, National Cancer Centre Singapore, Singapore, SG, National Cancer Center Singapore, Singapore, SG

18:00 - 18:00  **214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib**  

18:00 - 18:00  **215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications**  
**S. Singh**, MAX SUPERCIALITY HOSPITAL SHALIMAR BAGH, Delhi, IN
18:00 - 18:00  
**216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour**  
M. Mostafa1, Y. Ashraf2, 1Faculty of medicine surrey canal university, Ismailia, EG, 2Suez Canal University - Faculty of Medicine, Ismailia, EG

18:00 - 18:00  
**217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab**  
K. Ogihara1, E. Kikuchi1, T. Okabe2, S. Hattori3, R. Yamashita4, S. Yoshimine5, S. Shirotake2, K. Matsumoto1, R. Mizuno1, S. Hara3, M. Oyama2, M. Niwakawa4, M. Oya1, 1Keio University School of Medicine, Tokyo, JP, 2Saitama Medical University International Medical Center, Saitama, JP, 3Kawasaki Municipal Hospital, Kanagawa, JP, 4Shizuoka Cancer Center, Shizuoka, JP, 5Saitama City Hospital, Saitama, JP

18:00 - 18:00  
**219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients**  
A.D. Satiti1, H. Mistry2, Y.P. Song3, A. Choudhury2, 1Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, ID, 2University of Manchester, Manchester, GB, 3The Christie Hospital NHS Foundation Trust, Manchester, GB

18:00 - 18:00  
**220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma**  
A. Tamhankar, P. Ahluwalia, G. Gagan, S. Singh, Max institute of cancer care, Delhi, IN

18:00 - 18:00  
**221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence**  
H. Lai1, Y.-L. Su2, S.-Y. Huang1, C.-C. Wu1, 1Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TW, 2Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung, TW

18:00 - 18:00  
**222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis**  
R. Kanodia1, A. Jalan2, R. Malhotra1, S. Gurung2, 1All India Institute of Medical Sciences, Delhi, IN, 2BP Koirala Memorial Cancer Hospital, Chitwan, NP

18:00 - 18:00  
**223TIP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma**  
D. Petrylak1, J. Rosenberg2, J. Lee3, J. Yonese4, I. Duran5, Y. Loriot6, G. Sonpavde7, C. Wu8, E. Gartner9, A. Melhem-Bertrandt8, T. Powles10, 1Yale University School of Medicine, New Haven, US, 2Memorial Sloan Kettering Cancer Center, New York, US, 3Asan Medical Center, University of Uslan College of Medicine, Seoul, KR, 4Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JP, 5Hospital Universitario “Marqués de Valdecilla”, Santander, ES, 6Institut Gustave Roussy, Paris, FR, 7Dana Farber Cancer Institute, Boston, US, 8Astellas Pharma US, Inc., Northbrook, US, 9Seattle Genetics, Inc., Bothell, US, 10Barts Cancer Institute, Queen Mary University of London, London, GB
18:00 - 18:00  **Gynaecological cancers**

18:00 - 18:00  **230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort**

L. Wu¹, J. Zhu², R. Yin³, X. Wu⁴, G. Lou⁵, J. Wang⁶, Y. Gao⁷, B. Kong⁸, X. Lu⁹, Q. Zhou¹⁰, Y. Wang¹¹, Y. Chen¹², W. Lu¹³, W. Li¹⁴, Y. Cheng¹⁵, J. Liu¹⁶, X. Ma¹⁷, J. Zhang¹⁷, ¹Cancer Hospital - Chinese Academy of Medical Sciences, Beijing, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN, ³West China Second University Hospital, Sichuan University, Chengdu, CN, ⁴Obstetrics and Gynecology Hospital of Fudan University, Shanghai, CN, ⁵Harbin Medical University Cancer Hospital, Harbin, CN, ⁶Hunan Cancer Hospital, Changsha, CN, ⁷Beijing Cancer Hospital, Beijing, CN, ⁸Qilu Hospital of Shandong University, Jinan, CN, ⁹Obstetrics and Gynecology Hospital, Fudan University, Shanghai, CN, ¹⁰Chongqing Cancer Hospital, Chongqing, CN, ¹¹Xi'an Jiatong University, Xi'an, CN, ¹²The First Affiliated Hospital of Soochow University, Suzhou, CN, ¹³Women's Hospital, Zhejiang University, Hangzhou, CN, ¹⁴The First Hospital of Jilin University, Changchun, CN, ¹⁵Jilin Cancer Hospital, Changchun, CN, ¹⁶Sun Yat-sen University Cancer Center, Guangzhou, CN, ¹⁷AstraZeneca, Shanghai, CN

18:00 - 18:00  **231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore**

D.S. Tan¹, J.J. Chan², J.K. Loke³, R. Hettle⁴, W. Ghosh⁵, A. Viswambaram⁵, C.C. Yu³, ¹NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG, ²National Cancer Centre, Singapore, SG, ³AstraZeneca, Singapore, SG, ⁴PAREXEL Access, London, GB, ⁵Costello Medical Singapore Pte Ltd, Singapore, SG

18:00 - 18:00  **232P - (Withdrawn)**

18:00 - 18:00  **233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility**

N. Hitchen, A. Mweempwa, M. Wilson, Auckland City Hospital, Auckland, NZ

18:00 - 18:00  **234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre**

E. Wong, K. Chrystal, M. Wilson, L. Wilson, C. Forgeng, K. Gamet, R. Stephens, Auckland City Hospital, Auckland, NZ

18:00 - 18:00  **235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study**

J.-G. Zhou¹, S.-H. Jin², H. Ma³, ¹Zunyi Medical College Affiliated Hospital, Zunyi, CN, ²Zunyi Medical College Affiliated Stemmatological Hospital, Zunyi City, CN, ³Zunyi Medical College Affiliated Hospital, Zunyi City, CN

18:00 - 18:00  **236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What's next PARP inhibitors?**
18:00 - 18:00  
**237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience**  
S. Baghmar¹, A. Agarwal², C. Gauda³, S. Qureshi³, P. Malik⁴, V. Vaibhav³, ¹Institute of Liver and Biliary Sciences, New Delhi, IN, ²BLK Superspeciality Hospital, New Delhi, IN, ³BLK Superspeciality Hospital, new delhi, IN, ⁴B.R. Ambedkar Institute Rotary Cancer Hospital (AIMS), New Delhi, IN

18:00 - 18:00  
**238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center**  
V. Gupta, K. Raju, T.S. Rao, R. Iyer, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, IN

18:00 - 18:00  
**239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer**  
V. Pareek¹, R. Bhalavat², M. Chandra², ¹Jupiter Hospital, Mumbai, IN, ²Jupiter Hospital, Thane, IN

18:00 - 18:00  
**240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan**  
A. Zhabagina, Semey State Medical University, Semey, KZ

18:00 - 18:00  
**241P - Impact of genomic alterations and HPV genotypes on clinical outcomes of Japanese patients with locally advanced cervical cancer**  
I. Kuno¹, D. Takayanagi², H. Yoshida³, S. Hirose², N. Murakami³, M. Uno³, M. Ishikawa³, M. Matsuda², Y. Asami², Y. Shimada², K. Okuma³, T. Kohno², J. Itami³, K. Shiraishi², T. Kato³, ¹Osaka International Cancer Institute, Osaka, JP, ²National Cancer Center Research Institute, Tokyo, JP, ³National Cancer Center Hospital, Tokyo, JP

18:00 - 18:00  
**242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment**  
V. Pareek¹, R. Bhalavat², M. Chandra², ¹Jupiter Hospital, Mumbai, IN, ²Jupiter Hospital, Thane, IN

18:00 - 18:00  
**243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening**  
P. Wibisono¹, V. Damay¹, K. Waren⁴, I.K. Effendi², ¹University of Pelita Harapan, Tangerang, ID, ²Siloam Hospital Lippo Village, Tangerang, ID

18:00 - 18:00  
**245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia**  
H. Puspitaningtyas¹, D. Napitupulu², K. Mualim³, A. Kusumanto², L. Lazuardi⁴, S. Hutajulu¹, ¹Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, ID, ²Universitas Gadjah Mada, Sleman, ID, ³Temanggung Distric Health Office, Temanggung, ID, ⁴Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Sleman, ID
18:00 - 18:00  **246P - The main of reasons of advanced stage cervical cancer in Uzbekistan**

Z. Nargiza¹, O. Akhmedov², V. Saidakhmedova², E. Osmanova³, N. Umarova⁴, G. Nekova², M. Otajonov², ¹National Oncology Center, Fergana-Uzbekistan, Fergana, UZ, ²National Cancer Center, Tashkent, UZ, ³Republican Specialized Scientific Practical Medical Center of Oncology and Radiology, Tashkent, UZ, ⁴National Cancer Research Center of Uzbekistan, Tashkent, UZ

18:00 - 18:00  **247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease**

V.P.B. Koyyala, A. Jajodia, A. Chaturvedi, V. Mahawar, M. Sharma, P. Goyal, V. Talwar, S. Goyal, D.C. Doval, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN

18:00 - 18:00  **248P - Retrospective review of metastatic carcinoma of cervix from a tertiary cancer institute of south India**

A. Halder, D. Lokanatha, L. Jacob, M. Sureshbabu, K. Lokesh, A. Rudresha, L. Rajeev, S. Smitha, Kidwai Cancer Institute, Bangalore, IN

18:00 - 18:00  **249P - Accuracy of endometrial biopsy by Pipelle: A systematic review and meta-analysis**

J. Gou¹, Z.Y. Li², ¹West China Second Hospital, Chengdu, CN, ²West China Second Hospital, Sichuan University, Chengdu, CN

18:00 - 18:00  **250P - Non-endometrioid endometrial cancer: Analysis of different adjuvant treatment modalities**

G. Nogueira Da Costa¹, I. Eiriz², I. Fernandes³, M. Batista⁴, R. Vicente⁴, A. Mendes⁴, T. Tomás⁴, C. Santos⁴, S. Braga⁴, ¹Hospital Nossa Senhora do Rosário (Centro Hospitalar Barreiro Montijo, EPE), Barreiro, PT, ²Hospital Prof. Doutor Fernando Fonseca E.P.E (Amadora/Sintra), Amadora, PT, ³Centro Hospitalar Barreiro Montijo, Barreiro, PT, ⁴Hospital Prof. Dr Fernando Fonseca E.P.E (Amadora/Sintra), Amadora, PT

18:00 - 18:00  **251P - A prognostic index model for predicting long-term recurrence of uterine leiomyoma after initial myomectomy in women aged 18-44 years**

X. Ming¹, N. Li², D. Nie³, J.H. Gou⁴, L.Q. Xue⁴, Z.Y. Li⁴, ¹West China Second Hospital, Chengdu, CN, ²the First People’s Hospital of Zun Yi, Chengdu, CN, ³the Affiliated Hospital of Southwest Medical University, Chengdu, CN, ⁴West China Second Hospital, Sichuan University, Chengdu, CN

18:00 - 18:00  **252P - Uterine sarcomas in Qatar: Clinico-pathological characteristics and treatment outcome**

A. Fadlelseid, H. Mr Ghazouani, W. Al Saadi, N. Omar, H. Al Malik, Hamad Medical Corporation (HMC)-National Center for Cancer Care and Research (Al Amal Hospital), Doha, QA

18:00 - 18:00  **253P - Anti-PD-1-induced reinvigoration of tumour-infiltrating CD8+ T cells in epithelial ovarian cancer patients is correlated with T cell factor-1**

J. Park¹, G. Leem², E.-C. Shin³, Y.J. Lee¹, J.-Y. Lee¹, S.-H. Park², S. Kim¹, ¹Yonsei University College of Medicine, Seoul, KR, ²Korea Advanced Institute of Science and
254P - Cyclin E1 is a shared biomarker of subsets of high grade serous ovarian cancer (HGSOC) and basal like breast cancer (BLBC)
D. Aziz1, C. Lee2, V. Chin2, K. Fernandez2, D. Etemadmoghadam3, D. Bowtell4, P. Waring1, C.E. Caldon2, 1The University of Melbourne, Melbourne, AU, 2The Kinghorn Cancer Centre, Sydney, AU, 3Victorian Comprehensive Cancer Center, Parkville, AU, 4Peter MacCallum Cancer Center, Melbourne, AU

255P - MEX3A is a prognostic biomarker and correlates with RNA splicing and cell proliferation in endometrial cancer by analysis of RNA-seq data
H. Jing, West China Medical Center of Sichuan University, Chengdu, CN

256P - Lnc-AL445665.1-4 may be involved in the development of multiple uterine leiomyoma through interacting with miR-146b-5p
E. Yang, West China Second Hospital, Chengdu, CN

257P - Treatment results of low risk gestational trophoblastic neoplasia (GTN) from a tertiary hospital, Chennai, India
R. M. P, Madras Medical College, Chennai, IN

258P - Assessment of sexual health in patients treated for ovarian cancer
R. Madan, C. Dracham, A. Elangovan, B. Rai, S. Ghoshal, PGIMER - Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IN

259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
L. Na1, T.W.Y. Hu2, X. Ming2, Z.Y. Li3, 1Zunyi Medical College Affiliated Hospital, Zunyi, CN, 2West China Second Hospital, Chengdu, CN, 3West China Second Hospital, Sichuan University, Chengdu, CN

260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
D. Chekin1, A. Tryakin2, M. Fedyanin2, A. Bulanov3, I. Pokataev1, K. Zhordania4, E. Ignatova1, S. Tjulandin5, 1FSBI-N. Blokhin Russian Cancer Research Center, Moscow, RU, 2N. Blokhin Russian Cancer Research Center, Moscow, RU, 3No place of work provided Iran, Teheran, IR, 4Russian Cancer Research Center: NN Blokhin, Moscow, RU, 5FSBI “Center for strategic planning” of the Ministry of Health of the Russian Federation, Moscow, RU

261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
V. Sreedath, K. K, S.K. S, Madras Medical College, Chennai, IN

262P - Gestational trophoblastic tumours: Experience of the medical oncology
263TIP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib &\#x0002B; the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer

K. Fujiwara1, H.-H. Chou2, J.-W. Kim3, D.S. Tan4, K. Tamura5, N. Katsumata6, K. Harano6, K. Hasegawa7, S. Hume8, E. Jones9, S. Goble9, L. Sullivan9, D. Shih9, R. Coleman9, I. Mcneish10, B. Monk11, R. Kristeleit12, 1Saitama Medical University InternatIal Medical Centre, Saitama, JP 2Chang Gung Memorial Hospital, Taoyuan City, TW, 3Seoul National University College of Medicine, Seoul, KR, 4NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG, 5National Cancer Center Hospital (NCCH), Tokyo, JP 6Nippon Medical School Musashi Kosugi Hospital, Kawasaki, JP 71Saitama Medical University International Medical Center, Saitama, JP 8Clovis Oncology, Inc., Boulder, US, 9The University of Texas MD Anderson Cancer Center, Houston, US, 10Imperial College London - Hammersmith Hospital, London, GB, 11Arizona Oncology (US Oncology Network), Phoenix, US, 12UCL Cancer Institute/Paul O’Gorman Building, London, GB

264TIP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer

K. Fujiwara1, I. Vergote2, J. Sehouli3, V. Salutari4, P. Zola5, R. Madry6, R. Wenham7, J. Korach8, P. Pautier9, D. Cibula10, S. Lheureux11, K. Hasegawa12, B.-G. Kim13, C.-H. Lai14, A. Gonzalez-Martinez15, Q. Liu16, S. Keefe17, M. Puglisi18, S. Topuz19, 1Saitama Medical University InternatIal Medical Centre, Saitama, JP 2University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, 3Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, 4Policlinico Universitario A. Gemelli, Rome, IT, 5University of Turin, Turin, IT, 6Clinical Hospital of the Transfiguration-University of Medical Sciences, Poznan, PL, 7Moffitt Cancer Center, Tampa, US, 8Chaim Sheba Medical Center, Ramat Gan, IL, 9Gustave Roussy, Villejuif, FR, 10Charles University First Faculty of Medicine Department of Oncology, Prague, CZ, 11Princess Margaret Cancer Center, Toronto, CA, 12Saitama Medical University International Medical Center, Saitama, JP, 13Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, 14Linkou Chang Hung Memorial Hospital, Taipei, TW, 15Clínica Universidad de Navarra, Pamplona (Navarra), ES, 16Merck & Co., Inc., Kenilworth, US, 17Merck Sharp & Dohme Corp. USA, Whitehouse Station, US, 18Merck Sharp & Dohme Limited (MSD), Hoddesdon, GB, 19Istanbul Medical Faculty Hospital, Istanbul, TR

265TIP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer

K. Fujiwara1, R. Shapira-Frommer2, J. Alexandre3, B. Monk4, T. Fehm5, N. Colombo6, M.V. Caceres7, K. Hasegawa8, C. Dubot9, J. Li10, K. Stein11, S. Keefe11, K. Tewari12, 1Saitama Medical University InternatIal Medical Centre, Saitama, JP, 2Chaim Sheba Medical Center, Ramat Gan, IL, 3Hôpital Cochin, Paris, FR, 4Arizona Oncology (US Oncology Network), Phoenix, US, 5Universitätsklinikum Düsseldorf, Düsseldorf, DE,
18:00 - 18:00  **Haematological malignancies**

18:00 - 18:00  **271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India**

L. Moharan, D. Lokanatha, L. Jacob, M. Sureshbabu, K. Lokesh, A. Rudresha, L. Rajeev, S. Smitha, Kidwai Cancer Institute, Bangalore, IN

18:00 - 18:00  **272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway**

X. Sun, 2nd Affiliated Hospital of Dalian Medical University, Dalian, CN

18:00 - 18:00  **273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas**

A. Alhanafy¹, M. Elshafie², E.S. Abou Elnour², S. Genena², ¹Faculty of Medicine - Menoufia University, Shebin El Kom, EG, ²Faculty of Medicine - Menoufia University, sheben elkom, EG

18:00 - 18:00  **274P - Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene**

R. Karakulov¹, Z. Amankulov², ¹Kazakh Institute of Oncology & Radiology, ALMATY, KZ, ²Kazakh Reserch Institute of Oncology & Radiology, Almaty, KZ

18:00 - 18:00  **275P - Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam**

G. Nguyen Hoang¹, P. Nguyen², H. Nguyen², K. Do², ¹Hanoi Oncology Hospital, Hanoi, VN, ²K Hospital, Hanoi, VN

18:00 - 18:00  **276P - Chronic myeloid leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis**

G. Veni Prasanna¹, R.R. Boya², C. Bendi¹, P. Voonna², V. Murali Krishna¹, ¹Mahatma Gandhi Cancer Hospital & Research Institute, Visakhapatnam, IN, ²Mahatma Gandhi Cancer Hospital & Research Institute, VISAKHAPATNAM, IN

18:00 - 18:00  **277P - Characteristics of BCR-ABL rearrangement variants in Pakistani patients with chronic myeloid leukemia and acute lymphocytic leukemia**

Z. Ahmed, A. Nasir, M. Sheikh, A. Rizvi, T. Moatter, The Aga Khan University Hospital, Karachi, PK
18:00 - 18:00 278P - A systematic literature review of the cost-effectiveness of treatments, costs, and resource use in patients with Burkitt lymphoma
G. Mangat¹, N. Pilkhwal¹, N. Kayam², S. Attri¹, ¹PAREXEL International, Mohali, IN, ²PAREXEL International, Bangalore, IN

18:00 - 18:00 280P - Risk stratification of CML-CP in a real-world scenario, comparison of S.H.E. with rate of fall of BCR/ABL
K. Mishra¹, U. Yanamandra², A. Shukla², S. Pramanik², R. Kapoor², S. Das², ¹PGIMER, Chandigarh, Chandigarh, IN, ²Army Hospital (R&R), New Delhi, IN

18:00 - 18:00 281P - Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
J. Sun, Z. Zhang, D. Huang, X. Hu, X. Yu, The Second Affiliated Hospital - Zhejiang University School of Medicine - East Gate 1, Hangzhou, CN

18:00 - 18:00 282P - Inhibition of miR-144 and miR-199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling
N. Gupta, R. Kumar, A. Sharma, All India Institute of Medical Sciences, Delhi, IN

18:00 - 18:00 283P - Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis
J. Cho, J. Kim, J. Park, J.H. Lim, M.H. Lee, Inha University Hospital, Incheon, KR

18:00 - 18:00 284P - Differences in disease characteristics and survival outcomes of follicular lymphoma in young adults and older population: An institutional analysis
S. Goyal¹, A. Rudresha¹, D. Lokanatha¹, L. Jacob¹, S. Babu Mc¹, K. Lokesh¹, L. Rajeev¹, S. Smitha¹, B. Sansar², ¹Kidwai Cancer Institute, Bangalore, IN, ²Kidwai Memorial Institute of Oncology, Bangalore, IN

18:00 - 18:00 285TiP - Phase II, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667
C. Mauz-Koerholz¹, K. Kelly², F. Keller³, R. Ramchandren⁴, A. Nahar⁵, L. Giulino-Roth⁶, ¹Universitätsklinik Giessen, Giessen, DE, ²Roswell Park Comprehensive Cancer Center and University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, US, ³Children’s Healthcare of Atlanta and Emory University, Atlanta, US, ⁴Karamos Cancer Institute, Detroit, US, ⁵Merck & Co., Inc., Kenilworth, US, ⁶Weill Cornell Medical College, New York City, US

18:00 - 18:00 294P - Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with long-term follow-up
L.-R. Wu¹, X. He², ¹Jiangsu Province Cancer Hospital, Nanjing, CN, ²Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, CN

18:00 - 18:00 Head and neck cancer, excluding thyroid

18:00 - 18:00 294P - Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with long-term follow-up
L.-R. Wu¹, X. He², ¹Jiangsu Province Cancer Hospital, Nanjing, CN, ²Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, CN

Last update: 18-11-2019 08:34:53am

Final Programme
18:00 - 18:00 **295P - Development and validation of M1 substages for previously untreated metastatic nasopharyngeal carcinoma**

S.K. Chan¹, C.W. Choi², T.C. Chau², S.C. Chau², K.O. Lam², S.Y. Chan², C.C. Tong², W.L. Chan², D.L.W. Kwong², T.W. Leung², M.Y. Luk², A.W.M. Lee², V.H.F. Lee², ¹The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, HK, ²LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, HK

18:00 - 18:00 **296P - Nasopharyngeal carcinoma: A retrospective review of outcome in a single institution**

W.P. Ch' Ng¹, K.B. Law², J. Khoo¹, ¹National Cancer Institute (Institut Kanser Negara) Malaysia, Putrajaya, MY, ²National Institutes for Health, Shah Alam, MY

18:00 - 18:00 **297P - Global longitudinal assessment of treatment outcomes in nasopharyngeal carcinoma (GLANCE-NPC) study**

M.-J. Ahn¹, D. Chirovsky², H. Kuyas³, V. Auclair³, S. Abounit³, S. Joo², R. Shah², M.-H. Yang⁴, ¹Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ²MSD-Merck Sharp & Dohme, Kenilworth, US, ³Kantar, Paris, FR, ⁴Taipei Veterans General Hospital, Taipei, TW

18:00 - 18:00 **298P - Long-term complication and outcomes after induction chemotherapy with TPF followed by chemoradiotherapy for nasopharyngeal cancer**

S.-H. Cho, I.J. Chung, W.K. Bae, J. Hwang, Chonnam National University Medical School & Chonnam National University Hwasun Hospital, Hwasun, KR

18:00 - 18:00 **299P - Weekly versus triweekly concurrent chemoradiation for nasopharyngeal cancer**

S. Sudibio¹, H. Handoko², M. Auzan², G. Prajogi², ¹RSUPN - Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo, Central Jakarta/ Jakarta Pusat, ID, ²Cipto Mangunkusumo National General Hospital, Jakarta, ID

18:00 - 18:00 **300P - Endoscopic nasopharyngectomy for localized stage I nasopharyngeal carcinoma**

M.-Y. Chen¹, L. You-Ping², X. Zou¹, X. Ly¹, Y.-J. Hua¹, M.-H. Hong¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN

18:00 - 18:00 **301P - Oncological outcome following 3 Drug NACT for Bucco-Alveolar carcinoma with Supra-notch ITF extension**

K. Gupta¹, D. Mandlik², K. Patel², ¹Medanta-The Medicity, Gurgaon, IN, ²HCG Cancer Center, Ahmedabad, IN

18:00 - 18:00 **303P - Segmental mandibulectomy without reconstruction**

Y. Morishtita¹, R. Hayashi², K. Matsuura², T. Shinozaki², W. Okano², T. Tomioka², ¹National Cancer Center Hospital, Tokyo, JP, ²National Cancer Center Hospital East, Chiba, JP
18:00 - 18:00 304P - Survival outcomes and survival predictors in recurrent and metastatic head and neck squamous cell cancer (R/M-HNSCC) patients treated with chemotherapy (CT) plus cetuximab as first-line therapy in a real-world study
F. Pontes1, I. Rego1, I. Domingues2, L. Pinto3, R. Garcia1, M. Teixeira1, T. Serra1, L. Khoury1, M. Mariano4, G. Sousa2, 1Portuguese Oncology Institute of Coimbra, Coimbra, PT, 2Instituto Português Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT, 3Centro Hospitalar e Universitário de Coimbra, Coimbra, PT, 4Instituto Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT

18:00 - 18:00 305P - A retrospective study to evaluate patient characteristics for recurrent head and neck cancer after definitive treatment
T. Wakasugi1, H. Suzuki2, 1University of Occupational and Environmental, Japan, Kitakyushu, JP, 2University of Occupational and Environmental Health, Japan, Kitakyushu, JP

18:00 - 18:00 306P - Efficacy and safety of apatinib in heavily pretreated metastatic adenocarcinoma of the head and neck
L. Gui1, X. He2, 1CAMS and PUMC - National Cancer Center, Cancer Hospital, Beijing, CN, 2CAMS & PUMC ,Cancer Hospital, Beijing, CN

18:00 - 18:00 307P - Lacrimal gland tumours: Clinical and epidemiological patterns in the United States
M. Khalafallah1, M. Gouda2, A. Alfaar3, 1Faculty of Medicine - Menoufia University, Shebeen El-Kom, EG, 2Faculty of Medicine - Menoufia University, Shebin ElKom, EG, 3Charité - Universitätsmedizin Berlin, Berlin, DE

18:00 - 18:00 308P - Dental prophylaxis and 5-fluorouracil related oral mucositis in head and neck cancer patients: A population-based cohort study
Y.-F. Huang1, C.-T. Chang2, 1Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, 2Far Eastern Memorial Hospital, Taipei, TW

18:00 - 18:00 309P - Evaluation of a pharmacist-led opioid de-escalation (PLODE) program after chemoradiotherapy completion in head and neck cancer patients
A. Horinouchi1, S. Suzuki2, H. Kamata2, A. Kaneko2, T. Fujisawa2, Y. Ueda2, T. Enokida2, K. Ito2, S. Okano2, H. Makabe3, T. Kawasaki4, M. Tahara2, 1Saitama Medical University International Medical Center, Hidaka, JP, 2National Cancer Center Hospital East, Kashiwa, JP, 3Saitama medical university International medical center, Hidaka, JP, 4National Hospital Organization Tokyo Medical Center, Meguro, JP

18:00 - 18:00 310P - Laser and PDT for the oral leukoplakia
S. Rasul, Tashkent Medical Academy, Tashkent, UZ

18:00 - 18:00 311P - Incidence of thyroid carcinoma in the Philippines: A retrospective study from a tertiary university hospital
P. Caquiao1, K.G. Bebero2, M. Bendebel3, J. Saldana4, 1University of Santo Tomas Hospital, Manila, PH, 2USTH - University of Santo Tomas Hospital, Manila, PH, 3USTH - University of Santo Tomas Hospital - Benavides Cancer Institute,, Manila, PH, 4USTH -
18:00 - 18:00  312P - Oral health disparities among privileged and underprivileged tribes of south India - A study on precancerous oral lesions prevalence
S. Palliyal, DM Wayanad Institute of Medical Sciences, Kalpetta, IN

18:00 - 18:00  313P - Immunotherapy application for advanced cancers: One institution experiences since 2016 to 2019
J.P. Chen, National Taiwan University Hospital - Yunlin Branch, Douliu City, TW

18:00 - 18:00  314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
H. Kitano, A. Mamiya, Y. Masaoka, C. Hidai, Nihon University School of Medicine, Tokyo, JP

18:00 - 18:00  315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
J. Bonner1, H. Trummell2, E. Yang1, 1University of Alabama at Birmingham Hospital, Birmingham, US, 2University of Alabama at Birmingham, Birmingham, US

18:00 - 18:00  316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study

18:00 - 18:00  Immunotherapy of cancer

18:00 - 18:00  322P - Three-year overall survival update from the PACIFIC trial
18:00 - 18:00  **323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort**

Y. Li¹, Z. Chen², L. Wu³, W. Tao³, ¹Hubei General Hospital (Wuhan University Renmin Hospital), Wuhan, CN, ²Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ³Renmin Hospital of Wuhan University, Wuhan, CN

18:00 - 18:00  **324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy**

T.Y. Chao¹, C.L. Ho², W.H. Cheng³, C.L. Chang⁴, Y.Y. Hsieh¹, W. Jiang⁵, S. Liu⁵, A. Luk⁶, S.F. Lin⁷, T.C. Hsieh⁷, E. Liu⁵, ¹Shuang-Ho hospital, Taipei Medical University, New Taipei City, TW, ²Tri-Service General Hospital, National Defense Medical Center, Taipei, TW, ³School of Medicine, College of Medicine, Taipei Medical University, Taipei, TW, ⁴Wan Fang Hospital, Taipei Medical University, Taipei, TW, ⁵Shanghai Henlius Biotech, Inc., Shanghai, CN, ⁶Shanghai Henlius Biopharm, Shanghai, CN, ⁷Taiwan Henlix Biotech., Co., LTD., Taipei, TW

18:00 - 18:00  **325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma**

L. Wong¹, A. Ang¹, K. Ng², S.H. Tan², S.P. Choo², D. Tai³, J. Lee², ¹NUS-National University of Singapore-Yong Loo Lin School of Medicine (YLLSoM), Singapore, SG, ²NCCS - National Cancer Centre Singapore, Singapore, SG, ³National Cancer Centre Singapore (NCCS), Singapore, SG

18:00 - 18:00  **326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies**

E. Rozali, C. Chiang, P. Wang, H.C. Toh, NCCS - National Cancer Centre Singapore, Singapore, SG

18:00 - 18:00  **327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution**

X. Liu, Z. Li, Z. Cai, G. Chen, J. Liu, Fujian Medical University, Fuzhou, CN

18:00 - 18:00  **328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors**

F. Hayashi¹, H. Taniguchi¹, S. Takayuki¹, Y. Umeyama¹, Y. Dotsu¹, H. Gytoku¹, H. Senju¹, S. Takemoto¹, H. Yamaguchi¹, S. Ono², H. Tomono², M. Shimada², H. Soda², M. Fukuda³, M. Hiroshi¹, ¹Nagasaki University Hospital, Nagasaki, JP, ²Sasebo City General
18:00 - 18:00 329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy

X. Liu, Jinzhou Medical University, Jinzhou, CN

18:00 - 18:00 331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder

S. Ono1, H. Senju1, H. Taniguchi1, H. Tomono2, M. Shimada2, F. Hayashi1, T. Suyama1, N. Honda1, Y. Umeyama1, Y. Dotsu1, H. Gyotoku1, S. Takemoto1, H. Yamaguchi1, M. Fukuda1, H. Soda2, H. Mukae1, Nagasaki University Hospital, Nagasaki, JP, 2Sasebo City General Hospital, Sasebo, JP

18:00 - 18:00 332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)

C.-Y. Cheng1, P.-J. Su2, K.-C. Chang3, T.-C. Tsai3, H.-Y. Chen3, S.-T. Deng3, W.-C. Chang3, Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, 2Chang Gung Memorial Hospital, Linkou, Taoyuan, TW, 3Chang Gung Memorial Hospital, Linkou, Taoyuan City, TW

18:00 - 18:00 333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT

K. Kibata1, H. Izuno1, K. Nakahama1, Y. Yamanaka1, T. Kaneda1, H. Yoshioka2, T. Kurata1, S. Nomura1, Kansai Medical University, Hirakata, JP, 2Kurashiki Central Hospital, Kurashiki, JP

18:00 - 18:00 334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy

D. Etoh1, T. Harada2, A. Shimauchi2, R. Ibusuki2, T. Kayukawa2, Y. Okamatsu2, K. Inoue2, K. Tsubouchi2, Japan Community Healthcare Organization, Kyushu Hospital, Kitakyushu, JP, 2JCHO Kyusyu Hospital, Kitakyushu, JP

18:00 - 18:00 335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia

H. Handoko1, S. Gondhowardi1, M. Adham1, L. Lisnawati1, D. Tobing2, H. Kodrat1, I.M. Haryoga1, A. Dwiyono1, Y. Kristian1, T. Mayang Permata1, Faculty of Medicine University of Indonesia, Central Jakarta, ID, 2Dharmais Cancer Hospital, Central Jakarta, ID

18:00 - 18:00 336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world


18:00 - 18:00 337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint
inhibitor

18:00 - 18:00  338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
A. Dutta, D. Sengupta, S. Paul, S. Chakraborty, S. Mukherjee, T. Das, Bose Institute, Kolkata, IN

18:00 - 18:00  339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Y.-L. Wu1, L. Wang2, M.A.N. Sendur3, Y.-C. Kim4, Z. Zhu5, Y. Cheng6, P. Li7, Y. Qin7, E. Macpherson8, P. Dennis5, S. Lu10, 1Guangdong General Hospital and Guangdong Academy of Medical Sciences, Gaungzhou, CN, 2Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, 3Ankara Ataturk Research and Teaching Hospital, Ankara, TR, 4Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, KR, 5Fudan University Shanghai Cancer Center, CN, 6Jilin Provincial Cancer Hospital, Changchun, CN, 7AstraZeneca, Shanghai, CN, 8AstraZeneca, Macclesfield, GB, 9AstraZeneca USA, Gaithersburg, US, 10Shanghai Jiao Tong University, Shanghai, CN

18:00 - 18:00  340TiP - A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
S. Yan1, Y. Zhang2, X. Bi3, J. Zhao4, S. Du5, Z. Huang4, Y. Zhang3, D. Liu6, Z. Li3, J. Zhou3, J. Cai3, H. Zhao7, 1Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, CN, 2Affiliate Tumor Hospital of Harbin Medical University, Harbin, CN, 3Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, CN, 4Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, 5Peking Union Medical College Hospital, Beijing, CN, 6Xuanwu Hospital Capital Medical University, Beijing, CN, 7Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing, CN

18:00 - 18:00  Melanoma and other skin tumours

18:00 - 18:00  347P - Relationship between modified surgical margin and prognosis of cutaneous squamous cell carcinoma
Y. Teramoto1, N. Baba1, S. Saito1, K. Sasaki1, Y. Asami1, T. Matsuya1, A. Yamamoto1, Y. Nakamura2, 1Saitama Medical University Internatil Medical Centre, Saitama, JP, 2Saitama Medical University International Medical Center, Saitama, JP

18:00 - 18:00  348P - Malignant melanoma: A study of clinical profiles and treatment outcomes in Indian patients
S. Shishak1, S. Rastogi2, R. Pandey1, A. Barwad1, E. Dhamija1, A. Aggarwal3, K. Kalra4, S.A. Shamim1, M. Parisa1, 1AIIMS - All India Institute of Medical Sciences, New Delhi, IN, 2All India Institute of Medical Sciences (AIIMS), New Delhi, Delhi, IN, 3National Cancer Institute-AIIMS,Jhajjar, Haryana, IN, 4Vardhman Mahavir Medical College &
18:00 - 18:00  **349P - Flavonoids from ethanol extracts of euphorbia hirta inhibit melanoma growth and metastatic potential**  
S. Mishra, Barkatullah University, Bhopal, IN

18:00 - 18:00  **350P - Low-dose cisplatin and 5-fluorouracil combined concurrent chemoradiotherapy for unresectable cutaneous squamous cell carcinoma: Analysis of 23 cases**  
A. Hiura¹, K. Yoshino², T. Maeda¹, S. Oaku¹, K. Nagai¹, M. Kato¹, C. Yamashita¹, J. Uehara¹, Y. Fujisawa³, ¹Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, 2Komagome Hospital, Tokyo, JP, 3University of Tsukuba, Tsukuba, JP

18:00 - 18:00  **Palliative care**

18:00 - 18:00  **353P - A prediction model for the intents regarding life-sustaining treatment decisions in patients with terminal cancer**  
Y. Kim, K.A. Kwon, Dongnam Institute of Radological and Medical Sciences-DIRAMS, Busan, KR

18:00 - 18:00  **354P - Predictive factors and survival outcomes with stereotactic body radiation therapy in treatment of oligometastases in colorectal cancer**  
V. Pareek, Jupiter Hospital, Mumbai, IN

18:00 - 18:00  **355P - Cost analysis and overview of single versus multiple fraction palliative radiotherapy for painful bone metastasis**  
V. Selvaraj, D.K. Gudipudi, Basavataramak Indo American Cancer Hospital & Research Institute, Hyderabad, IN

18:00 - 18:00  **356P - Observational study on role of crude cannabis in pain control and quality of life in terminally ill cancer patients: An Indian perspective**  
V. Dusi¹, S. Attili², M. Singaraju¹, ¹Omega Hospitals, HYDERABAD, IN, ²Omega Hospitals, Hyderabad, IN

18:00 - 18:00  **357P - Application of multi-modal approach to palliation in end of life head and neck cancer pain**  
S. Joga¹, M.S. Sahi¹, V.P.B. Koyyala¹, P. Medisetty², A. Jajodia¹, K. Chaudhari¹, S. Goyal¹, S. Bommera¹, M. Gairola¹, ¹Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, ²Baba Saheb Ambedkar Hospital, New Delhi, IN

18:00 - 18:00  **358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies**  
S. Revannasiddaiah¹, K. Pandey¹, I. Madabhavi², N. Pant¹, S. Singh¹, S. Susheela³, M. Rastogi⁴, ¹Swami Rama Cancer Hospital & Research Institute, Uttarakhand, IN, ²Gujarat
18:00 - 18:00  **359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community**

M. Yuki¹, K. Kosugi¹, Y. Nishiguchi², T. Miura¹, D. Fujisawa³, Y. Uehara¹, T. Kawaguchi⁴, K. Izumi⁵, J. Takehana⁵, Y. Matsumoto¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²General Incorporated Association Cancer Parents, Tokyo, JP, ³Keio University School of Medicine, Tokyo, JP, ⁴Tokyo University of Pharmacy and Life Sciences, Hachioji, JP, ⁵Medilead Inc, Tokyo, JP

18:00 - 18:00  **360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic**

B. De Guzman¹, N. Cabaya², F. I. Ting¹, J. Tan³, ¹University of the Philippines - Philippine General Hospital, Manila, PH, ²Corazon Locsin Montelibano Memorial Regional Hospital, Bacolod City, PH, ³Division of Medical Oncology, Manila, PH

18:00 - 18:00  **361P - The role of volunteers in quality palliative care delivery**

N. Mandal, Narikeldaha Prayas, East Medinipur, IN

18:00 - 18:00  **362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison**

R. D. Arora, All India Institute of Medical Sciences, Delhi, IN

18:00 - 18:00  **Precision medicine**

18:00 - 18:00  **366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours**

D. Ziegler¹, F. Doz², B. Geoerger³, S. Dubois⁴, J. Grilley-Olson⁵, C. Van Tilburg⁶, A. Italiano⁷, A. Lissat⁸, J.-H. Kang⁹, M. Tahara¹⁰, V. Boni¹¹, S. Perreault¹², M. Capra¹³, S. Nanda¹⁴, N. Brega¹⁴, A. Holynskyj¹⁴, D. Hong¹⁵, D. Hyman¹⁶, A. Drilon¹⁷, ¹Sydney Children's Hospital, Randwick, AU, ²Paris Descartes University, Paris, FR, ³Université Paris-Sud, Université Paris-Saclay, Villejuif, FR, ⁴Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, US, ⁵University of North Carolina Hospitals, Chapel Hill, US, ⁶Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, DE, ⁷Institute Bergonie, Bordeaux, FR, ⁸Universitätsmedizin Berlin Charité Campus, Berlin, DE, ⁹Seoul St Marys Hospital, Seoul, KR, ¹⁰National Cancer Center Hospital East, Kashiwa, JP, ¹¹START Madrid CIOCC, Madrid, ES, ¹²CHU Sainte Justine, Montreal, CA, ¹³Our Lady Children's Hospital, Dublin, IE, ¹⁴Bayer HealthCare Pharmaceuticals, Inc., Whippany, US, ¹⁵MD Anderson Cancer Center, Houston, US, ¹⁶Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US, ¹⁷Memorial Sloan Kettering Cancer Center, New York, US

18:00 - 18:00  **367P - Molecular characteristics and efficacy of crizotinib among different**
subsets of MET Amplification detected by next-generation sequencing in lung cancer
J. Li, Y. Wang, J. Xu, S. Cao, H. Zhong, Shanghai Chest Hospital, Shanghai, CN

18:00 - 18:00 368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers
S.-H. Teg1, M. Zabidi1, J.W. Pan1, P.S. Ng1, M.Y. Meng1, N. Hasan1, B. Sandey2, C.H. Yip3, P. Rajadurai3, O. Rueda2, C. Caldas4, S.F. Chin2, 1Cancer Research Malaysia, Subang Jaya, MY, 2CRUK Cambridge Cancer Institute, Cambridge, GB, 3Sime Darby Medical Centre Subang Jaya, Subang Jaya, MY, 4Cancer Research UK & University of Cambridge UK, Cambridge, GB

18:00 - 18:00 369P - Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases
H. Loong1, C. Chow2, K. Ho2, J. Fung2, J. Koh2, T.-C. Chan2, L. Leung2, W. Yeo1, B. Ma1, S. Chan2, E. Hui1, K. Lee2, A. Wong2, D.C.M. Lam3, K.C.W. Wong3, S. T. Mok2, K.-F. To2, 1The Chinese University of Hong Kong, Shatin, HK, 2The Chinese University of Hong Kong, Hong Kong, HK, 3State Key Laboratory of Translational Oncology, Sir YK Pao Cancer Center, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, HK

18:00 - 18:00 370P - Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden
Y.-S. Zang1, X.-D. Jiao4, X.-C. Zhang2, B. Qin1, D. Liu2, L. Liu3, J. Ni3, Z. Ning3, L. Chen4, L. Zhu4, S. Qin5, J. Zhou6, S. Ying7, X. Chen8, A. Li9, T. Hou10, A. Lizaso10, H.-H. Zhang10, K. Liu1, Z. Wang1, 1Shanghai Changzheng Hospital, Shanghai, CN, 2The Affiliated Hospital of Qingdao University, Qingdao, CN, 3Fudan University Shanghai Cancer Center, Shanghai, CN, 4The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, CN, 5The First Affiliated Hospital of Suzhou University, Suzhou, CN, 6First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, 7Taizhou Central Hospital, Taizhou, CN, 8Hangzhou Cancer Hospital, Hangzhou, CN, 9Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, CN, 10Burning Rock Biotech, Shanghai, CN

18:00 - 18:00 371P - Clinical utility of Encyclopedic tumour analysis to treat patients advanced refractory head and neck cancers
R. Nagarkar1, D. Patil2, V. Palwe1, V. Datta2, A. Ghaisas2, N. Srivastava2, A. Srinivasan2, D. Akolkar2, R. Datar2, 1HCG Manavata Cancer Centre, Nasik, IN, 2Datar Cancer Genetics, Nashik, IN

18:00 - 18:00 372P - Real-world fusion landscape in advanced Chinese pancreatic cancer using next generation sequencing: A multicenter study
Y. Shen1, S. Fang2, X. Cai3, Y. Fang4, R. Lin5, Y. Zhang6, J. Li7, X. Liang8, L. Wang9, L. Lin9, L. Zhang11, H. Feng12, S. Lan13, X. Cai14, C. Xu5, W. Wang15, M. Fang15, J. Zhang16, 1The Second Affiliated Hospital of Jiaxing Medical College, Jiaxing, CN, 2Daping Hospital and Research Institute of Surgery, Army Medical University, Chongqing, CN, 3Sun Yat-sen University Cancer Hospital, Guangzhou, CN, 4Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, CN, 5Fujian Cancer Hospital, Fuzhou, CN, 6The Second Affiliated Hospital of Medical College, Xi’an Jiaotong University, Xi’an, CN, 7Xiamen
18:00 - 18:00 373P - Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001)

A. Tan1, H. Loong2, G.F. Ho3, A. Seet4, B. Chiam5, D. Cheah5, G.S. Tan6, K.H. Lim6, J.C.-H. Yang7, T.S.K. Mok8, D.-W. Kim9, D.S.W. Tan10, 1RNSH - Royal North Shore Hospital, St Leonards, AU, 2The Chinese University of Hong Kong, Shatin, HK, 3University Malaya Medical Center, Kuala Lumpur, MY, 4NCCS - National Cancer Centre Singapore, Singapore, SG, 5National Cancer Centre Singapore, Singapore, SG, 6Singapore General Hospital, Singapore, SG, 7National Taiwan University Hospital and National Taiwan University Cancer Center, 100, Taipei, TW, 8Prince of Wales Hospital, Shatin, HK, 9Seoul National University Hospital, Seoul, KR, 10National Cancer Center Singapore, Singapore, SG

18:00 - 18:00 374P - Circulating tumour DNA (ctDNA) identifies actionable genetic alterations in Middle Eastern and Asian (MEA) patients diagnosed with carcinoma of unknown primary (CUP)

N. Peled1, H. Okuma2, O. Rotem3, E. Dudnik3, S. Ikeda4, S. Stemmer3, S. Olsen5, 1Ben-Gurion University, Beer Sheva, IL, 2National Cancer Center Hospital, Tokyo, JP, 3Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL, 4Tokyo Medical and Dental University, Tokyo, JP, 5Guardant Health Pte. Ltd., Singapore, SG

18:00 - 18:00 375P - Whole-exome sequencing of tumour-only samples reveals the association between somatic alterations and clinical features in pancreatic cancer

H. Lin1, W. Ran2, X. Chen1, B. Wang1, P. Yang3, Y. Li2, Y. Xiao2, X. Wang2, G. Li2, L. Wang2, Y. Han1, Y. Peng1, J. Lang1, Y. Liang1, G. Tian1, D. Yuan1, J. Yang1, C. Deng1, X. Xing2, 1Geneis Co. LTD, Beijing, CN, 2The Affiliated Hospital of Qingdao University, Qingdao, CN, 3Yantai Yuhuangding Hospital, Yantai, CN

18:00 - 18:00 376P - Adoption of molecular testing in breast cancer in a tertiary care center in a developing country

P. Dash1, V.P.B. Koyyala2, M. Suryavanshi3, A. Jajodia2, S. Pasricha2, V. Goel2, S. Bothra4, S. Goyal2, U. Batra2, D.C. Doval2, 1Rajiv Gandhi Cancer Institute & Research Center, New Delhi, IN, 2Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, 3Rajiv Gandhi Cancer Institute and Research Centre, Delhi, IN, 4Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, IN

18:00 - 18:00 377P - NGS in advanced NSCLC in a developing country: Ready for prime time?

A. B P1, M. Sharma1, P. Jain1, S. Joga1, V.P.B. Koyyala1, A. Mehta2, U. Batra1, 1Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, 2Rajiv Gandhi Cancer
378P - Germline BRCA1/2 testing: Trend in Tan Tock Seng Hospital Singapore
C.W. Lim¹, J. Samol¹, M. Flook¹, L.L. Goh¹, M.-H. Tan², ¹NHG-National Healthcare Group-Tan Tock Seng Hospital, Singapore, SG, ²Lucence Diagnostics Pte Ltd, Singapore, SG

379P - Study of germline mutations in high risk cancer patients from a tertiary care center in India
P. Kulkarni¹, S. Gandhi², A. Dastane³, C. Deshmukh², S. Hingmire², G. Karve³, A. Prayag⁴, D. Kelkar², ¹Noble Hospital, Pune, IN, ²Deenanath Mangeshkar Hospital & Research Centre, Pune, IN, ³Deenanath Mangeshkar Hospital, Pune, IN, ⁴Deenanath Mangeshkar Hospital and Research Centre, Pune, IN

380P - Ventricular-subventricular zone involvement: A predictive factor for survival in glioblastoma
V. Pareek¹, R. Bhalavat², M. Chandra², ¹Jupiter Hospital, Mumbai, IN, ²Jupiter Hospital, Thane, IN

381P - XKR8 is a promising potential prognostic marker in glioblastoma multiforme patients
K. Havrysh¹, M. Bogdanov², A. Nurgalieva³, R. Kiyamova³, ¹Taras Shevchenko National University of Kyiv, Educational and scientific centre "Institute of biology", Kiev, UA, ²University of Texas Health Science Center, McGovern Medical School, Houston, US, ³Institute of Fundamental Medicine and Biology of Kazan Federal University, Kazan, RU

382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
S. Bhatia¹, V. Chauhan², M. Verman², ¹Amity University, Noida, IN, ²Amity Institute of Biotechnology, Noida, IN

383P - Screening of prognostic molecular biomarker for resectable pancreatic cancer
Y. Peng¹, H. Lin², Y. Zhang², ¹Geneis (Beijing) Co. Ltd., Beijing, CN, ²the Geneis Co. Ltd., Beijing, CN

384P - Prevalence of abnormal microsatellite instability test among ovary and endometrial cancer patients
M.K. Kim, Samsung Changwon Hospital Sung Kyun Kwan University, Changwon, KR

385P - Identifying CASP8 polymorphisms associated with breast cancer risk in an Iranian population
A. Pasdar¹, F. Azaljavan², F. Homaei Shandiz², M.M. Kooshyar³, ¹Mashhad University of Medical Science, Mashhad, IR, ²Mashhad University of Medical Sciences, Mashhad, IR, ³Mshhad univaersity of Medical sciences, Mashhad, IR

386P - Unusual folding of NaPi2b transporter extramembrane domain 4 during
malignant transformation

L. Minigulova¹, V. Skripova¹, A. Nurgalieva², N. Ionova², D. Reshetnikova¹, M. Bogdanov³, R. Kiyamova², ¹Kazan Federal University, Kazan, RU, ²Institute of Fundamental Medicine and Biology of Kazan Federal University, Kazan, RU, ³University of Texas Health Science Center, McGovern Medical School, Houston, US

18:00 - 18:00 387P - 5-years conditional disease free survival and overall survival for breast cancer patients in South Korea


18:00 - 18:00 388P - To identify circulating tumour cells by machine learning approach

Y. Liang, H. Lin, G. Tian, J. Yang, Geneis Co. LTD, Beijing, CN

18:00 - 18:00 389P - The establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer

J.H. Chen¹, X.-P. Chu¹, J.-T. Zhang¹, Q. Nie¹, J. Su¹, H.-H. Yan¹, H.-P. Zheng², X. Chen², M.-M. Song³, L.-P. Chang³, P.-S. Li³, Y.-F. Guan³, Y.-L. Wu², W.-Z. Zhong¹, ¹Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, Guangzhou, CN, ²Accurate International Biotechnology Co., Guangzhou, CN, ³Geneplus Beijing, Beijing, CN

18:00 - 18:00 Public policy

18:00 - 18:00 395P - Filipinos and lung cancer: An infodemiological assessment using Google trends from 2009 to 2019

L.I. Catedral¹, C.M. Berba², J. Tan², J.T. Tan³, ¹University of the Philippines - Philippine General Hospital, Manila, PH, ²Division of Medical Oncology, Manila, PH, ³Medical Informatics Unit, Manila, PH

18:00 - 18:00 396P - Determinants of visiting a referral hospital for cervical cancer screening at Uganda Cancer Institute

C. Mpamani, Uganda Cancer Institute, Kampala, UG

18:00 - 18:00 397P - Development of prediction model for hepatocellular carcinoma in chronic hepatitis B patients

T. Ungtrakul¹, K. Soontklang², J. Dechma², P. Kusuman², W. Pongpun², ¹Chulabhorn Hospital, Bangkok, TH, ²Chulabhorn Royal Academy, Bangkok, TH

18:00 - 18:00 398P - Planning for future cancer control programs in Uganda: Projections of top five cancers & incidence in the next decade

J. Asasira¹, T. Maj², S. Lee², H. Wabinga³, Y. Chang², S.-Y. Jung², H. Cho², ¹NCC-National Cancer Center, Goyang, KR, ²NCC-National Cancer Center, Goyang-si, KR, ³Kampala cancer registry, Kampala, UG
18:00 - 18:00  **399P - Prevalence of colorectal cancer risk factors in apparently healthy adults in Suluhan Village, Bali**

C. Trisina¹, C. Driansha¹, C. Driansha¹, R. Martianus¹, L. Soesilopranoto¹, I.W. Sudarsa², ¹Medical Faculty Of Udayana University, Denpasar, ID, ²RSUP Sanglah Denpasar, Denpasar, ID

18:00 - 18:00  **400P - Female lung cancer: Emerging issue in Bangladesh**

M.R. Islam, M. Rahman, A.A.M. Khan, M. Alam, S. Siddiqua, National Institute of Cancer Research & Hospital, Dhaka, BD

18:00 - 18:00  **401P - Women in oncology: Alarming figures from India**

S. Mailankody¹, J. Bajpai², ¹Cancer Institute Adyar Chennai, Chennai, IN, ²Tata Memorial Centre, Mumbai, IN

18:00 - 18:00  **402P - Work-related outcomes among cancer survivors in Singapore**

C.J. Tan¹, L.C. Tan¹, K. Loh², P.S.H. Neo³, E. Finkelstein⁴, A. Chan¹, ¹National University of Singapore, Singapore, SG, ²Singapore Society of Oncology, Singapore, SG, ³National Cancer Centre Singapore, Singapore, SG, ⁴Duke-NUS Medical School, Singapore, SG

18:00 - 18:00  **Focal treatments for metastatic soft tissue sarcoma (mSTS) is associated with improved overall survival**

C.T. Chen¹, T.W.-W. Chen², H.-W. Chen¹, C.-Y. Hsu¹, W.-H. Lin¹, P.-M. Huang¹, J.-C. Lee¹, K.-H. Huang¹, R.-S. Yang¹, R.-L. Hong¹, H.-M. Chen³, C.Y. Yang¹, C.-C. Chang¹, ¹National Taiwan University Hospital, Taipei City, TW, ²National Taiwan University Hospital, Taipei, TW, ³National Taiwan University, Taipei City, TW

18:00 - 18:00  **The Asian sarcoma consortium sarcoma preceptorship program: A program evaluation study utilizing the Kirkpatrick model (Level 1 and 2)**

F. Gracieux Jr., Philippine General Hospital, Manila, PH

18:00 - 18:00  **Integrated genomic and transcriptomic analysis revealed mutagenic patterns of dedifferentiated liposarcoma and leiomyosarcoma in Chinese patients**

Y. Zhou¹, W. Lu², Y. Zhang², H. Tong², W. Liu³, R. Zhuang², H. Guo⁴, ¹Zhongshan Hospital - Fudan University, Shanghai, CN, ²Zhongshan Hospital, Fudan University, Shanghai, CN, ³Zhongshan Hospital (South Branch), Fudan University, Shanghai, CN, ⁴GenomiCare Biotechnology, Shanghai, CN

18:00 - 18:00  **Treatment patterns and outcomes of elderly patients with metastatic soft tissue sarcomas (mSTS)**

Y.-J. Kuo¹, T.W.-W. Chen², H.-W. Chen¹, C.-Y. Hsu¹, W.-H. Lin¹, P.-M. Huang¹, J.-C. Lee¹, H.-M. Chen³, K.-H. Huang¹, C.Y. Yang¹, C.-C. Chang¹, R.-S. Yang¹, R.-L. Hong¹, ¹National...
18:00 - 18:00 411P - Comparative analysis of protein profiles of prognosis-associated proteins and KIT-related proteins in gastrointestinal stromal tumour

18:00 - 18:00 412P - The evaluation of chromosomal changes in patients with osteosarcoma
N. Karimova, National Cancer Research Center of Uzbekistan, Tashkent, UZ

18:00 - 18:00 413P - The state of molecular biological markers in osteosarcoma
D. Polatova, Republican Oncology Research Center of Uzbekistan, Tashkent, UZ

18:00 - 18:00 414P - Clinical profile of gastrointestinal stromal tumour in Yangon General Hospital
K. Mu, M. Maw, M. Aung, A. Win, K. Kyaw, T. Tun, Yangon General Hospital, Yangon, MM

18:00 - 18:00 415P - Adult soft tissue myoepithelial carcinoma: Treatment outcomes and efficacy of chemotherapy
F. Chamberlain¹, E. Cojocaru¹, M. Scaranti¹, J. Noujaim², K. Thway¹, C. Fisher³, C. Messiou¹, D. Strauss¹, A. Miah¹, S. Zaidi¹, C. Benson¹, S. Gennatas¹, R. Jones¹, ¹The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ²Maisonneuve-Rosemont Hospital, Montreal, CA, ³University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB

18:00 - 18:00 416P - (Withdrawn)

18:00 - 18:00 417P - Clinicopathological profile and survival outcomes of sarcomas from a regional cancer centre in South India
D. Bharathi, G. Karunanidhi, P. Sethi, M. Muthukarthikeyan, M. Manivannan, JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IN

18:00 - 18:00 418P - Lessons learnt from treatment of foot sarcomas: Analysis from dedicated sarcoma clinic in North India
S. Pawar¹, S. Rastogi¹, E. Dhamija¹, A. Barwad¹, V. Kumar¹, R. Pandey¹, S. Shishak¹, K. Kalra², A. Aggarwal³, A. Garg¹, A. Mridha¹, J. Chaubey¹, S.A. Khan¹, ¹AIIMS - All India Institute of Medical Sciences, New Delhi, IN, ²Vardhman Mahavir Medical College & Safdarjung Hospital(VMMC-SJH), New Delhi, IN, ³National Cancer Institute, AIIMS Jhajjar, Badsa, IN

18:00 - 18:00 Supportive care

18:00 - 18:00 423P - Effectiveness of first-generation 5HT3 receptor antagonist plus dexamethasone plus aprepitant in controlling delayed chemotherapy-induced nausea and vomiting in patients with colorectal cancer: A propensity score-
matched analysis

T. Hayashi1, M. Shimokawa2, K. Matsuo3, H. Iihara4, J. Nishimura5, T. Nakano1, T. Egawa1, 1Fukuoka University, Fukuoka, JP, 2National Hospital Organization Kyusyu Cancer Center, Hakata, JP, 3Fukuoka University Chikushino Hospital, Chikushino, JP, 4Gifu University Hospital, Gifu, JP, 5Osaka International Cancer Institute, Osaka, JP

18:00 - 18:00  424P - Cancer worry, genetic knowledge, and attitudes towards NGS multigene panel testing among Korean breast cancer patients

J.S. Park1, Y.J. Lee1, S.-T. Lee1, J.W. Han1, T.I. Kim1, E.J. Nam1, H.S. Park2, 1Yonsei University, Seoul, KR, 2Severance Hospital, Yonsei University College of Medicine, Seoul, KR

18:00 - 18:00  425P - Economic and safety evaluation of 5-HT3 receptor antagonist conversion from palonosetron to granisetron in highly and moderately emetogenic chemotherapy: A prospective study

K. Yamakita1, Y. Kitano2, Y. Suzuki3, H. Iwamoto3, K. Takahashi3, T. Ota3, 1Asahikawa Medical University Hospital, Asahikawa, JP, 2Asahikawa Medical University Hospital, Asahikawa Hokkaido, JP, 3Asahikawa Medical University, Asahikawa, JP

18:00 - 18:00  426P - Impaired quality of life of caregivers of patients with gastrointestinal cancer undergoing palliative chemotherapy

N. Takeuchi, S. Kurosawa, K. Koike, S. Yoshida, Ina Central Hospital, Ina, JP

18:00 - 18:00  427P - Sahai: A restorative support to address unmet needs of women with cancer &gt; 02013; impact on quality of life

P. Maurya1, A. Sadanandan1, M. Aal2, S. Ravi3, P.P. Bapsy4, 1Apollo Hospitals, Bangalore, IN, 2Health Care Global (HCG), Bangalore, IN, 3Prameya Health Care Pvt. Ltd., Bangalore, IN, 4Apollo Hospitals - Bangalore, Bangalore, IN

18:00 - 18:00  428P - A pilot study on comparative efficacy of tramadol or eutectic mixture of local anaesthetics (prilocaine plus lignocaine) in preventing bone marrow aspiration associated pain

B. Sansar1, A. Rudresha2, D. Lokanatha2, L. Jacob2, M. Sureshbabu2, K. Lokesh2, L. Rajeev2, S. Smitha2, S. Goyal2, S. Hassan2, 1Kidwai Memorial Institute of Oncology, Bangalore, IN, 2Kidwai Cancer Institute, Bangalore, IN

18:00 - 18:00  429P - Skin pathologic change evaluation of the patients who had EGFR inhibitor-related skin adverse events

S.Y. Oh1, J.H. Ji2, Y. Kim3, S. Lee1, S.J. Huh1, J.H. Lee1, K.-H. Song1, C.H. Son1, J.H. Kang4, M.S. Roh1, J.M. Kim5, J.E. Choo5, 1Dong-A University College of Medicine, Busan, KR, 2Samsung Changwon Hospital, Changwon, KR, 3Gachon University Gil Medical Center, Inchon, KR, 4Gyeongsang National UniversityHospital, Jinju, KR, 5Daewoong Pharmacy, Yongin, KR

18:00 - 18:00  430P - Emetic risk of carboplatin plus pemetrexed is higher than that of carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis
18:00 - 18:00 431P - An in vitro evaluation of CYP2D6 enzymatic inhibition activities of a Chinese herbal medicine formulation (Xiang Bei Yangrong Tang) for the management of cancer-related fatigue

N.Y. Yap1, H.K. Ho1, H.F. Zheng2, C.J. Tan1, Y.L. Toh1, C.C. Ng1, A. Chan1, 1National University of Singapore, Singapore, SG, 2Singapore Thong Chai Medical Institute, Singapore, SG

18:00 - 18:00 432P - Chemotherapy induced extravasation: Incidence and possible predictors

S. Somayaji1, S. Reddy1, M. Krishna Murthy1, V. Maka2, 1M. S. Ramaiah University of Applied Sciences, Bangalore, IN, 2M. S. Ramaiah Medical College and Hospitals, Bangalore, IN

18:00 - 18:00 433P - Prospective outcomes of adolescent and young adult (AYA) patients received treatment from a tertiary cancer hospital in Bangladesh

A.A.M. Khan1, M. Islam1, M. Sumon2, M. Alam1, A.T.M. Hasan1, 1National Institute of Cancer Research & Hospital, Dhaka, BD, 2Kurmitola General Hospital, Dhaka, BD

18:00 - 18:00 434P - Pneumonitis induced antineoplastic agents: Mortality and risk factors in 129 consecutive cases

S. Kaku1, H. Horinouchi2, H. Watanabe1, K. Tamura3, T. Okusaka2, N. Boku2, N. Yamazaki2, Y. Ohe2, M. Kusumoto2, 1National Cancer Center Hospital, Tokyo, Japan, Tokyo, JP, 2National Cancer Center Hospital, Tokyo, JP, 3National Cancer Center Hospital (NCCH), Tokyo, JP

18:00 - 18:00 435P - Telephonic communication in palliative care for better management of terminal cancer patients in rural India: An NGO based approach

N. Mandal, Narikeldaha Prayas, East Medinipur, IN

18:00 - 18:00 436P - Assessing the quality of life of Filipino cancer patients: A survey of Filipino oncologists

F.I. Ting, J.M. Callueng, J. Vallente, R.A. Hurtado, A. Ramirez, L.I. Catedral, R.E. King, K.A. Mondragon, R. Velasco, Jr., J. Ignacio, C. Ngelangel, University of the Philippines - Philippine General Hospital, Manila, PH

18:00 - 18:00 437P - Correlation between bio-impedance analysis and abdominal CT scan to diagnose decreased muscle mass in adult cancer patients

A. Kurniawan1, R. Hatma2, A. Adisasmita2, N. Soetandyo3, F. Wijaksono3, S. Panigoro3, D. Rivami4, R. Sumantri5, T. Tamin3, F. Wijovi6, H. Putri6, W. Raffaello6, O. Saroso6, J. Rahman6, D. Halm6, 1Siloam Hospital/Medical faculty of Pelita Harapan University, Tangerang, ID, 2Faculty of Public Health, Universitas Indonesia, Depok, ID, 3Faculty of Medicine, Universitas Indonesia, Jakarta, ID, 4Faculty of Medicine, Pelita Harapan University, Jakarta, ID, 5Faculty of Medicine, Padjadajaran University, Bandung, ID,
438P - Evaluating mitochondrial biomarkers between fatigue subclasses identified using latent class analysis in early-stage breast cancer patients
Y.L. Toh1, S. Maung2, A. Chan2, 1NUS- National University of Singapore-Department Of Pharmacy, Singapore, SG, 2National University of Singapore, Singapore, SG

440P - Accuracy of risk scoring system to determine delayed chemotherapy induced nausea and vomiting (CINV) in cancer patients
J. Harika1, V. Maka2, A. D3, M. Krishna Murthy3, A. Mandepudi3, P. Paibhavi3, S.P. Kanneganti3, S. Vungarala4, 1MS Ramaiah Memorial Hospital, Bangalore, IN, 2M. S. Ramaiah Medical College and Hospitals, Bangalore, IN, 3M. S. Ramaiah University of Applied Sciences, Bangalore, IN, 4M. S. Ramaiah University of Applied Sciences, bangalore, IN

441P - A pilot cross-sectional study on incidence of liver toxicity in cancer patients on western anti-cancer drug therapy with or without concurrent Chinese herbal medicine
T.H. So1, Z. Chow2, K.S. Chan2, K.O. Lam3, V.H.F. Lee3, H. Choi2, 1Queen Mary Hospital, Hong Kong, HK, 2University of Hong Kong, Hong Kong, HK, 3LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, HK

442P - Relationship between QOL and support elderly patients with permanent colostomies
Y. Orii, Kanagawa University of Health Services, Tokyo, JP

443P - The effectiveness of individual nutritional counselling for patients with advanced cancer undergoing chemotherapy: A preliminary study
S. Koshimoto1, M. Arimoto2, K. Saitou2, A. Hashizume2, J. Kako3, K. Mcmanus1, K. Amano4, Y. Nakajima2, H. Uetake2, E. Matsushima5, 1Tokiwa University, Mito, JP, 2Tokyo Medical and Dental University Hospital, Tokyo, JP, 3Hiroshima University, Hiroshima, JP, 4Osaka City General Hospital, Osaka, JP, 5Tokyo Medical and Dental University, Tokyo, JP

444P - The prophylactic effect of 0.1% fluorometholone eye drops on eye disorders caused by high-dose cytarabine
T. Tsuchiya1, T. Kume1, K. Akiyama1, K. Yoshitsugu2, M. Fukaya2, T. Enami2, R. Tatara2, M. Shino1, T. Ikeda1, 1Shizuoka Cancer Center Hospital, Nagaizumi, JP, 2Shizuoka Cancer Center, Shizuoka, JP

445P - Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments
S.B. Oh, J.-J. Kim, S.-Y. Oh, K. Park, Pusan National University Yangsan Hospital, Yangsan, KR

446P - Accuracy of risk scoring system to determine chemotherapy induced nausea and vomiting (CINV) in cancer patients receiving first cycle
chemotherapy

J. Harika¹, V. Maka², A. D³, M. Krishna Murthy³, A. Mandepudi³, P. Paibhavi³, S.P. Kanneganti³, S. Vungarala⁴, 1IMS Ramaiah Memorial Hospital, Bangalore, IN, ²M. S. Ramaiah Medical College and Hospitals, Bangalore, IN, ³M. S. Ramaiah University of Applied Sciences, Bangalore, IN, ⁴M. S. Ramaiah University of Applied Sciences, bangalore, IN

18:00 - 18:00  447P - Hypomagnesaemia: An unnoticed problem in lung cancer patients treated with concurrent chemoradiation

S. Ahmed¹, A.K. Sengupta¹, M.R.U. Nabi¹, M. Sumon², ¹United Hospital Ltd, Dhaka, BD, ²Kurmitola General Hospital, Dhaka, BD

18:00 - 18:00  448P - Incidence and severity of chemotherapy induced peripheral neuropathy in geriatric population who are receiving chemotherapy

A. Mandepudi¹, P. Paibhavi¹, M. M¹, V. Maka², J. Harika³, ¹M. S. Ramaiah University of Applied Sciences, Bangalore, IN, ²M. S. Ramaiah Medical College and Hospitals, Bangalore, IN, ³M.S Ramaiah Memorial Hospital, Bangalore, IN

18:00 - 18:00  449P - Utility of screening tool for assessment of chemotherapy induced peripheral neuropathy in cancer patients

P. Paibhavi¹, M.K. Muddiguba¹, V. Maka², A. Mandepudi¹, S.P. Kanneganti¹, ¹M. S. Ramaiah University of Applied Sciences, Bangalore, IN, ²M. S. Ramaiah Medical College and Hospitals, Bangalore, IN

18:00 - 18:00  450P - Supportive care to control nausea and dizziness in malignant tumours: A systematic review

R. Spiegel¹, S. Rothschild², R. Kalla³, ¹Berufsgenossenschaftliche Unfallklinik Tübingen, Tuebingen, DE, ²Universitätsspital Basel, Basel, CH, ³Bern University Hospital, Bern, CH

18:00 - 18:00  451P - The safety of ramucirumab without H1-antihistamines as a premedication in patients with solid cancers: A retrospective study

N. Hattori¹, T. Yamaguchi², H. Kodama³, T. Miyamoto⁴, T. Terazawa¹, T. Kii⁵, E. Gotoh¹, M. Gotoh¹, ¹Osaka Medical College, Takatsuki, JP, ²National Cancer Center Hospital, Tokyo, JP, ³Rakuwakai Otowa Hospital, Kyoto-fu, JP, ⁴National Cancer Center Research Institute, Chuo-ku, JP, ⁵Osaka Medical College Hospital, Osaka, JP

18:00 - 18:00  452P - Expression of erythropoietin receptor in patient with anemia related chemotherapy and its correlation with absolute reticulocyte count

I. Wahid, Faculty of Medicine, Andalas University, Padang, ID

18:00 - 18:00  453P - Body mass index did not correlate with short term overall survival in breast cancers

J. Lee, Inje University Haeundae Paik Hospital, Busan, KR

18:00 - 18:00  454P - Predictors of severity and comparison of CTCAE V3.0 vs V4.3 in assessing chemotherapy induced extravasation injuries
18:00 - 18:00 455P - Assessment of nutritional status and quality of life among cancer patients undergoing chemotherapy
S. Prathima1, M. Murthy2, V. Maka3, P. Paibhavi1, J. Harika4, S. Vungarala2, M. S. Ramaiah University of Applied Sciences, Bangalore, IN, 2M. S. Ramaiah Medical College and Hospitals, Bangalore, IN

18:00 - 18:00 456P - Use of gamma irradiated bone allografts in treatment of various bone tumours
A. Mishra1, S. Kapoor2, S. Mishra3, Y. Mishra4, 1Gandhi Medical College, Bhopal, IN, 2ISIC, new delhi, IN, 3Barkatullah University, Bhopal, IN, 4peoples college of medical sciences, bhopal, IN

18:00 - 18:00 457P - The prevalence of vitamin D deficiency in Thai cancer patients, its dynamics and association with cancer survival
C. Ngokngarm1, C. Bandidwattanawong2, 1Queen Savang Vadhana Memorial Hospital, Amphoe Si Racha, TH, 2Bangkok Metropolitan Administration Medical School and Vajira Hospital, Pathumwan, TH

18:00 - 18:00 Thoracic tumours, early stage

18:00 - 18:00 458P - Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC
M. Filipits1, M.J. Hochmair2, A. Buder1, S. Watzka3, 1Institute of Cancer Research - Medical University of Vienna, Vienna, AT, 2Otto Wagner Hospital, Sanatoriumstrasse 2, 1140, Vienna, AT, 3Otto Wagner Spital, Vienna, AT

18:00 - 18:00 460P - Mendelian randomization study showed no causality between metformin use and lung cancer risk
J. Shen1, H. Zhou2, W. Fang2, J. Liu1, Y. Zhang2, Y. Huang2, L. Zhang2, 1Zhongshan School of Medicine, Sun Yat-sen University North campus, Guangzhou, CN, 2Sun Yat-sen University Cancer Center, Guangzhou, CN

18:00 - 18:00 461P - Blood trace minerals and lung cancer: A Mendelian randomization study
W. Xian1, H. Zhou2, Y. Zhang2, J. Shen1, J. Liu2, L. Zhang2, 1Zhongshan School of Medicine, Sun Yat-sen University North campus, Guangzhou, CN, 2Sun Yat-sen University Cancer Center, Guangzhou, CN

18:00 - 18:00 463P - Prediction of invasiveness in lung adenocarcinoma using machine learning algorithm based on 3D-CT imaging
Y. Saeki, S. Kitazawa, N. Kobayashi, S. Kikuchi, Y. Goto, Y. Sato, University of Tsukuba, Tsukuba, JP
18:00 - 18:00  **459P** - Fish intake, dietary polyunsaturated fatty acids, and lung cancer: systematic review and dose-response meta-analysis of 1.7 million men and women  
C. Cao, Y. Li, Q. Jiang, Ningbo No.1 Hospital, Ningbo, CN

18:00 - 18:00  **462P** - Usefulness for prevention of postoperative cerebrovascular complications in patients with lung cancer using carotid ultrasonography  
S. Takeo¹, F. Shoji², G. Toyokawa², K. Yamazaki², Y. Kozuma², ¹Kyushu University, Fukuoka, JP, ²National Hospital Organization Kyushu Medical Center, Fukuoka, JP

18:00 - 18:00  **Thoracic tumours, locally advanced**

18:00 - 18:00  **468P** - Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer  
M. Tsuboi¹, Y. Zenke¹, Y. Chiba², M. Satouchi³, S. Mitsuoka⁴, J. Shimizu⁵, H. Daga⁶, D. Fujimoto⁷, M. Mori⁸, T. Aoki⁹, T. Sawa¹⁰, S. Omori¹¹, H. Saka¹², Y. Iwamoto¹³, M. Okuno¹⁴, T. Hirashima¹⁵, K. Kashiwabara¹⁶, M. Tachihara¹⁷, N. Yamamoto¹⁸, K. Nakagawa², ¹National Cancer Center Hospital East, Kashiwa, JP, ²Kindai University Hospital, Osaka, JP, ³Hyogo Cancer Center, Akashi, JP, ⁴Osaka City University Medical School, Osaka, JP, ⁵Aichi Cancer Center Hospital, Nagoya, JP, ⁶Osaka City General Hospital, Osaka, JP, ⁷Kobe City Medical Center General Hospital, Kobe, JP, ⁸National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Osaka, JP, ⁹Tokai University School of Medicine, Kanagawa, JP, ¹⁰Gifu Municipal Hospital, Gifu, JP, ¹¹Shizuoka Cancer Center, Shizuoka, JP, ¹²National Hospital Organization Nagoya Medical Center, Aichi, JP, ¹³Hiroshima City Hospital, Hiroshima, JP, ¹⁴Okayama City Aichi Hospital, Aichi, JP, ¹⁵Osaka Habikino Medical Center, Habikino Osaka, JP, ¹⁶Kumamoto Regional Medical Center, Kumamoto, JP, ¹⁷Kobe University Graduate School of Medicine, Kobe, JP, ¹⁸Wakayama Medical University, Wakayama, JP

18:00 - 18:00  **469P** - Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small cell lung cancer: A randomised phase III trial  
A. Ata¹, A. Küçük², Ş. Eskici², T. Şanlı², E. Nayır³, ¹Mersin State Hospital, Mersin, TR, ²Mersin State Hospital, MERSİN, TR, ³Medical Park Mersin Hospital, MERSİN, TR

18:00 - 18:00  **472P** - Integration of expression rate and absolute cell counts of PD-1 B; stromal tumour-infiltrating lymphocytes: Prognostic significance in esophageal squamous cell carcinoma  
Q. Song, F. Shi, Q. Zhou, H. Chang, Beijing Shijitan hospital, Beijing, CN

18:00 - 18:00  **467P** - The free-circulating mtDNA copies number in plasma of patients with NSCLC  
O. Bulgakova, A. Kussainova, A. Kausbekova, R. Bersimbaev, L.N.Gumilyov Eurasian National University, Astana, KZ
18:00 - 18:00  **465P - A phase IIIb open-label study of afatinib in EGFR TKI-naive patients**

J. Wang¹, J. Zhao², H. Bai¹, X. Wang¹, Y. Wang², J. Duan¹, H. Chen³, S. Meng⁴, Y. Tian³, D.C.-L. Huang⁵, Y.-L. Wu⁶, ¹National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ²Peking University Cancer Hospital & Institute, Beijing, CN, ³Beijing Cancer Hospital, Beijing, CN, ⁴Ltd, Shanghai, CN, ⁵Boehringer Ingelheim Taiwan, Taipei, TW, ⁶Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN

18:00 - 18:00  **470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review**

R. Velasco¹, C.E. Barbon², D.B. Sacdalan³, ¹Philippine General Hospital, Manila, PH, ²University of the Philippines - Philippine General Hospital, Manila, PH

18:00 - 18:00  **471P - Chemotherapy in advanced thymic malignancies**

A. Varshney¹, I. Vanidassane², D. Ramavth², P. Malik³, S. Khurana⁴, V. Garg¹, S. Vadlamani², K. Kalra⁵, S. Gunasekar⁶, S. Kumar⁷, S. Sethi², M. Yadav², S. Pathy⁷, D. Jain², ¹AIIMS - All India Institute of Medical Sciences, New Delhi, IN, ²AIIMS - All India Institute of Medical Sciences, NEW DELHI, IN, ³B.R. Ambedkar Institute Rotary Cancer Hospital (AIMS), New Delhi, IN, ⁴AIIMS - All India Institute of Medical Sciences, Delhi, IN, ⁵Vardhman Mahavir Medical College & Safdarjung Hospital(VMMC-SJH), New Delhi, IN, ⁶Institute Rotary Cancer Hospital, New Delhi, IN, ⁷All India Institute of Medical Sciences, New Delhi, IN

18:00 - 18:00  **466P - Cancer immunotherapy efficacy and patients' age: A systematic review and meta-analysis**

Y. Jiang, Z. Su, The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN

18:00 - 18:00  **Thoracic tumours, metastatic**

---

18:00 - 18:00  **506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)**

J. Ward¹, M. Shum², E. Bertino³, V. Lin⁴, V. Kuruvadi⁴, T. Heineman⁴, ¹Washington University School of Medicine, St. Louis, US, ²The Oncology Institute of Hope and Innovation, Whittier, US, ³Ohio State University, Columbus, US, ⁴Halozyme Inc., San Diego, US

18:00 - 18:00  **480P - Safety and efficacy of dacomitinib for EGFR-wildtype NSCLC in the subgroup of Asian patients from ARCHER 1050**

T.S.K. Mok¹, Y. Cheng², X. Zhou³, K.H. Lee⁴, K. Nakagawa⁵, S. Niho⁶, R. Rosell⁷, R. Linke⁸, C.H. Wong⁹, Y. Tang¹⁰, M. Singh¹¹, K. Wilner¹², Y.-L. Wu¹², ¹Prince of Wales Hospital, Shatin, HK, ²Jilin Provincial Cancer Hospital, Changchun, CN, ³First Affiliated Hospital of Third Military Medical University, Chongqing, CN, ⁴Chungbuk National University Hospital, Cheongju, KR, ⁵Kindai University Hospital, Osaka, JP, ⁶National
18:00 - 18:00  
**503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIIB trials**  
1European Institute of Oncology, Milan, IT, 2Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, 3Russian Academy of Medical Sciences, Moscow, RU, 4Jiangsu Provincial Tumor Hospital, Jiangsu, CN, 5Petrov Research Institute of Oncology, St Petersburg, RU, 6Peking University Cancer Hospital & Institute, Beijing, CN, 7National Cancer Centre, Singapore, SG, 8Tel Aviv University, Tel Aviv, IL, 9The University of Hong Kong, Hong Kong, CN, 10Oncology Centre and Institute, Waspl, 11Chang Gung Memorial Hospital, 33305, Taoyuan, TW, 12HCG Hospital, Bangalore, IN, 13S.p.A., Milan, IT, 14Boehringer Ingelheim Pharmaceuticals, Ridgefield, US, 15Boehringer Ingelheim Taiwan, Taipei, TW, 16Boehringer Ingelheim, Vienna, AT, 17Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, 18Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN

18:00 - 18:00  
**488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)**  
K. Kusaka1, A. Tamura2, T. Kozuki3, Y. Koreeda4, T. Kita5, T. Endo6, T. Shibayama7, N. Hatakeyama8, M. Miura9, N. Yamashita10, M. Takenoyama11, 1National Hospital Organization - Tokyo National Hospital, Kiyose City, JP, 2National Hospital Organization, Tokyo National Hospital, Tokyo, JP, 3National Hospital Organization Shikoku Cancer Center, matsuyama, JP, 4National Hospital Organization Minami-kyushu National Hospital, Aira, JP, 5National Hospital Organization Kanazawa Medical Center, Kanazawa, JP, 6National Hospital Organization Mito Medical Center, Ibaraki, JP, 7National Hospital Organization Okayama Medical Center, Okayama, JP, 8National Hospital Organization Kochi Hospital, Kochi, JP, 9Akita University Hospital, Akita, JP, 10National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, 11National Hospital Organization Kyusyu Cancer Center, Fukuoka, JP

18:00 - 18:00  
**495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib**  
A. Buder1, M.J. Hochmaier2, U. Setinek3, M. Filipits1, 1Institute of Cancer Research - Medical University of Vienna, Vienna, AT, 2Otto Wagner Hospital, Sanatoriumstrasse 2, 1140, Vienna, AT, 3Otto Wagner Hospital, Vienna, AT

18:00 - 18:00  
**520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)**  
18:00 - 18:00 504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
P. Song, L. Zhang, PUMCH-Peking Union Medical College Hospital (East), Beijing, CN

18:00 - 18:00 519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
C.-H. Kuo1, K. Yoh2, C.-T. Yang3, C.-C. Wang3, T.-C. Yen4, K.-J. Lin4, T. Ikeda2, Y. Zenke2, S. Matsumoto2, K. Goto2, 1Chang Gung Memorial Hospital, Linko, Taipei, TW, 2National Cancer Center Hospital East, Kashiwa, JP, 3Chang Gung Memorial Hospital, Kaoshiung, Kaoshiung, TW, 4Chang Gung Memorial Hospital, Taipei, TW

18:00 - 18:00 521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
K. Baba1, H. Tanaka2, Y. Fujita3, A. Nakamura4, E. Kikuchi5, Y. Kawai6, T. Harada7, N. Watanabe8, H. Yokouchi9, K. Usui10, R. Saito11, H. Watanabe12, T. Masuda13, T. Fukuhara14, K. Kudo15, R. Honda16, S. Oizumi17, M. Maemondo18, A. Inoue11, N. Morikawa18, 1Hiroasaki University - Center for Advanced Medical Research, Hiroasaki, JP, 2Hiroasaki University, Hiroasaki, JP, 3National Hospital Organization Asahikawa Medical Center, Asahikawa, JP, 4Sendai Kousei Hospital, Sendai, JP, 5Hokkaido University Hospital, Sapporo, JP, 6Oji General Hospital, Tomakomai, JP, 7JCHO Hokkaido Hospital, Sapporo, JP, 8Sunagawa City Medical Center, Sunagawa, JP, 9Fukushima Medical University School of Medicine, Fukushima, JP, 10NTT Medical Center Tokyo, Tokyo, JP, 11Tohoku University School of Medicine, Sendai, JP, 12Saka General Hospital, Sendai, JP, 13Gunma University, Maebashi, JP, 14Miyagi Cancer Center, Sendai, JP, 15National Hospital Organization Osaka Minami Medical Center, Osaka, JP, 16Asahi General Hospital, Chiba, JP, 17National Hospital Organization Hokkaido Cancer Center, Sapporo, JP, 18Iwate Medical University, Morioka, JP

18:00 - 18:00 526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
L. Chu1, F. Liang2, J. Zhang2, J. Deng2, Y. Chen2, Q. Liu2, D. Ai2, Z. Zhu3, K. Zhao2, 1Fudan University Shanghai Cancer Center; Shanghai, CN, 2Shanghai Cancer Center Fudan University, Shanghai, CN, 3Fudan University Shanghai Cancer Center, CN

18:00 - 18:00 499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung
cancer (NSCLC) patients in Hong Kong

Q.S.H. Chan¹, G. Cheung², M.M.L. Lee³, S. Olsen⁴, ¹Hong Kong Integrated Oncology Centre, Hong Kong, HK, ²The Chinese University of Hong Kong, Shatin, HK, ³Guardant Health AMEA, Singapore, SG, ⁴Guardant Health Pte. Ltd., Singapore, SG

18:00 - 18:00

489P - Overall survival in patients with EGFRm&##0002B; NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study

M.J. Hochmair¹, A. Morabito², D. Hao³, C.-T. Yang⁴, R.A. Soo⁵, J.C.-H. Yang⁶, R. Guçalp⁷, B. Halms⁸, L. Wang⁹, A. Martin⁹, T. Cufer¹⁰, ¹Otto Wagner Hospital, Sanatoriumstrasse 2, 1140, Vienna, AT, ²Istituto Nazionale Tumori, "Fondazione G.Pascale"-IRCCS, 80131, Napoli, IT, ³Cummings School of Medicine, University of Calgary, T2N 4N2, Calgary, CA, ⁴Chang Gung Memorial Hospital, 33305, Taoyuan, TW, ⁵National University Hospital, 119047, Singapore, SG, ⁶National Taiwan University Hospital and National Taiwan University Cancer Center, 100, Taipei, TW, ⁷Montefiore/Albert Einstein Cancer Center, 10461, Bronx, US, ⁸Taiwan Limited, 104, Taipei City, TW, ⁹International GmbH, 55216, Ingelheim am Rhein, DE, ¹⁰University of Ljubljana, Ljubljana, SI

18:00 - 18:00

509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial

A. Camerini¹, A. Morabito², A. Montanino³, R. Bernabe Caro⁴, F. Grossi⁵, R. Ramla⁵, ¹- Tony Chiricuta Oncology Institute-IOCN, Cluj-Napoca, RO, ²Humanitas Gavazzeni, Bergamo, IT, ³Istituto Oncologico Veneto IRCCS, Padova, IT, ⁴Istituto Europeo di Oncologia, Milan, IT, ⁵ICO - Institut Català d'Oncologia Girona (Hospital Universitari Josep Trueta Hospital Universitari Josep Trueta), Girona, ES, ⁶Pierre Fabre Oncology, Boulogne-Billancourt, FR, ⁷Pierre Fabre Oncology, France, Boulogne-Billancourt, FR, ¹⁵Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warsaw, PL

18:00 - 18:00

500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations

J. Duan¹, H. Bai¹, X. Wang¹, R. Wan¹, H. Cheng², H. Wang², F. Lou², S. Cao², J. Wang¹, ¹National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Beijing, CN, ²Beijing Acornmed Biotechnology Co., Ltd., Beijing, CN

18:00 - 18:00

527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing

X. Li¹, W. Wang², C. Xu³, X. Pu⁴, S. Fang⁵, X. Cai⁶, Y. Fang⁷, Y. Zhu¹, H. Wang⁸, X. Liang⁹, W. Zhuang³, Y. Zhang¹⁰, L. Wang¹¹, X. Cai¹², J. Li¹³, H. Feng¹⁴, M. Fang², G. Chen³, T. Lv¹⁵, Y. Song¹⁵, ¹Zhijie Rongjun Hospital, Jiaxing, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN, ³Fujian Cancer Hospital, Fuzhou, CN, ⁴HuNan Cancer Hospital, Changsha, CN, ⁵Daping Hospital and Research Institute of Surgery, Army Medical
18:00 - 18:00 481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)

T. Yokoyama, H. Yoshioka, D. Fujimoto, Y. Demura, K. Hirano, T. Kawai, R. Kagami, T. Ishida, K. Tomii, M. Akai, M. Hiramayashi, T. Nishimura, Y. Nakahara, Y. Kim, K. Yoshimura, T. Hirai, Kurashiki Central Hospital, Kurashiki, JP, 2Kobe City Medical Center General Hospital, Kobe, JP, 3Japanese Red Cross Fuku Hospital, Hukui, JP, 4Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, JP, 5Kyoto-Katsura Hospital, Kyoto, JP, 6National Hospital Organization Himeji Medical Center, Himeji, JP, 7Kyoto University Hospital, Kyoto, JP, 8Kanazawa University, Kanazawa, JP

18:00 - 18:00 490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience

Y. Ang, R. Wong, C.S. Tan, M.V. Blanco, Y. Huang, B.C. Goh, R.A. Soo, 1NUH-National University Hospital (S) Pte. Ltd., Singapore, SG, 2OncoCare Cancer Centre, Singapore, SG, 3National University Hospital, 119047, Singapore, SG

18:00 - 18:00 498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study

S.-G. Wu, C.-L. Chiang, C.-Y. Liu, C.-C. Wang, P.-L. Su, T.-C. Hsia, J.-Y. Shih, G.-C. Chang, 1National Taiwan University Hospital, Taipei City, TW, 2Taipei Veterans General Hospital, Taipei, TW, 3Linkou Chang Gung Memorial Hospital, New Taipei, TW, 4Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, TW, 5National Cheng Kung University Hospital, Tainan, TW, 6China Medical University Hospital, Taichung, TW, 7National Taiwan University Hospital, Taipei, TW, 8Taichung Veterans General Hospital, +-- ext., TW

18:00 - 18:00 501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification

X. Gao, X.-W. Wei, Y.-L. Wu, Q. Zhou, 1Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, Guangzhou, CN, 2Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, 3Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN

18:00 - 18:00 502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
18:00 - 18:00

**482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC:** A biomarker analysis

F. De Marinis, K.K. Laktionov, A. Poltoratskiy, I. Egorova, M. Hochmair, A. Passaro, M.R. Migliorino, G. Metro, M. Gottfried, D. Tsoi, G. Ostoros, S. Rizzato, G.Z. Mukhametshina, S. Schumacher, S. Novello, R. Dziadziuszko, W. Tang, L. Clementi, A. Cseh, D. Kowalski, European Institute of Oncology, Milan, Italy; 1European Academy of Medical Sciences, Moscow, Russia; 2Petrov Research Institute of Oncology, St Petersburg, Russia; 3City Clinical Oncological Center (CCOC), Saint Petersburg, Russia; 4Otto Wagner Hospital, Vienna, Austria; 5San Camillo-Forlanini Hospital, Rome, Italy; 7Santa Maria della Misericordia Hospital, Perugia, Italy; 8Tel Aviv University, Tel Aviv, Israel; 9St. John of God Murdoch Hospital, Murdoch, US; 10OTPI-Korányi National Institute for Tuberculosis and Pulmonology, Budapest, Hungary; 11Azienda Sanitaria-Università 13Integrata, Udine, Italy; 12Ministry of Health of the Republic of Tatarstan, Kazan, Russia; 13Ordensklinikum Elisabethinen, Linz, Austria; 14University of Turin, Turin, Italy; 15Medical University of Gdansk, Gdansk, Poland; 16Boehringer Ingelheim Pharmaceuticals, Ridgefield, US; 17S.p.A., Milan, Italy; 18Boehringer Ingelheim, Vienna, Austria; 19Oncology Centre and Institute, Warsaw, Poland.

18:00 - 18:00

**483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis**

R. Rosell, A. Poltoratskiy, M. Hochmair, K.K. Laktionov, R. Ramla, M. Alonso Garcia, J. Skrckova, P.L. Piovano, S. Rizzato, P. Bidoli, D. Kowalski, L. Clementi, A. Cseh, F. De Marinis, Catalan Institute of Oncology, Barcelona, Spain; 2Petrov Research Institute of Oncology, St Petersburg, Russia; 3Otto Wagner Hospital, Vienna, Austria; 4Russian Academy of Medical Sciences, Moscow, Russia; 5Poznan University of Medical Sciences, Poznan, Poland; 6Oncology Hospital del Rocio, Seville, Spain; 7University Hospital Brno, Jihlavska, Czech Republic; 8Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy; 9Azienda Sanitaria-Università 11Integrata, Udine, Italy; 10San Gerardo Hospital, Monza, Italy; 11Oncology Centre and Institute, Warsaw, Poland; 12S.p.A., Milan, Italy; 13Boehringer Ingelheim, Vienna, Austria; 14European Institute of Oncology, Milan, Italy.

18:00 - 18:00

**484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials**

M. Gottfried, F. De Marinis, H. Tu, K.K. Laktionov, J. Feng, A. Poltoratskiy, J. Zhao, E.-H. Tan, V. Lee, D. Kowalski, C.-T. Yang, B. Srinivasa, A. Passaro, L. Clementi, W. Tang, D.C.-L. Huang, A. Cseh, K. Park, C. Zhou, Y.-L. Wu, Y. Wu, Tel Aviv University, Tel Aviv, Israel; 2Istituto Europeo di Oncologia, Milan, Italy; 3Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China; 4Russian Academy of Medical Sciences, Moscow, Russia; 5Jiangsu Provincial Tumor Hospital, Jiangsu, China; 6Petrov Research Institute of Oncology, St Petersburg, Russia; 7Peking University Hospital, Beijing, China.

Last update: 18-11-2019 08:34:53am
Final Programme
18:00 - 18:00  **491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma**  C.-I. Shen, C.-H. Chiu, Taipei Veterans General Hospital, Taipei, TW

18:00 - 18:00  **510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer**  S. Gohar\(^1\), K. Abd El Aziz\(^2\), N. Abd El Bary\(^2\), M. Shehata\(^2\), S. Alhassanin\(^2\), A. Hegazy\(^2\), \(^1\)Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG, \(^2\)Faculty of Medicine - Menoufia University, Shebin El Kom, EG

18:00 - 18:00  **496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs**  T. Ninomaru, A. Hata, C. Kokan, H. Okada, Kobe Minimally Invasive Cancer Center, Kobe, JP

18:00 - 18:00  **511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)**  T. Kubo\(^1\), N. Nogami\(^2\), A. Bessho\(^3\), A. Morita\(^3\), S. Ikeo\(^4\), T. Yokoyama\(^4\), M. Ishihara\(^5\), T. Honda\(^5\), N. Fujimoto\(^6\), S. Murakami\(^7\), K. Kaira\(^8\), T. Harada\(^9\), K. Nakamura\(^10\), S. Iwasawa\(^11\), T. Shimokawa\(^12\), K. Kiura\(^1\), N. Yamashita\(^13\), H. Okamoto\(^12\), 1Okayama University Hospital, Okayama, JP, 2Shikoku Cancer Center, Matsuyama, JP, 3Japanese Red Cross Okayama Hospital, Okayama, JP, 4Kurashiki Central Hospital, Kurashiki, JP, 5Teikyo University School of Medicine, Tokyo, JP, 6Okayama Rosai Hospital, Okayama, JP, 7Kanagawa Cancer Center, Yokohama, JP, 8Gunma University Graduate School of Medicine, Maebashi, JP, 9JCHO Hokkaido Hospital, Sapporo, JP, 10Japanese Red Cross Himeji Hospital, Himeji, JP, 11Chiba University Graduate School of Medicine, Chiba, JP, 12Yokohama Municipal Citizen's Hospital, Yokohama, JP, 13National Hospital Organization Shikoku Cancer Center, Matsuyama, JP

18:00 - 18:00  **485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer**  S.H. Yoon\(^1\), Y.S. Kim\(^1\), J.H. Chung\(^1\), H.Y. Seol\(^1\), M.H. Kim\(^2\), \(^1\)Pusan National University Yangsan Hospital, Yangsan, KR, \(^2\)Pusan National University Hospital, Busan, KR

18:00 - 18:00  **522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer**  H. Oi\(^1\), Y. Yamano\(^1\), T. Yokoyama\(^1\), T. Matsuda\(^1\), M. Morise\(^2\), K. Kataoka\(^1\), T. Kimura\(^1\), Y. Kondoh\(^1\), \(^1\)Tosei General Hospital, Seto, JP, \(^2\)Nagoya University, Graduate School of Medicine, Nagoya, JP
18:00 - 18:00 512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
H. Imai¹, T. Kasai², K. Mori³, K. Kishi⁴, T. Kaburagi⁵, M. Yomota⁶, T. Sugano⁷, Y. Hosomi⁸, Y. Yamada⁵, S. Moriguchi⁴, K. Minato¹, A. Gemma⁷, ¹Gunma Prefectural Cancer Center, Ota, JP, ²Tochigi Cancer Center, Utsunomiya, JP, ³Jizankai Medical Foundation Tsuboi Cancer Center Hospital, Koriyama, JP, ⁴Toranomon Hospital, Tokyo, JP, ⁵Ibaraki Prefectural Central Hospital, Kasama, JP, ⁶Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, JP, ⁷Graduate School, Nippon Medical School, Tokyo, JP

18:00 - 18:00 497P - Real-world efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
X. Ye¹, S. Lu², ¹Shanghai Chest Hospital, Shanghai, CN, ²Shanghai Jiao Tong University, Shanghai, CN

18:00 - 18:00 507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
T. Uenami¹, M. Mori², T. Shiroyama³, I. Nagatomo³, S. Ihara⁴, K. Komuta⁴, H. Suzuki⁵, T. Hirashima⁵, M. Kimura⁶, F. Imamura⁶, ¹National Hospital Organization Toneyama Hospital, Toyonaka, JP, ²National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Osaka, JP, ³Graduate School of Medicine, Osaka University, Suita Osaka, JP, ⁴Osaka Police Hospital, Osaka, JP, ⁵Osaka Habikino Medical Center, Habikino Osaka, JP, ⁶Osaka International Cancer Institute, Osaka, JP

18:00 - 18:00 523P - Co-morbidities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
W. Xiu, Y. Huang, X. Zhou, L. Zhou, J. Xue, J. Zhu, M. Huang, F. Peng, Y. Liu, Y. Xu, Y. Zhang, M. Yu, Y. Li, Y. Wang, Y. Lu, Y. Gong, West China Hospital of Sichuan University, Chengdu, CN

18:00 - 18:00 516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
M. Shimada¹, M. Kanazu², M. Shimokawa³, R. Saito⁴, M. Mori⁵, A. Tamura¹, Y. Okano⁶, Y. Fujita⁷, T. Endo⁸, M. Motegi⁹, S. Takata¹⁰, T. Kita¹¹, N. Sukoh¹², M. Takenoyama¹³, S. Atagi¹⁴, ¹National Hospital Organization, Tokyo National Hospital, Tokyo, JP, ²National Hospital Organization Toneyama Hospital, Toyonaka, JP, ³National Hospital Organization Kyusyu Cancer Center, Hakata, JP, ⁴National Hospital Organization Shibukawa Medical Center, Shibukawa, JP, ⁵National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, JP, ⁶National Hospital Organization, Kochi National Hospital, Kochi, JP, ⁷National Hospital Organization Asahikawa Medical Center, Asahikawa, JP, ⁸National Hospital Organization Mito Medical Center, Ibaraki, JP, ⁹National Hospital Organization Takasaki General Medical Center, Takasaki, JP, ¹⁰National Hospital Organization
18:00 - 18:00  
**486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)**

M. Morita¹, A. Nakamura², H. Tanaka³, R. Saito⁴, S. Inoue⁵, T. Harada⁶, T. Yamada⁷, T. Nakagawa⁸, D. Jing⁹, S. Sugawara², ¹Miyagi Cancer Center, Natori, JP, ²Sendai Kousei Hospital, Sendai, JP, ³Hirosaki University, Hirosaki, JP, ⁴Tohoku University Hospital, Sendai, JP, ⁵Yamagata University Faculty of Medicine, Yamagata, JP, ⁶CHO Hokkaido Hospital, Sapporo, JP, ⁷Toyama University Hospital, Toyama, JP, ⁸Omagari Kosei Medical Center, Omagari, JP, ⁹Saka General Hospital, Shigama, JP

18:00 - 18:00  
**515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors**

T. Hakozaki, R. Kitadai, Y. Hosomi, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP

18:00 - 18:00  
**518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer**

B.C. Ahn¹, S. Lee², Y.J. Chun¹, M.H. Hong², H.R. Kim³, B.C. Cho⁴, Severance Hospital, Seoul, KR, ²Yonsei Cancer Center Yonsei University, Seoul, KR, ³Yonsei University Severance Hospital, Seoul, KR, ⁴Yonsei University, Seoul, KR

18:00 - 18:00  
**508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study**

J. Wang¹, Z. Zhang², F. Zhang¹, Q. Song¹, L. Zhang¹, Z. Liu², J. Ma², X. Yan², L. Wang², H. Tao², S. Zhang², X. Li², X. Zhi², Y. Hu², S. Jiao², ¹Chinese PLA General Hospital (301 Military Hospital), Beijing, CN, ²The First Medical Center of Chinese PLA General Hospital, Beijing, CN

18:00 - 18:00  
**525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma**

A. Fukuda¹, M. Yamota², Y. Hosomi¹, ¹Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, ²Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, JP

18:00 - 18:00  
**524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital**

L. Moharana, D. Lokanatha, L. Jacob, M. Sureshbabu, K. Lokesh, A. Rudresha, L. Rajeev, S. Smitha, Kidwai Cancer Institute, Bangalore, IN

18:00 - 18:00  
**505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?**

A. B. P¹, M. Sharma¹, P. Jain¹, S. Joga¹, S. Bothra², A. Jajodia¹, R. Sood³, S. Pasricha¹, U.
18:00 - 18:00  487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma  
C.S. Chai1, C.K. Liam2, O. Po Lin3, Y.K. Pang4, G.F. Ho5, A. Alip5, C.K. Wong2, M.E. Poh2, J.L. Tan2, 1Faculty of Medicine and Health Science, University Malaysia Sarawak, Kota Samarahan, MY, 2University Malaya Medical Centre (UMMC), Kuala Lumpur, MY, 3UMMC - University Malaya Medical Centre, Kuala Lumpur, MY, 4University Malaya Medical Center, Kuala Lumpur, MY, 5University of Malaya Faculty of Medicine, Kuala Lumpur, MY

18:00 - 18:00  492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer  

18:00 - 18:00  513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed  
S. Kitagawa1, K. Watanabe2, Y. Takagi3, Y. Hosomi2, 1tokyo metropolitan komagome hospital, Tokyo, JP, 2Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, 3Teikyo University School of Medicine, Tokyo, JP

18:00 - 18:00  493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience  
S. Shrivastva, B. Stalin, S. Gundeti, Nizam's Institute of Medical Sciences, Hyderabad, IN

18:00 - 18:00  494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib  
C.S. Chai1, O. Po Lin2, C.K. Liam3, Y.K. Pang4, G.F. Ho5, A. Alip5, C.K. Wong3, M.E. Poh3, J.L. Tan3, 1Faculty of Medicine and Health Science, University Malaysia Sarawak, Kota Samarahan, MY, 2UMMC - University Malaya Medical Centre, Kuala Lumpur, MY, 3University Malaya Medical Centre (UMMC), Kuala Lumpur, MY, 4University Malaya Medical Center, Kuala Lumpur, MY, 5University of Malaya Faculty of Medicine, Kuala Lumpur, MY

18:00 - 18:00  517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses  
F. Guo, Y. Zhang, Z. Li, L. Tu, J. He, Y. Huang, K. Liu, F. Luo, West China Hospital of Sichuan University, Chengdu, CN

18:00 - 18:00  528P - High-biologically effective dose radiotherapy may improve local control of small cell lung cancer patients with brain metastases: A propensity-matching analysis
18:00 - 18:00 529P - (Withdrawn)

18:00 - 18:00 530P - Prognostic value of C-reactive protein, albumin and C-reactive protein to albumin ratio in small cell lung cancer: A meta-analysis
C.E. Barbon1, R. Velasco, Jr.1, D.B. Sacdalan2, R.R. Angeles1, 1University of the Philippines - Philippine General Hospital, Manila, PH, 2Philippine General Hospital, Manila, PH

18:00 - 18:00 531TiP - CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC
B.C. Cho1, G.-C. Chang2, Y.-C. Kim3, S. Geater4, S. Saeteng5, C.-T. Yang6, Y. Goto7, S. Lu8, A. Ardizzoni9, F. Barlesi10, P. De Marchi11, L. Paz-Ares12, D.R. Spigel13, M. Thomas14, E. Garon15, M. Leung16, J. Baum17, Z. Zewen18, B. Mookerjee18, J.-C.H. Yang19, 1Yonsei University, Seoul, KR, 2Taichung Veterans General Hospital, +-- ext., TW, 3Chonnam National University Medical School, and CNU Hwasun Hospital, Jeonnam, KR, 4Prince of Songkla University, Songkhla, TH, 5Chiang Mai University, Chiang Mai, TH, 6Chang Gung Memorial Hospital, Taoyuan, TW, 7National Cancer Center Hospital, Tokyo, JP, 8Shanghai Jiao Tong University, Shanghai, CN, 9S.Osma-Malpighi University Polyclinic, Bologna, IT, 10Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, 11Barretos Cancer Hospital, Barretos, BR, 12University Hospital 12 De Octubre, Madrid, ES, 13Sarah Cannon Research Institute, Nashville, TN, US, 14Thoraxklinik Heidelberg gGmbH - Universitätsklinikum Heidelberg, Heidelberg, DE, 15UCLA Hematology/Oncology Santa Monica, Santa Monica, US, 16Novartis, East Hanover, US, 17Novartis Pharmaceuticals Corporation, Cambridge, US, 18Novartis Pharmaceuticals Corporation, East Hanover, US, 19National Taiwan University Hospital and National Taiwan University Cancer Center, 100, Taipei, TW

18:00 - 18:00 532TiP - CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC
D.S.W. Tan1, T.M. Kim2, B.J. Solomon3, W.L. Tan4, C.J. Yu5, S. Geater6, G. De Castro Jr.7, A. Greystoke8, E. Felip9, B.E. Johnson10, S. Deudon11, A.-L. Louveau12, V.Q. Passos13, B.C. Cho14, 1National Cancer Center Singapore, Singapore, SG, 2Seoul National University Hospital, Seoul, KR, 3Peter MacCallum Cancer Centre, Melbourne, AU, 4National Cancer Centre, Singapore, Singapore, SG, 5National Taiwan University Hospital, Taipei, TW, 6Songkla University, Songkla, TH, 7ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR, 8Newcastle upon Tyne Hospitals, Newcastle upon Tyne, GB, 9Vall d’Hebron University Hospital, Barcelona, ES, 10Dana-Farber Cancer Institute, Boston, US, 11Novartis Pharma AG, Basel, CH, 12Novartis Pharma SAS, Rueil-Malmaison, FR, 13Novartis Pharmaceuticals Corporation, East Hanover, NJ, US, 14Yonsei University, Seoul, KR

18:00 - 18:00 533TiP - CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx)
18:00 - 18:00  
**534TiP - A randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for NSCLC with IPF (J-SONIC)**  
K. Otsubo¹, J. Kishimoto², H. Kenmotsu³, Y. Minegishi⁴, H. Horinouchi⁵, T. Kato⁶, E. Ichihara⁷, A. Shiraki⁸, S. Atagi⁹, M. Ando¹⁰, N. Yamamoto¹¹, I. Okamoto¹², K. Kitakyushu Municipal Medical Center, Kitakyushu, JP, ²Kyushu University, Fukuoka, JP, ³Shizuoka Cancer Center, Shizuoka, JP, ⁴Nippon Medical School Main Hospital, Tokyo, JP, ⁵National Cancer Center Hospital, Tokyo, JP, ⁶Kanagawa Cancer Center, Yokohama, JP, ⁷Okayama University Hospital, Okayama, JP, ⁸Osaka Municipal Hospital, Ogaki, JP, ⁹National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, JP, ¹⁰Nagoya University Hospital, Nagoya, JP, ¹¹Wakayama Medical University, Wakayama, JP, ¹²Kyushu University Hospital, Fukuoka, JP

18:00 - 18:00  
**535TiP - Phase II study of atezolizumab for pretreated advanced / recurrent non-small cell lung cancer with idiopathic interstitial pneumonia (TORG1936 / AMBITIOUS study)**  
S. Ikeda¹, T. Kato², H. Kenmotsu³, T. Ogura¹, S. Iwasawa⁴, T. Iwasawa¹, R. Kasajima², Y. Miyagi², T. Misumi³, T. Yamanaka⁵, H. Okamoto⁶, ¹Kanagawa Cardiovascular and Respiratory Center, Yokohama, JP, ²Kanagawa Cancer Center, Yokohama, JP, ³Shizuoka Cancer Center, Shizuoka, JP, ⁴Chiba University Graduate School of Medicine, Chiba, JP, ⁵Yokohama City University School of Medicine, Yokohama, JP, ⁶Yokohama Municipal Citizen's Hospital, Yokohama, JP

18:00 - 18:00  
**536TiP - INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study**  
J.C.-H. Yang¹, B. Eilers-Lenz², J. Straub³, A. Johne³, Y.-L. Wu⁴, ¹National Taiwan University Hospital and National Taiwan University Cancer Center, 100, Taipei, TW, ²Merck Healthcare KGaA, Darmstadt, DE, ³Merck KGaA - Germany, Darmstadt, DE, ⁴Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN

18:00 - 18:00  
**Young Oncologist Patient Case (Presenter must be under 40 years of age)**

18:00 - 18:00  
**YO8 - Carcinosarcoma of the Breast in a Filipino Female: A Case Report**
18:00 - 18:00  **YO09 - Small Malignant Phyllodes Tumor of the Breast with Metastases to the Lung and Bone**  
G. Harti¹, I. Wijaya², ¹RSUP Dr Hasan Sadikin Hospital Bandung, Bandung, ID, ²Hasan Sadikin General Hospital, Bandung, ID

18:00 - 18:00  **YO10 - Rectal Follicular Dendritic Cell Sarcoma**  
K. Bajaj, Tata Memorial Hospital, Mumbai, IN

18:00 - 18:00  **YO11 - Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer**  
L. Tao¹, D. Xiu², D. Li³, ¹Henan Province Hospital of TCM, Zhengzhou, CN, ²Peking university third hospital, Beijing, CN, ³Henan Provincial People’s Hospital, Zhengzhou, CN

18:00 - 18:00  **YO12 - Case report of Hepatic EBV-associated smooth muscle tumor in AIDS patient**  
G. Kerkarchachai, Vajira Hospital Centre, Bangkok, TH

18:00 - 18:00  **YO13 - IgG4-related pseudo-tumor of the kidney and multiple organ involvement mimicked malignancy**  
W. Mahaparn, J. Surintrspanont, A. Sanpawat, K. Sasiwimonphan, P. Sitthideatphaiboon, King Chulalongkorn Memorial Hospital, Bangkok, TH

18:00 - 18:00  **YO14 - Urachal Adenocarcinoma: Case Report**  
M.J. Alcantara, C. Gorospe, St. Luke’s Medical Center, Quezon City, PH

18:00 - 18:00  **YO15 - Concurrent Atezolizumab-Radiotherapy in Locally Recurrent Urinary Bladder Carcinoma: A Case Report**  
M.A.L. Dantes, Jose R. Reyes Memorial Medical Center, Manila, PH

18:00 - 18:00  **YO16 - Clear cell RCC with synchronous metastasis at transplanted kidney and bone in patient post Cadaveric donor kidney transplantation**  
P. Cheewasathianchai, Khon Kaen University - Faculty of Veterinary Medicine, Khon Kaen, TH

18:00 - 18:00  **YO17 - Serous ovarian cancer treated with palbociclib and letrozole**  
D.W. Lee¹, G.F. Ho², ¹University Malaya Medical Centre (UMMC), Kuala Lumpur, MY, ²University Malaya Medical Center, Kuala Lumpur, MY

18:00 - 18:00  **YO18 - A patient with Peutz-Jegher syndrome who incidentally found sex cord stromal tumor: a case report**  
P. Pimsa¹, N. Ngamphaiboon², K. Paiwattanupant³, ¹Sappasit Prasong Hospital, Ubon Ratchathani, TH, ²ramathibodi,prayathia, TH, ³Ramathibodi, prayathai, TH
18:00 - 18:00  
**YO19** - A case of CLL/SLL with transdifferentiation to dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm: The missing link?  
**Y. Chen**, J. Lu, J. Wang, C. Xu, G. Chen, Fujian Cancer Hospital, Fuzhou, CN

18:00 - 18:00  
**YO20** - Can "Superman" have Chronic Myelomonocytic Leukemia?  
**A. Luchinin**, V. Ovsepyan, Kirov Scientific Research Institute of Hematology and Blood Transfusion, Kirov, RU

18:00 - 18:00  
**YO21** - Sanctuary Site Central Nervous System Relapse-Refractory DLBCL Responding to Nivolumab and Lenalidomide.  
**I. Madabhavi**, Gujarat Cancer and Research Institute, Ahmedabad, IN

18:00 - 18:00  
**YO22** - External Auditory Canal Mass: A Case Series of Squamous Cell Carcinoma  
**M.V. Cruz-Ordinario**, E.C. Cuaresma, M. Guevarra, E. Lim, M.S. Imasa, 1St. Luke's Medical Center - Quezon City, Quezon City, PH, 2St. Luke's Medical Center – Quezon City, Quezon City, PH

18:00 - 18:00  
**YO23** - Soft tissue Giant cell tumor presented as Nasopharyngeal mass: A case report  
**E. Buenacosa-Nepucpan**, Jose R. Reyes Memorial Medical Center, Manila, PH

18:00 - 18:00  
**YO25** - Hyperprogression after pembrolizumab in recurrent oropharyngeal cancer and the use of nab-paclitaxel as salvage treatment- A case report.  
**I. Rosli**, C.T. Chong, G.F. Ho, UMMC - University Malaya Medical Centre, Kuala Lumpur, MY, 2University Malaya Medical Center, Kuala Lumpur, MY

18:00 - 18:00  
**YO26** - Exacerbation of radiation necrosis around the radiotherapy-pretreated brain metastases site after immune checkpoint inhibitors.  

18:00 - 18:00  
**YO27** - Comparative Study Of 20Gray/5Fraction And 30Gray/10 Fraction Whole Brain Radiation In Brain Metastasis  
**P. Bhandari**, NAMS, Bir Hospital, Kathmandu, NP

18:00 - 18:00  
**YO28P** - The response to anaplastic lymphoma kinase (ALK) inhibitor in metastatic anaplastic thyroid carcinoma (ATC)  
**N.F. Ab Munir**, G.F. Ho, Hospital Universiti Kebangsaan Malaysia, Kuala Lumpur, MY, 2University Malaya Medical Center, Kuala Lumpur, MY

18:00 - 18:00  
**YO29** - Acute kidney injury secondary to bilateral renal artery tumor thrombosis in a case of posterior mediastinal undifferentiated sarcoma: case report  
**R. Ibusuki**, T. Harada, A. Shimauchi, T. Kayukawa, D. Etoh, Y. Okamatsu, K. Tsubouchi, K. Inoue, 1JCHO Kyusyu Hospital, Kitakyushu, JP, 2Japan Community Healthcare Organization, Kyushu Hospital, Kitakyushu, JP
18:00 - 18:00  YO30 - Follicular dendritic cell sarcoma of the tonsil- a multimodality approach  
R.E. King¹, A. Villaruel², J.P. Magno¹, S.P. De Guzman¹, L.I. Catedral¹, K.A. Mondragon¹, F.I. Ting¹, R. Velasco, Jr.¹, F. Gracieux Jr.², ¹University of the Philippines - Philippine General Hospital, Manila, PH, ²Philippine General Hospital, Manila, PH

18:00 - 18:00  YO31 - Primary pulmonary sarcoma  
K. Ubaydullaeva, National Cancer Research Center of Uzbekistan, Tashkent, UZ

18:00 - 18:00  YO32 - prostatic rhabdomyosarcoma in an adult patient: A case study  
M.R. Islam, M. Islam, National Institute of Cancer Research & Hospital, Dhaka, BD

18:00 - 18:00  YO33 - Hyponatremia - slaying the dragon or chasing a mirage- a Case report  
R. D. Arora, All India Institute of Medical Sciences, Delhi, IN

18:00 - 18:00  YO34 - A rare endocrinological syndrome presenting with weakness in Soft tissue sarcoma - a Case report  
R. D. Arora, All India Institute of Medical Sciences, Delhi, IN

18:00 - 18:00  YO35 - Gefitinib induced movement disorder - a Case report  
R. D. Arora, All India Institute of Medical Sciences, Delhi, IN

18:00 - 18:00  YO36 - A case of BRAF V600E mutated non-small-cell lung cancer with pleomorphic features  
R. Matsuzawa, M. Morise, I. Tanaka, T. Hase, K. Wakahara, N. Hashimoto, Nagoya University, Graduate School of Medicine, Nagoya, JP

18:00 - 18:00  YO37 - Intraventricular metastasis as the first presentation of non-small cell lung cancer  
S. Putraveephong, K. Wirasorn, J. Chindaprasirt, A. Sookprasert, P. Chadbunchachai, Khon Kaen University - Faculty of Medicine - Srinagarind Hospital, Khon Kaen, TH

18:00 - 18:00  YO38 - Cerebral metastases from a thymic malignancy: a case report  
M. Nik Eezamuddeen¹, M. Amir², N. Bakar², M. Kream², ¹University technology Mara, Sungai buloh, Sungai Buloh, MY, ²university teknologi mara, sungai buloh, MY

18:00 - 18:00  YO39 - Primary Follicular Thyroid Carcinoma Metastatic to the Kidney Mimicking Renal Cell Carcinoma: A Case Report  
J. Aranilla, National Kidney and Transplant Institute, Quezon City, PH

18:00 - 18:00  YO40 - A Rare Case of Primary Malignant Giant Cell Tumor of Tibia  
G. Venugopal, M. Malik, Nizam Institute of Medical Sciences, Hyderabad, IN
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:15</td>
<td>Session DOI</td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td><strong>Minimal residual disease (overview lecture)</strong></td>
</tr>
<tr>
<td></td>
<td>J. Tie, Peter MacCallum Cancer Centre, Melbourne, AU</td>
</tr>
<tr>
<td>09:30 - 09:45</td>
<td><strong>Colorectal cancer</strong></td>
</tr>
<tr>
<td></td>
<td>A. Sobrero, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT</td>
</tr>
<tr>
<td>09:45 - 10:00</td>
<td><strong>Pancreatic cancer</strong></td>
</tr>
<tr>
<td></td>
<td>M. Ducreux, Gustave Roussy - Cancer Campus, Villejuif, FR</td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td><strong>Gastric cancer</strong></td>
</tr>
<tr>
<td></td>
<td>Y. Kodera, Nagoya University, Graduate School of Medicine, Nagoya, JP</td>
</tr>
<tr>
<td>10:15 - 10:45</td>
<td><strong>Discussion</strong></td>
</tr>
</tbody>
</table>
09:15 - 09:15  Session DOI

09:15 - 09:20  Presentation of case/condition
S. Popat, Royal Marsden Hospital NHS Foundation Trust, London, GB

09:20 - 09:40  Medical oncologist’s perspective
E. Felip, Vall d’Hebron University Hospital, Barcelona, ES

09:40 - 10:00  Radiation oncologist’s perspective
Y.C. Ahn, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

10:00 - 10:20  Thoracic surgeon’s perspective
T. Mitsudomi, Kindai University - Faculty of Medicine, Osaka, JP

10:20 - 10:45  Discussion
09:15 - 10:45  Type: Multidisciplinary tumour board  Title: Advanced prostate cancer (hormone-naïve case)  Chair: Ravindran Kanesvaran, SG

09:15 - 09:15  Session DOI

09:15 - 09:20  Presentation of case/condition
R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG

09:20 - 09:40  Medical oncology perspective
S. Gillessen, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

09:40 - 09:55  Surgery perspective
L.S. Lee, SGH-Singapore General Hospital/Singhealth-Academia, Singapore, SG

09:55 - 10:15  Radiation oncology perspective
D. Poon, Prince of Wales Hospital, Shatin, HK

10:15 - 10:45  Discussion

09:15 - 10:45  Type: Proffered Paper session  Title: Proffered paper session - Gynaecological cancers  Chair: Sudeep Gupta, IN; Mansoor Raza Mirza, DK

09:15 - 09:15  Session DOI

09:15 - 09:25  224O - Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)
M. Friedlander1, K. Moore2, N. Colombo3, G. Scambia4, B.-G. Kim5, A. Oaknin6, A. Lisyanskaya7, A. Floquet8, A. Leary9, G. Sonke10, C. Gourley11, S. Banerjee12, A. Oza13, A. González-Martín14, C. Aghajanian15, W. Bradley16, E. Lowe17, R. Hettle18, E. Flood17, P. Disilvestro19, 1Prince of Wales Hospital, Randwick, AU, 2Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, 3Istituto Europeo di Oncologia, Milan, IT, 4Policlinico Universitario A. Gemelli, Roma, IT, 5Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, 6Vall d’Hebron University Hospital, Barcelona, ES, 7St Petersburg City Oncology Dispensary, St Petersburg, RU, 8Institute Bergonié, Bordeaux, FR, 9Institut Gustave Roussy, Villejuif, FR, 10The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, 11Edinburgh Cancer Research UK Centre, Edinburgh, GB, 12Royal Marsden Hospital NHS Foundation Trust, London, GB, 13Princess Margaret Cancer Centre, Toronto, CA,
09:25 - 09:35  **225O - Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy**

M. Friedlander¹, R. Hettle², E. Parkhomenko³, ¹Prince of Wales Hospital, Randwick, AU, ²PAREXEL Access, London, GB, ³PAREXEL, London, GB

09:35 - 09:50  **LBA10 - Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev**


09:50 - 10:05  **Invited Discussant 224O, 225O and LBA10**

C. Sessa, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

10:05 - 10:17  **LBA11 - Mainstreaming genetic counselling for genetic testing of BRCA1/2 in ovarian cancer patients in Malaysia (MaGIC study)**

S.Y. Yoon¹, S.W. Wong¹, N.S. Ahmad¹, S. Mariapun¹, T. Hassan¹, H. Padmanabhan¹, J. Lim¹, A. George², M.K. Thong³, G.S. Chng⁴, S.H. Teo¹, E. Bleiker⁵, Y.L. Woo⁶, ¹Cancer Research Malaysia, Subang Jaya, MY, ²Institute of Cancer Research, London, GB, ³University Malaya Medical Centre, Kuala Lumpur, MY, ⁴Hospital Kuala Lumpur, Kuala Lumpur, MY, ⁵Netherlands Cancer Institute, Amsterdam, NL

10:17 - 10:29  **226O - Prevalence of germline BRCA1 and BRCA2 mutations and variants among ovarian, primary peritoneal and fallopian tube cancer patients: A multicentre Indian study**

S. Gupta¹, S. Rajappa², S. Advani³, A. Agarwal⁴, S. Aggarwal⁵, C. Goswami⁶, S. Dattatreya Palanki⁷, D. Arya⁸, S. Patil⁹, R. Kodagali¹⁰, ¹Tata Memorial Hospital Centre,
Invited Discussant One LBA11 and 2260
M.R. Mirza, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK

Type: Educational session
Title: Perspective of liquid biomarkers for cancer care
Chair: Kohei Shitara, JP; Noboru Yamamoto, JP

Methodology of liquid biopsy
I. Tan, National Cancer Centre Singapore, Singapore, SG

Liquid biomarkers for NSCLC
Y. Goto, National Cancer Center Hospital, Tokyo, JP

Liquid biomarkers for advanced GI cancer
K. Shitara, National Cancer Center Hospital East, Kashiwa, JP

Liquid biomarkers for immunotherapy
F.C. Bidard, Institut Curie, Paris, FR

Discussion

Type: Mini Oral session
Title: Mini Oral session - Immunotherapy of cancer
Chair: Daniel Shao Weng Tan, SG; Michele Teng, AU; Anders Skanderup, SG

LBA14 - Genomic HLA heterozygosity as a predictive marker for survival in lung cancer patients post immunotherapy
A. Abed1, A. Khattak2, M. Millward3, A. Chopra4, E. Gray5, 1Fiona Stanley Hospital, Perth, AU, 2Fiona Stanley Hospital, Murdoch, AU, 3Sir Charles Gairdner Hospital, Nedlands, AU, 4Institute for Immunology and Infectious Diseases (IIID), Murdoch, AU, 5Edith Cowan University, Joondalup, AU
09:20 - 09:25  **Discussion led by moderators**  
**D.S.W. Tan¹, M. Teng², A. Skanderup³**, ¹National Cancer Center Singapore, Singapore, SG, ²QIMR Berghofer Medical Research Institute, Brisbane, AU, ³A*STAR - Genome Institute of Singapore (GIS), Singapore, SG

09:25 - 09:30  **317O - Association of survival and blood-based genomic signature with atezolizumab for patients with second-line and third-line EGFR wild-type non-small cell lung cancer: Pooled analysis of individual patient data from the POPLAR and OAK trials**  
**Y. Yu¹, A. Li², Y. Chen², Q. Li³, Q. Ou³, D. Lin³, W. Zhang³, Z. Li³, H. Hu³, H. Yao³**, ¹2nd Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ²Guangdong Medical University, Zhanjiang, CN, ³Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN

09:30 - 09:35  **318O - Both low and high blood tumour mutational burden are favourable predictors with atezolizumab**  
**W. Nie, B. Han**, Shanghai Chest Hospital, Shanghai, CN

09:35 - 09:40  **319O - Combined model of frameshift mutations and TMB in predicting response to immunotherapy in NSCLC**  
**H. Zhou, J. Liu, Y. Zhang, W. Fang, L. Zhang**, Sun Yat-sen University Cancer Center, Guangzhou, CN

09:40 - 09:55  **Discussion led by moderators**  
**D.S.W. Tan¹, M. Teng², A. Skanderup³**, ¹National Cancer Center Singapore, Singapore, SG, ²QIMR Berghofer Medical Research Institute, Brisbane, AU, ³A*STAR - Genome Institute of Singapore (GIS), Singapore, SG

09:55 - 10:00  **320O - PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in NSCLC**  
**J. Liu, H. Zhou, Y. Zhang, Y. Huang, Y. Yang, W. Fang, L. Zhang**, Sun Yat-sen University Cancer Center, Guangzhou, CN

10:00 - 10:05  **321O - Data-driven miRNA classifier as response predictor for immune checkpoint inhibitor treatment in advanced-stage cancer patients**  
**C.-H. Hsieh¹, S.-T. Kang², W.-M. Chen², Y.-C. Lin¹, H.-M. Wang¹, J.-S. Chen¹, Y.-S. Hsieh², E. Yang²**, ¹Chang Gung Memorial Hospital, Taoyuan, TW, ²Quark Biosciences, Inc., Hsinchu City, TW

10:05 - 10:15  **Discussion led by moderators**  
**D.S.W. Tan¹, M. Teng², A. Skanderup³**, ¹National Cancer Center Singapore, Singapore, SG, ²QIMR Berghofer Medical Research Institute, Brisbane, AU, ³A*STAR - Genome Institute of Singapore (GIS), Singapore, SG
11:00 - 11:05  
**Introduction**  
D. Tai\(^1\), Y.-H. Huang\(^2\),  
\(^1\)National Cancer Centre Singapore (NCCS), Singapore, SG,  
\(^2\)Taipei Veterans General Hospital, Taipei City, TW

11:05 - 11:25  
**Changing paradigm of treatment strategy for intermediate and advanced HCC**  
M. Ikeda, National Cancer Center Hospital East, Kashiwa, JP

11:25 - 11:35  
**Adopting new paradigm of treatment strategy into clinical practice: Multidisciplinary approach (from loco-regional interventionist perspective)**  
S.-M. Lin, Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW

11:35 - 11:45  
**Adopting new paradigm of treatment strategy into clinical practice: Multidisciplinary approach (from hepatologist perspective)**  
D.Y. Kim, Pusan National University Hospital, Busan, KR

11:45 - 11:55  
**Adopting new paradigm of treatment strategy into clinical practice: Multidisciplinary approach (from medical oncologist perspective)**  
S.P. Choo, NCCS - National Cancer Centre Singapore, Singapore, SG

11:55 - 12:25  
**Panel discussion**  
M. Ikeda\(^1\), S.-M. Lin\(^2\), D.Y. Kim\(^3\), S.P. Choo\(^4\),  
\(^1\)National Cancer Center Hospital East, Kashiwa, JP,  
\(^2\)Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW,  
\(^3\)Pusan National University Hospital, Busan, KR,  
\(^4\)NCCS - National Cancer Centre Singapore, Singapore, SG

12:25 - 12:30  
**Conclusions**  
D. Tai\(^1\), Y.-H. Huang\(^2\),  
\(^1\)National Cancer Centre Singapore (NCCS), Singapore, SG,  
\(^2\)Taipei Veterans General Hospital, Taipei City, TW
11:00 - 12:30  Type: Industry Satellite Symposium  Title: Roche - Cancer immunotherapy in HCC: The combination revolution  Hall 404  Chair: Pierce Chow, SG

11:00 - 11:05  Welcome and introductions  P. Chow, National Cancer Centre Singapore, Singapore, SG

11:05 - 11:25  Review of phase III data in advanced HCC  A.-L. Cheng, National Taiwan University, Taipei, TW

11:25 - 11:45  Navigating HCC treatment decisions: What are the clinical implications for patients?  H.C. Toh, NCCS - National Cancer Centre Singapore, Singapore, SG

11:45 - 12:00  Cancer immunotherapy in intermediate or early HCC  D. Pinato, Imperial College London - Hammersmith Hospital, London, GB

12:00 - 12:20  The patient perspective: Awareness and involvement in clinical decision making  J. Tsai, Formosa Cancer Foundation, Taipei City, TW

12:20 - 12:30  Q&A and meeting close

11:00 - 12:30  Type: Industry Satellite Symposium  Title: Takeda - Redefining ALK+ NSCLC management  Hall 407  Chair: Tony S.K. Mok, HK

11:00 - 11:05  Welcome  T.S.K. Mok, Prince of Wales Hospital, Shatin, HK

11:05 - 11:20  Present and future of molecular testing in lung cancer  T.S.K. Mok, Prince of Wales Hospital, Shatin, HK

11:20 - 12:00  Evolving ALK + NSCLC paradigm  R. Camidge, University Of Colorado Hospital, Aurora, US

12:00 - 12:20  Optimal sequencing strategies in second line and beyond  M.-J. Ahn, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

12:20 - 12:30  Conclusion  T.S.K. Mok, Prince of Wales Hospital, Shatin, HK
11:00 - 11:05  Welcome
T. Yoshino, National Cancer Center Hospital East, Kashiwa, JP

11:05 - 11:20  Tumor location is a key decision factor for 1st-line mCRC treatment
Y. Deng, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN

11:20 - 11:50  Choosing the best 1st-line treatment for RAS wt mCRC patients
D. Aderka, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL

11:50 - 12:05  Cetuximab rechallenge in 3rd line mCRC can provide a new standard of care
M. Scartozzi, AOU Ospedali Riuniti Ancona, Torrette di Ancona, IT

12:05 - 12:25  Panel discussion: Asian hot topics
J.Y. Wang1, T. Yoshino2, 1Chung-Ho Memorial Hospital, Kaohsiung Medical University Hospital, Kaohsiung City, TW, 2National Cancer Center Hospital East, Kashiwa, JP

12:25 - 12:30  Conclusions
T. Yoshino, National Cancer Center Hospital East, Kashiwa, JP
11:00 - 12:30  Type: ESMO Colloquium
Title: ESMO Colloquium supported by Astellas - State of the art management of mCPRC
Chair: Ravindran Kanesvaran, SG; Arun Azad, AU

11:00 - 11:00  Session DOI

11:00 - 11:05  Introduction
A. Azad, Monash Medical Centre, Clayton, AU

11:05 - 11:15  mCRPC definition and benefits of treatment
R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG

11:15 - 11:30  Optimal first-line treatment in mCRPC after either chemo or ARI in mHSPC
C. Sternberg, Weill Cornell Medicine, New York, US

11:30 - 11:45  Changing treatment algorithms in mCRPC: Role of PARP inhibitors
A. Azad, Monash Medical Centre, Clayton, AU

11:45 - 12:00  Is there an optimal sequencing strategy in mCRPC?
B. Tran, Peter MacCallum Cancer Centre, Melbourne, AU

12:00 - 12:15  Immunotherapy in mCRPC management
A. Azad, Monash Medical Centre, Clayton, AU

12:15 - 12:30  Conclusion and wrap up
R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Title</th>
</tr>
</thead>
</table>
| 11:00 - 12:30 | **Type:** ESMO Colloquium  
**Title:** ESMO Colloquium supported by Guardant Health: Liquid biopsy in the management of solid tumours  
Chair: Byoung Chul Cho, KR |
| 11:00 - 11:00 | **Session DOI**                                                                                   |
| 11:00 - 11:05 | **Introduction**  
B.C. Cho, Yonsei University, Seoul, KR |
| 11:05 - 11:30 | **What does liquid biopsy mean?**  
F.C. Bidard, Institut Curie, Paris, FR |
| 11:30 - 11:55 | **Use of liquid biopsies in colorectal cancers**  
T. Yoshino, National Cancer Center Hospital East, Kashiwa, JP |
| 11:55 - 12:10 | **Use of liquid biopsy in breast cancer**  
P. Mainwaring, ICON Cancer Care, Brisbane, AU |
| 12:10 - 12:25 | **Use of liquid biopsy in non-small cell lung cancer** |
| 12:25 - 12:30 | **Conclusion**  
B.C. Cho, Yonsei University, Seoul, KR |
| 11:00 - 11:45 | **Type:** Young Oncologist session  
**Title:** Vesalius talk: The role of the Mentor in shaping oncology career paths  
Chair: Guillem Argiles Martinez, ES; Fabrice André, FR; Daniel Shao Weng Tan, SG |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 - 12:45</td>
<td><strong>Session DOI</strong></td>
</tr>
<tr>
<td>12:45 - 12:50</td>
<td><strong>Presentation of case/condition</strong></td>
</tr>
<tr>
<td>E. Oki</td>
<td>National Kyushu Cancer Center, Fukuoka, JP</td>
</tr>
<tr>
<td>12:50 - 13:10</td>
<td><strong>The viewpoint of a Medical oncologist</strong></td>
</tr>
<tr>
<td>T. Yoshino</td>
<td>National Cancer Center Hospital East, Kashiwa, JP</td>
</tr>
<tr>
<td>13:10 - 13:30</td>
<td><strong>The viewpoint of a Surgical oncologist</strong></td>
</tr>
<tr>
<td>J. Xu</td>
<td>Zhongshan Hospital, Fudan University, Shanghai, CN</td>
</tr>
<tr>
<td>13:30 - 13:50</td>
<td><strong>The viewpoint of an Interventional radiologist</strong></td>
</tr>
<tr>
<td>T. De Baere</td>
<td>Institut Gustave Roussy, Villejuif, FR</td>
</tr>
<tr>
<td>13:50 - 14:15</td>
<td><strong>Discussion</strong></td>
</tr>
</tbody>
</table>
**12:45 - 14:15**  
**Type:** Educational session  
**Title:** Melanoma treatment today and tomorrow  
**Chair:** Caroline Robert, FR; Atsushi Otsuka, JP

12:45 - 12:45  **Session DOI**

12:45 - 13:05  **Adjuvant vs neoadjuvant therapy**  
R. Dummer, Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH

13:05 - 13:25  **New combinations in metastatic disease**  
C. Robert, Institut Gustave Roussy, Villejuif, FR

13:25 - 13:45  **Update on mucosal melanoma**  
L. Si, Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN

13:45 - 14:05  **Management of acral melanoma**  
A. Otsuka, Kyoto University-Graduate school of medicine, Kyoto, JP

14:05 - 14:15  **Discussion**

**12:45 - 14:15**  
**Type:** Educational session  
**Title:** Early integration of palliative care  
**Chair:** Lalit Krishna, SG

12:45 - 12:45  **Session DOI**

12:45 - 13:15  **Current status and future directions of ESMO Designated Centers: A global perspective**  
S. Kaasa¹, Y. Matsumoto², ¹Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ²National Cancer Center Hospital East, Kashiwa, JP

13:15 - 13:45  **Focus on the top 4 symptoms and guidelines**  
M. Mori¹, P. Stone², ¹Seirei Christopher University, Hamamatsu, JP, ²University College London, London, GB

13:45 - 14:00  **ESMO supportive and palliative care Guidelines**  
K. Jordan, University of Heidelberg, Heidelberg, DE

14:00 - 14:15  **Discussion**
**Type:** Mini Oral session  
**Title:** Mini Oral session - Gynaecological cancers  
**Room:** 324

**Chair:** Amita Maheshwari, IN; David SP Tan, SG; Sandro Pignata, IT

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 - 12:45</td>
<td><strong>Session DOI</strong></td>
</tr>
</tbody>
</table>
| 12:45 - 12:50 | **227O - Laparoscopic radical hysterectomy leads to poorer prognosis compared with abdominal radical hysterectomy in patients with locally advanced cervical cancer**  
*T.W.Y. Hu,* West China Second Hospital, Chengdu, CN

| 12:50 - 12:55 | **228O - Comparison of long-term oncologic outcomes between laparoscopy and laparotomy for stage Ia1-Ib3 cervical cancer: A matched cohort study**  
*D. Dai,* H. Huang, J. Liu, Sun Yat-sen University Cancer Center, Guangzhou, CN

| 12:55 - 13:05 | **Discussion led by moderator**  
*S. Pignata,* Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

| 13:05 - 13:10 | **LBA12 - Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601)**  
*Y. Antill*¹, P.S. Kok², M. Stockler³, K. Robledo², S. Yip², M. Parry², D. Smith⁴, A. Spurdle⁵, E. Barnes², M. Friedlander⁶, S. Baron-Hay⁷, C. Shannon⁴, J. Coward⁸, P. Beale⁹, G. Goss¹⁰, T. Meniawy¹¹, J. Andrews², M. Kelly², L. Mileskhtnin¹², ¹Cabrini Health, Malvern, AU, ²NHMRC Clinical Trials Centre, Camperdown, AU, ³Chris O’Brien Lifehouse, Camperdown, AU, ⁴Mater Adult Hospital, Brisbane, AU, ⁵10.QIMR Berghofer Medical Research Institute, Brisbane, AU, ⁶Prince of Wales Hospital, Randwick, AU, ⁷Royal North Shore Hospital, St Leonards, AU, ⁸ICON Cancer Care, Brisbane, AU, ⁹Sydney Local Health District, Concord Cancer Centre, Sydney, AU, ¹⁰Box Hill Hospital-Eastern health, Box Hill, AU, ¹¹School of Medicine and Pharmacology Sir Charles Gairdner Hospital, Nedlands, AU, ¹²Peter MacCallum Cancer Center, Melbourne, AU

| 13:10 - 13:15 | **Discussion led by moderator**  
*D.S. Tan,* NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG

| 13:15 - 13:20 | **229O - Application of hysterectomy in treatment of trophoblastic neoplasia**  
*Y. Liu*¹, Y. He², Y. Long², ¹West China Second Hospital, Chengdu, CN, ²West China Second University Hospital, Sichuan University, Chengdu, CN

| 13:20 - 13:35 | **Discussion led by moderator**  
*A. Maheshwari,* Tata Memorial Hospital Centre, Mumbai, IN
12:45 - 14:15  Type: Collaborative session  
Title: ESMO - AACR Collaborative Session: CAR-T cells / NK cells  
Chair: John Haanen, NL; Shannon Maude, US

12:45 - 12:45  Session DOI

12:45 - 12:50  Introduction  

12:50 - 13:10  New directions in CAR-T therapy  
F. Thistlethwaite, The Christie NHS Foundation Trust, Manchester, GB

13:10 - 13:30  CAR-T for solid tumours  

13:30 - 13:50  Targeting BCMA with CAR-T  
B. Wang, The Second Affiliated Hospital of Xi'an Jiaotong University, Shaanxi Sheng, CN

13:50 - 14:10  Using NK cells for immunotherapy  
D. Lee, Nationwide Children's Hospital, Columbus, US

14:10 - 14:15  Conclusions and clinical perspectives  
F. Thistlethwaite, The Christie NHS Foundation Trust, Manchester, GB

12:45 - 13:45  Type: Mini Oral session  
Title: Mini Oral session - Haematological malignancies  
Chair: Soon Thye Lim, SG; Martin Dreyling, DE; Marco Ladetto, IT; Won Seog Kim, KR

12:45 - 12:45  Session DOI

12:45 - 12:50  LBA13 - Clinical outcomes of ibrutinib in patients with relapsed or refractory mantle cell lymphoma: Korean multicenter, retrospective analysis  
12:50 - 12:55 266O - A population pharmacokinetic model: Assessment of pharmacokinetic similarity of HLX01 and rituximab in diffuse large B-cell lymphoma

Y. Shi1, Y. Qin2, S. Zhao3, P. Hu4, X. Zeng4, X. Zhang5, W. Jiang5, S. Liu5, E. Liu5, K. Chai5, A. Lu5, D. Yao5, 1Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, CN, 2National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, 3Certara Strategic Consulting China, Shanghai, CN, 4Peking Union Medical College Hospital, Beijing, CN, 5Shanghai Henlius Biopharm, Shanghai, CN

12:55 - 13:00 267O - Treatment outcome for gastric mucosa-associated lymphoid tissue lymphoma with Helicobacter Pylori negative

S.-N. Lim1, B.S. Sohn2, 1Inje University Haeundae Paik Hospital, Busan, KR, 2Sanggye Paik Hospital, Seoul, KR

13:00 - 13:15 Discussion led by moderators

S.T. Lim1, M. Dreyling2, M. Ladetto3, W.S. Kim4, 1National Cancer Center Singapore, Singapore, SG, 2Ludwig Maximilians University - Grosshadern, Munich, DE, 3Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arigo, Alessandria, IT, 4Samsung Medical Center (SMC), Seoul, KR

13:15 - 13:20 268O - Genetic variations in hematopoietic and mesenchymal stem cells in de novo myelodysplastic syndromes

M. Bandara1, I. Rathnayake2, N. Neththikumara3, H. Goonasekara3, V. Dissanayake3, 1University of Peradeniya - Faculty of Medicine, Peradeniya, LR, 2Faculty of Medicine, General Sir John Kotelawala Defence University, Rathmalana, LR, 3Faculty of Medicine, University of Colombo, Colombo, LR

13:20 - 13:25 Discussion led by moderators

S.T. Lim1, M. Dreyling2, M. Ladetto3, T.W. Kim4, 1National Cancer Center Singapore, Singapore, SG, 2Ludwig Maximilians University - Grosshadern, Munich, DE, 3Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arigo, Alessandria, IT, 4Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR

13:25 - 13:30 269O - Efficacy and safety of isatuximab plus pomalidomide and dexamethasone in East Asian patients with relapsed/refractory multiple myeloma: A subgroup analysis of ICARIA-MM study

T. Ikeda1, K. Sunami2, S.-Y. Huang3, M.-C. Wang4, Y.I. Koh5, C.G. Min6, S.-P. Yeh7, M. Matsumoto8, M. Uchiyama9, S. Iyama10, C. Shimazaki11, J.H. Lee12, K.H. Kim13, H. Kaneko14, J.S. Kim15, T.-L. Lin16, F. Campana17, K. Tada18, S. Iida19, K. Suzuki20, 1Shizuoka Cancer Center, Shizuoka, JP, 2National Hospital Organization Okayama Medical Center, Okayama, JP, 3National Taiwan University Hospital, Taipei, TW, 4Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TW, 5Seoul National University Hospital, Seoul, KR, 6Seoul St. Mary’s Hospital, Seoul, KR, 7China Medical University Hospital,
Taichung, TW, 8National Hospital Organization Shibukawa Medical Center, Shibukawa, JP, 9Japanese Red Cross Society Suwa Hospital, Nagano, JP, 10Sapporo Medical University School of Medicine, Sapporo, JP, 11Japan Community Health care Organization Kyoto Kuriamauchi Medical Center, Kyoto, JP, 12Gil Gacheon Hospital, Incheon, KR, 13Samsung Medical Center, Seoul, KR, 14Japanese Red Cross Osaka Hospital, Osaka, JP, 15Sevrance Hospital, Seoul, KR, 16Chang Gung Memorial Hospital, Linkou, Taoyuan, TW, 17Sanofi, CAMBRIDGE, US, 18Sanofi, Tokyo, JP, 19Nagoya City University Graduate School of Medical Sciences, Nagoya, JP, 20Japanese Red Cross Medical Center, Tokyo, JP

13:30 - 13:35 Discussion led by moderators
S.T. Lim1, M. Dreyling2, M. Ladetto3, W.S. Kim4, 1National Cancer Center Singapore, Singapore, SG, 2Ludwig Maximilians University - Grosshadern, Munich, DE, 3Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT, 4Samsung Medical Center (SMC), Seoul, KR

13:35 - 13:40 270O - Imatinib induced toxicity and its influence on cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia
H. Natarajan1, L. Kumar2, S. Bakhshi2, A. Sharma2, T. Velpandian2, M. Kabra2, A. Gogia2, N.R. Biswas2, Y.K. Gupta2, 1AIIMS - All India Institute of Medical Sciences, Delhi, IN, 2All India Institute of Medical Sciences (AIIMS), New Delhi, New Delhi, IN

13:40 - 13:45 Discussion led by moderators
S.T. Lim1, M. Dreyling2, M. Ladetto3, W.S. Kim4, 1National Cancer Center Singapore, Singapore, SG, 2Ludwig Maximilians University - Grosshadern, Munich, DE, 3Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT, 4Samsung Medical Center (SMC), Seoul, KR

14:30 - 14:30 Session DOI

14:30 - 14:35 LBA4 - Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)
M. Untch1, C. Geyer, Jr.2, C. Huang3, S. Loibl4, N. Wolmark5, M. Mano6, G. Von Minckwitz4, A. Bruksky7, X. Pivot8, J. Poliok9, A. Fontana10, B. Kaufman11, J.C. Aledo12, T. Boulet13, H. Liu14, C. Song14, E. Mamounas15, 1Helios Klinikum Berlin Buch, Berlin, DE, 2NSABP Foundation and Virginia Commonwealth University Massey Cancer Center, Richmond, US, 3National Taiwan University Hospital, New Taipei city, TW, 4German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, 5Allegheny General Hospital, Pittsburgh, US, 6Hospital Sirio Libanes, Sao Paulo, BR, 7University of Pittsburgh School of Medicine, US, 8Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, 9Southern California Kaiser Permanente Medical Group, San Diego, US, 10Azienda Ospedaliera Universitaria S.Chiara, Pisa, IT, 11Chaim Sheba Medical Center, Ramat Gan,
14:35 - 14:40  
**LBA5 - The role of radiation therapy in clinically node-positive, pathological negative nodes after neoadjuvant chemotherapy in breast cancer patients: In sentinel node biopsy and trastuzumab era**

J.H. Joo¹, Y. Ki², S.S. Kim³, ¹Pusan National University Yangsan Hospital, Yangsan, KR, ²Pusan National University Yangsan Hospital, Yangsan-si, KR, ³Asan Medical Center, Seoul, KR

14:40 - 14:45  
**26O - De-escalating axillary surgery according to neoadjuvant single or dual HER2 blockade in clinically node-positive, HER2-positive breast cancer**

C. Cha¹, D. Kim¹, J. Lee¹, S. Park¹, S.J. Bae¹, J.Y. Kim², S.G. Ahn¹, H.S. Park², S. Park², S.I. Kim², Y.U. Cho², J. Jeong¹, ¹Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, ²Severance Hospital, Yonsei University College of Medicine, Seoul, KR

14:45 - 15:00  
**Discussion led by moderators**

P. Dubsky¹, B. Chua², ¹Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, CH, ²Peter MacCallum Cancer Center, Melbourne, AU

15:00 - 15:05  
**39O - Pooled analysis of efficacy and safety in Asian patients (pts) in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials of ribociclib (RIB) plus endocrine therapy (ET)**

S.-A. Im¹, Y.-S. Yap², J. Sohn³, K.S. Lee⁴, K.H. Jung⁵, L.M. Tseng⁶, S.C. Lee⁷, K.G. Babu⁸, Y.H. Park⁹, I. Gounaris¹⁰, M. Sondhi¹¹, A. Ridolfi¹¹, J.P. Zarate¹¹, Y.-S. Lu¹², ¹Seoul National University Hospital, Seoul National University College of Medicine, Seoul, KR, ²Severance Hospital, Yonsei University College of Medicine, Seoul, KR, ³Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, ⁴National Cancer Center, Gyeonggi-d, KR, ⁵Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁶Taipei-Veterans General Hospital, National Yang-Ming University, Taipei, TW, ⁷NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG, ⁸Curie Centre Of Oncology-Hcg Hospital Koramangala, Bangalore, IN, ⁹Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ¹⁰Novartis Pharma AG, Basel, CH, ¹¹Novartis Pharmaceutical Corporation, East Hanover, US, ¹²National Taiwan University Hospital, Taipei, TW

15:05 - 15:10  
**40O - Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with advanced breast cancer (ABC): Final results from EVEREXES**

Y.-H. Im¹, B. Karabulut², K.S. Lee³, A. Adhav⁴, B.-W. Park⁵, H. Yesil Cinkir⁶, J. Bowles⁷, T. Delgar Alfaro⁸, H.L. Xue⁹, S.B. Kim¹⁰, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ²Ege University Medical Faculty, Izmir, TR, ³National Cancer Center, Korea, Seoul, KP, ⁴HCG Manavata Cancer Centre, Nashik, IN, ⁵Yonsei University Hospital, Seoul, KR, ⁶Gaziantep University Medical Faculty, Şehitkamil, TR, ⁷Novartis pharmaceutical AG, Basel, CH, ⁸Novartis, Basel, CH, ⁹Novartis, Mapletree Business City, SG, ¹⁰Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR
15:10 - 15:15  
**20 - Protective effects of bisoprolol against acute anthracycline-induced cardiotoxicity: A randomized control study**

S. Sandoughdaran, M. Malekzadeh Moghani, N. Tabatabai, Shahid Beheshti University of Medical Sciences, Tehran, IR

15:15 - 15:20  
**30 - Integrative analysis of metabolic subtypes in triple-negative breast cancer reveals new therapeutic strategies**

Y. Gong, P. Ji, Y. Xiao, D. Ma, M.-L. Jin, X. Hu, Y.-Z. Jiang, Z.-M. Shao, Fudan University Shanghai Cancer Center, Shanghai, CN

15:20 - 15:40  
**Discussion led by moderators**

A. Eniu, The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca, RO

---

**14:30 - 16:00**

**Type:** Multidisciplinary tumour board  
**Title:** Multidisciplinary tumour board on salivary glands and unknown primary cancers  
**Hall:** 404  
**Chair:** Christian Simon, CH

---

14:30 - 14:30  
**Session DOI**

14:30 - 14:35  
**Paranasal sinus: Case presentation**

R. Nagadia, SGH-Singapore General Hospital/Singhealth-Academia, Singapore, SG

14:35 - 15:00  
**Paranasal sinus**

M.L.K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG

15:00 - 15:05  
**Salivary glands: Case presentation**

C.K.H. Wong, NCCS - National Cancer Centre Singapore, Singapore, SG

15:05 - 15:30  
**The role of chemotherapy for salivary gland cancer: Recent updates**

B. Keam, Seoul National University Hospital, Seoul, KR

15:30 - 15:35  
**Unknown primary cancers: Case presentation**

M.T.L. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG

15:35 - 16:00  
**Unknown primary cancers**

C. Simon, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH
14:30 - 14:30  **Session DOI**

14:30 - 14:30  **Factors affecting decision making for the use of adjuvant therapy in older adults**

14:30 - 14:40  **Case presentation**  
J. Lee, NCCS - National Cancer Centre Singapore, Singapore, SG

14:40 - 14:50  **Discussion - European perspective**  
D. Papamichael, Bank of Cyprus Oncology Centre, Nicosia, CY

14:50 - 15:00  **Discussion - Asian perspective**  
I. Tan, National Cancer Centre Singapore, Singapore, SG

15:00 - 15:15  **Q&A**

15:15 - 15:15  **Metastatic colon cancer: managing older patients and individuals with co-morbidities**

15:15 - 15:25  **Case presentation**  
J. Lee, NCCS - National Cancer Centre Singapore, Singapore, SG

15:25 - 15:35  **Discussion - European perspective**  
D. Papamichael, Bank of Cyprus Oncology Centre, Nicosia, CY

15:35 - 15:45  **Discussion - Asian perspective**  
I. Tan, National Cancer Centre Singapore, Singapore, SG

15:45 - 16:00  **Q&A**
14:30 - 14:42 341O - Clinical and FDG-PET markers of immune checkpoint inhibitor (ICI) response in patients with metastatic Merkel cell carcinoma (mMCC)
A. Weppler¹, P. Bhave², P. De Ieso³, M. Chua³, J. Raleigh³, A. Hatzimihalis³, A. Gill⁴, S. Balachander⁵, J. Callahan³, A. Pattison⁵, A. Caneborg⁵, A. Hatzimihalis³, A. Gill⁴, S. Balachander⁵, J. Callahan³, A. Pattison⁵, A. Caneborg⁵, ¹Peter MacCallum Cancer Center, Melbourne, AU, ²Alfred Hospital, Melbourne, AU, ³Peter MacCallum Cancer Centre, Melbourne, AU, ⁴Royal North Shore Hospital, Sydney, AU, ⁵University of Melbourne, Melbourne, AU

14:42 - 14:54 342O - Response of nivolumab monotherapy in 124 Japanese patients with advanced melanoma: Interim analysis of prospective observational study (CREATIVE study)
N. Yamazaki¹, A. Takahashi¹, K. Namikawa¹, T. Takenouchi², Y. Nakamura³, S. Kitano¹, T. Fujita⁴, K. Kubota⁵, T. Yamanaka⁵, Y. Kawakami⁵, ¹National Cancer Center Hospital, Tokyo, JP, ²Niigata Cancer Center Hospital, Niigata, JP, ³Saitama Medical University International Medical Center, Saitama, JP, ⁴Keio University School of Medicine, Tokyo, JP, ⁵Yokohama City University School of Medicine, Yokohama, JP

14:54 - 15:06 Invited Discussant 341O and 342O
M.F. Harunul Rashid, NCCS - National Cancer Centre Singapore, Singapore, SG

15:06 - 15:16 343O - Global patterns in the incidence of acral melanoma: Systematic review and meta-analysis
K. Cho¹, A. Cust², Y.M. Foo³, G. Eslick⁴, ¹University of Sydney - Nepean Clinical School, Kingswood, AU, ²University of Sydney, Sydney, AU, ³Western Sydney University, Campbelltown, AU, ⁴University of Sydney, Sydney, AU

15:16 - 15:26 344O - Metastatic acral melanoma treatment outcomes: A systematic review and meta-analysis
K. Cho¹, A. Cust², Y.M. Foo³, G. Eslick⁴, ¹University of Sydney - Nepean Clinical School, Kingswood, AU, ²University of Sydney, Sydney, AU, ³Western Sydney University, Campbelltown, AU, ⁴University of Sydney, Kingswood, AU

15:26 - 15:38 Invited Discussant 343O and 344O

15:38 - 15:43 345O - Melanomas and stress patterns on the plantar surface of the foot: A systematic review and meta-analysis
Y.M. Foo¹, K. Cho², A. Cust³, G. Eslick⁴, ¹Western Sydney University, Campbelltown, AU, ²University of Sydney - Nepean Clinical School, Kingswood, AU, ³University of Sydney, Sydney, AU, ⁴University of Sydney, Kingswood, AU

15:43 - 15:48 346O - Association of BAP1 with ATR protein and their clinical significance with
patient outcome in uveal melanoma

J. Jha1, N. Pushker1, M. Singh1, L. Singh2, S. Sen1, J. Kaur1, S. Kashyap3, 1AIIMS - All India Institute of Medical Sciences, Delhi, IN, 2Jamia Millia Islamia, Delhi, IN, 3AIIMS - All India Institute of Medical Sciences, NEW DELHI, IN

15:48 - 15:58  Discussion led by moderators

C. Robert1, P. Lorigan2, 1Institut Gustave Roussy, Villejuif, FR, 2The Christie NHS Foundation Trust, Manchester, GB

14:30 - 16:00  Type: Educational session  Summit 2
Title: New advances in the management of challenging lymphomas
Chair: Marco Ladetto, IT; Won Seog Kim, KR; Yok-Lam Kwong, HK

14:30 - 14:30  Session DOI

14:30 - 14:50  Checkpoint inhibition in lymphoma management
Y.-L. Kwong, Queen Mary Hospital, Hong Kong, HK

14:50 - 15:10  What is the best regiment and sequencing for treatment of mantle cell lymphoma
M. Dreyling, Ludwig Maximilians University - Grosshadern, Munich, DE

15:10 - 15:30  New genetic insights to peripheral t cell lymphoma with a focus on angioimmunoblastic T cell lymphoma
M. Sakata-Yanagimoto, University of Tsukuba, Tsukuba, JP

15:30 - 15:50  Current and novel treatment options for peripheral t cell Lymphoma on genetic insights
S.T. Lim, National Cancer Center Singapore, Singapore, SG

15:50 - 16:00  Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>Session DOI</td>
<td>Room 311</td>
</tr>
<tr>
<td>14:30 - 14:40</td>
<td>Breast cancer</td>
<td>Room 311</td>
</tr>
<tr>
<td>14:30 - 14:40</td>
<td>Clinical case</td>
<td>Room 311</td>
</tr>
<tr>
<td>14:40 - 15:00</td>
<td>Discussion of the case</td>
<td>Room 311</td>
</tr>
<tr>
<td>15:00 - 15:00</td>
<td>Lung SARB-IO</td>
<td>Room 311</td>
</tr>
<tr>
<td>15:00 - 15:10</td>
<td>Clinical case</td>
<td>Room 311</td>
</tr>
<tr>
<td>15:10 - 15:30</td>
<td>Discussion</td>
<td>Room 311</td>
</tr>
</tbody>
</table>

**Clinical case**

G. Kusumawidjaja, NCCS - National Cancer Centre Singapore, Singapore, SG

F. Mornex, Centre Hospitalier Lyon Sud, Pierre Bénite, FR

F. Hegi-Johnson, Gosford Hospital, Gosford, AU
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:45 - 15:45</td>
<td><strong>Session DOI</strong></td>
</tr>
<tr>
<td>15:45 - 15:55</td>
<td><strong>Oligometastatic disease (case1)</strong></td>
</tr>
<tr>
<td>15:55 - 16:15</td>
<td><strong>Clinical case</strong></td>
</tr>
<tr>
<td></td>
<td>K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG</td>
</tr>
<tr>
<td>15:55 - 16:15</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td></td>
<td>Y.Y. Soon, National University of Singapore, Singapore, SG</td>
</tr>
<tr>
<td>16:15 - 16:15</td>
<td><strong>Oligometastatic disease (case2)</strong></td>
</tr>
<tr>
<td>16:15 - 16:25</td>
<td><strong>Clinical case</strong></td>
</tr>
<tr>
<td></td>
<td>J. Miao, Sun Yat-sen University Cancer Center, Guangzhou, CN</td>
</tr>
<tr>
<td>16:25 - 16:45</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td></td>
<td>C. Yip, National Cancer Center Singapore, Singapore, SG</td>
</tr>
</tbody>
</table>

**Room 311**

Type: Special Session
Title: What did you learn from the rad-onc session?
Chair: Kevin Chua, SG; Françoise Mornex, FR